Outcome of elderly patients who receive intensive care at a regional hospital in Hong Kong

Hong Kong Med J 2015 Dec;21(6):490–8 | Epub 29 Sep 2015
DOI: 10.12809/hkmj144445
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE    CME
Outcome of elderly patients who receive intensive care at a regional hospital in Hong Kong
HP Shum, FHKCP, FHKAM (Medicine)1; KC Chan, FHKCA, FHKAM (Anaesthesiology)2; HY Wong, BSN, MSN1; WW Yan, FHKCP, FHKAM (Medicine)1
1 Department of Intensive Care, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong
2 Department of Anaesthesia and Intensive Care, Tuen Mun Hospital, Tuen Mun, Hong Kong
 
Corresponding author: Dr HP Shum (shumhp@ha.org.hk)
 
 Full paper in PDF
Abstract
Objective: To evaluate the clinical outcome (180-day mortality) of very elderly critically ill patients (age ≥80 years) and compare with those aged 60 to 79 years.
 
Design: Historical cohort study.
 
Setting: Regional hospital, Hong Kong.
 
Patients: Patients aged ≥60 years admitted between 1 January 2009 and 31 December 2013 to the Intensive Care Unit of the hospital.
 
Results: Over 5 years, 4226 patients aged ≥60 years were admitted (55.5% total intensive care unit admissions), of whom 32.8% were aged ≥80 years. The proportion of patients aged ≥80 years increased over 5 years. As expected, those aged ≥80 years carried more significant co-morbidities and a higher disease severity compared with those aged 60 to 79 years. They required more mechanical ventilatory support, were less likely to receive renal replacement therapy, and had a higher intensive care unit/hospital/180-day mortality compared with those aged 60 to 79 years. Nonetheless, 71.8% were discharged home and 62.2% survived >180 days following intensive care unit admission. Cox regression analysis revealed that Acute Physiology and Chronic Health Evaluation IV-minus-Age score, emergency admission, intensive care unit admission due to cardiovascular problem, neurosurgical cases, presence of significant co-morbidities (diabetes mellitus, metastatic carcinoma, leukaemia, or myeloma), and requirement for mechanical ventilation independently predicted 180-day mortality.
 
Conclusions: The proportion of critically ill patients aged ≥80 years increased over a 5-year period. Despite having more significant co-morbidities, greater disease severity, and higher intensive care unit/hospital/180-day mortality rate compared with those aged 60 to 79 years, 71.8% of those ≥80 years could be discharged home and 62.2% survived >180 days following intensive care unit admission. Disease severity, presence of co-morbidities, requirement for mechanical ventilation, emergency cases, and admission diagnosis independently predicted 180-day mortality.
 
New knowledge added by this study
  • This study provides up-to-date information on the outcome for critically ill elderly patients. It is currently the largest study focused on the local population.
Implications for clinical practice or policy
  • Despite having more significant co-morbidities, greater disease severity, and a higher intensive care unit (ICU)/hospital/180-day mortality rate compared with those aged 60 to 79 years, our study showed that >70% of critically ill patients aged ≥80 years could be discharged home and their 180-day survival rate was >60%. Such information supports ICU admission for those aged ≥80 years. We recommend further studies to explore the long-term functional outcome of those critically ill elderly patients and the potential health economic impact associated with increased ICU admission for those aged ≥80 years.
 
 
Introduction
According to the Hong Kong Population Projections 2012-2041 report, the proportion of Hong Kong population aged ≥80 years is projected to increase markedly from 273 000 (3.9%) to 957 000 (11.3%) by the year 2041.1 Improvements to health-care provision and environmental factors are responsible for this change. The very elderly patients consume a higher proportion of health-care resources due to the presence of significant co-morbidities.2 Similar to most other specialties, intensive care units (ICUs) face an increasing demand for care by elderly patients. A large multicentre cohort study conducted in Australia and New Zealand reported that the ICU admission rate for those aged ≥80 years increased by 5.6% per year.3 An Austrian group noted a similar trend.4 Intensive care unit is an expensive and limited resource. In theory, the decision to admit or decline a patient from ICU care should not depend solely on the patient’s age, although some earlier studies hinted at such practice.5 6 The debate on the role of advanced age, as opposed to severity of illness, on clinical outcome of these critically ill elderly patients remains unresolved. Commonly used ICU prognostic scores, eg Acute Physiology and Chronic Health Evaluation (APACHE) score and simplified acute physiology score (SAPS), include ‘age’ as one of the components of a mortality risk prediction model. Although some studies have highlighted the importance of age in patient outcome,3 7 8 others have concluded that age was not predictive of a poor prognosis in ICU.9 10 They suggest that severity of illness or premorbid functional status are more important determinants of ICU outcome.9 10 Hong Kong, which has the longest life expectancy in the world, has few data focused on the outcome for critically ill elderly patients.11 Our primary objective of this study was to evaluate the clinical outcome (180-day mortality) of very elderly patients (≥80 years old) and compare it with that of patients aged 60 to 79 years. The secondary objective was to determine factors associated with the survival of elderly patients (aged ≥60 years) who require ICU care.
 
Methods
This study was approved by the hospital Ethics Committee and written informed consent was waived. This study was a retrospective, single-centre, cohort study conducted at the ICU of Pamela Youde Nethersole Eastern Hospital (PYNEH), a 2000-bed acute care regional hospital that provides comprehensive services except cardiothoracic surgery, transplant surgery, and burns. The ICU is a 22-bed closed mixed medical-surgical unit with an average admission of 1400 patients per year. All patients who were admitted to the ICU between 1 January 2009 and 31 December 2013 were evaluated. During the study period, there were no changes to ICU operation guidelines or major clinical decision makers. Patients aged ≥60 years were recruited for this study. The cutoff value of 60 years was adopted based on the United Nations definition of an older or elderly person.12 Those for whom there were insufficient data for analysis or who remained in the ICU for <4 hours were excluded. Admissions that involved the same patient for different hospitalisation episodes were treated independently.
 
The following data were collected: demographics, significant co-morbidities (hypertension, congestive heart failure, diabetes mellitus, ischaemic heart disease, ischaemic or haemorrhagic stroke, chronic respiratory failure, end-stage renal failure requiring dialytic support, liver cirrhosis or liver failure, haematological malignancy, or immunosuppressed status), admission diagnosis, emergency or elective cases, ICU and hospital length of stay, and ICU and hospital outcomes. Mortality in ICU was defined as PYNEH ICU death within the index admission. Hospital mortality was defined as PYNEH death within the index admission. The 180-day mortality was defined as death within 180 days, calculated from ICU admission.
 
Patient’s severity of illness was quantified using the APACHE IV system.13 This is a severity-adjusted methodology that predicts outcome for critically ill adult patients and comprises the following major components: (1) acute physiology score focused on cardiopulmonary parameters and laboratory data retrieved as the worst value within the first 24 hours of ICU admission, (2) significant co-morbidities, (3) age, (4) ICU admission disease classification, and (5) patient’s length of stay in the hospital prior to ICU admission. All patient data were collected from the hospital’s information system and an ICU clinical information system (IntelliVue Clinical Information Portfolio, Philips Medical Systems, Amsterdam, The Netherlands). Patients were followed up until death or 180 days from ICU admission, whichever was the earlier. The most updated mortality and survival data were obtained from the Clinical Management System.
 
Statistical analyses
Data were reported as frequencies, percentages, means, and standard deviations. Univariate analyses were performed using Chi squared test, Fisher’s exact test, and Student’s t test where appropriate. Cox regression analysis using a forward stepwise strategy was performed (on factors with P<0.1 in univariate analyses) to determine the independent predictors of 180-day mortality. The interpretation of multivariable Cox regression analyses may carry significant problems in the presence of collinear variables such as age together with APACHE IV score, in which age is one of the prognostic components. In order to examine the effect of age per se and to avoid collinearity, age points were deducted from the total APACHE IV score to generate the APACHE IV-minus-Age score. Trend analysis was performed using Chi squared test for trend in proportions. All analyses were performed using the Statistical Package for the Social Sciences (Windows version 16.0; SPSS Inc, Chicago [IL], US) and R statistical program version 3.2 (R Foundation, http://www.r-project.org/). A P value of <0.05 was considered statistically significant and all statistical tests were two-tailed. The APACHE IV standardised mortality ratio (SMR) was calculated by dividing the observed mortality by the predicted mortality based on the APACHE IV score. An SMR of <1 indicated better performance than expected and >1 indicated suboptimal performance.13
 
Results
All patients aged ≥60 years
Over the 5-year period, 4247 patients aged ≥60 years were admitted to the ICU. After exclusion of 21 patients who had insufficient data for analysis (due to incomplete APACHE form data entry) or who remained in the ICU for <4 hours, 4226 patients were recruited. They represented 55.5% of total ICU admissions. This proportion was similar across 5 years (57.4% in 2009, 55.9% in 2010, 51.9% in 2011, 56.6% in 2012, and 55.9% in 2013; P value not significant). Emergency admission accounted for 83.8% of cases and 39.6% were for postoperative care. The mean APACHE IV predicted risk of death was 32%. The overall observed ICU mortality was 12.5% and the hospital mortality was 20.8% that translated into an APACHE IV SMR of 0.66. The ICU mortality (13.8% in 2009, 12.9% in 2010, 10.8% in 2011, 11.7% in 2012, and 13.2% in 2013) and hospital mortality (21.5% in 2009, 21.0% in 2010, 17.4% in 2011, 22.3% in 2012, and 21.6% in 2013) did not change significantly over 5 years. The overall 180-day mortality was 29.5% and likewise showed no significant change over 5 years. The outcome for all patients was successfully traced from the Clinical Management System.
 
Difference between patients aged 60 to 79 years and those ≥80 years
Among those ≥60 years old (4226 patients), 32.8% were aged ≥80 years, representing 18.2% of total ICU admissions during the study period. The proportion of patients aged ≥80 years increased over 5 years (16.2% in 2009, 18.9% in 2010, 16.0% in 2011, 20.3% in 2012, and 19.4% in 2013; P=0.006). Compared with patients aged 60 to 79 years, those ≥80 years old were more commonly female, admitted as an emergency, had more co-morbidities (had more ischaemic heart disease, but less likely to have renal failure on dialysis, cirrhosis, or malignancy), and had greater disease severity as assessed by APACHE IV-minus-Age score (Table 1). With regard to clinical outcome, those ≥80 years required more mechanical ventilatory support (55.5% for ≥80 years vs 48.2% for 60-79 years; P<0.001) and were less likely to receive renal replacement therapy (12.2% for ≥80 years vs 16.3% for 60-79 years; P=0.001). They also had higher ICU mortality (16.9% for ≥80 years vs 10.3% for 60-79 years; P<0.001), hospital mortality (28.3% for ≥80 years vs 17.2% for 60-79 years; P<0.001), and 180-day mortality (37.8% for ≥80 years vs 25.5% for 60-79 years; P<0.001). Their ICU and hospital length of stay were nonetheless similar. Despite having more significant co-morbidities, greater disease severity, and higher ICU/hospital/180-day mortality rate than those aged 60 to 79 years, 71.8% of those aged ≥80 years could be discharged home and 62.2% survived >180 days from ICU admission. Patients were divided into three age-groups namely 60-69, 70-79, and ≥80 years. Kaplan-Meier survival plot indicated a significant survival difference between the groups (log rank test P<0.001 for both ≥80 vs 60-69 and ≥80 vs 70-79 years; Fig 1). Half of all deaths occurred within the first 15 days from ICU admission. The ratio of hospital death versus ICU death was the same across the three groups of patients (1.67 for all three groups of patients).
 

Table 1. Patients’ baseline characteristics and outcome
 

Figure 1. 180-Day survival plot for three groups of patients
 
Independent predictors of 180-day mortality
For those aged ≥80 years (Table 2), Cox regression analysis revealed that APACHE IV-minus-Age score, emergency admission, ICU admission due to cardiovascular cause, neurosurgical cases, presence of significant co-morbidities (diabetes mellitus, metastatic carcinoma, leukaemia, or myeloma), and requirement for mechanical ventilation independently predicted 180-day mortality. The findings of Cox regression analysis for those aged ≥60 are shown in Table 3. Age, APACHE IV-minus-Age score, emergency admission, ICU admission due to cardiovascular or renal cause, neurosurgical cases, presence of significant co-morbidities (diabetes mellitus, metastatic carcinoma, leukaemia, or myeloma), and requirement for mechanical ventilation or renal replacement therapy were likewise independent predictors of 180-day mortality for elderly patients ≥60 years old who received intensive care.
 

Table 2. Independent risk factors for 180-day mortality in critically ill elderly patients (≥80 years old)
 

Table 3. Independent risk factors for 180-day mortality in critically ill elderly patients (≥60 years old)
 
Relationship between age, disease severity, and 180-day mortality
Patient disease severity was stratified into four groups (quartiles) according to APACHE IV-minus-Age score (1st quartile ≤37, 2nd quartile 38-55, 3rd quartile 56-81, 4th quartile >81 years). In general, the 180-day mortality rate increased with disease severity (Fig 2). The mortality rates were quite similar (with <5% difference) for those ≥80 years and those aged 60 to 79 years with low disease severity (quartiles 1 and 2) but the gap widened (with 10%-15% difference) with higher disease severity (quartiles 3 and 4).
 

Figure 2. Percentage of 180-day mortality stratified by age and APACHE IV-minus-Age score
 
Discussion
Our results show that the proportion of patients aged ≥80 years who required ICU care increased over 5 years (16.2% in 2009, 18.9% in 2010, 16.0% in 2011, 20.3% in 2012 and 19.4% in 2013; P=0.006). This is similar to the population growth in Hong Kong of this age-group (3.4% in 2009, 3.6% in 2010, 3.8% in 2011, 4.0% in 2012 and 4.4% in 2013).14 They usually have more co-morbidity, are admitted to ICU as an emergency, and have higher disease severity. Their 180-day mortality rate was 1.7-fold that of 60-69 years old. The 180-day mortality rate also increased with disease severity (Fig 2). The mortality rates were quite similar (with <5% difference) for those aged ≥80 years and those aged 60 to 79 years with low disease severity but the gap widened (with 10%-15% difference) with higher disease severity. This may be due to a lower physiological reserve in the ≥80s that manifests when illness is severe. This study could not demonstrate how physiological reserve diminishes with age. As this was a retrospective observational study, we cannot tell whether the greater hazard for death in those ≥80 years is really related to a ‘lower’ physiological reserve, or whether ICU doctors/family are more likely to withhold/withdraw life support. The decision to limit therapy involves assessment of a patient’s quality of life; such data were not available in this study. These findings also indicate the importance of early management of clinical deterioration in those aged ≥80 years. When disease severity progresses, mortality risk increases much faster among those ≥80 years than in those aged 60 to 79 years.
 
With regard to the level of treatment in the ICU, previous studies have shown that very elderly patients receive less aggressive treatment than younger patients.15 16 17 18 In our cohort, the elderly patients were less likely to receive renal replacement therapy. Mechanical ventilation, however, was commonly performed even in those aged ≥80 years (55.5%), which is in contrast to previous studies.4 19 20 This may have been due to a difference in case-mix and clinical practice. Lerolle et al21 showed that the intensity of ICU treatment has increased and survival has improved over a decade for those aged ≥80 years. Ihra et al4 also showed that the prognosis of those aged >80 years improved by 3% per year. Thus admission of such patients to ICU for a trial period of therapy is warranted.
 
The impact of age on mortality has been demonstrated in our study and previous studies.3 8 18 Similar to previous studies, however, the presence of significant co-morbidities, disease severity, and use of mechanical ventilation also independently predicted mortality.3 4 22 These findings are not surprising and indicate that the decision to refuse ICU care for those aged ≥80 years should be based not on age alone, but also on multiple factors listed in Tables 2 and 3. Co-morbidities may manifest as impaired pre-admission functional status or increment of complication rate during hospital stay. Functional status usually includes physical, cognitive, and social functioning. Impaired functioning in daily life is more prevalent in the elderly patients and independently predicts mortality.23 24 Previous studies have also shown that elderly patients have a higher surgical complication rate and risk of nosocomial infection.25 26 With regard to mechanical ventilation, animal study has shown that ageing increases susceptibility to injurious mechanical ventilation–induced pulmonary injury.27 Although no human study has confirmed this finding, survival rates in patients with acute respiratory failure correlate with age and decrease with duration of mechanical ventilation.28 29
 
Post-ICU discharge mortality is determined by care in general wards and end-of-life decisions. Calculating the ratio of hospital deaths versus ICU deaths can provide some insight into this issue. A higher ratio implies that more patients die in the general ward than in the ICU. In our study, the ratio was the same across the three groups of elderly patients (1.67), indicating a similar level of care after ICU discharge. Our finding was similar to the study by Andersen and Kvåle,19 but our ratios were lower than those in other overseas studies.3 4 30
 
Compared with other multicentre studies,3 4 19 20 30 we admitted more patients aged ≥80 years (18% vs 9-13%) [Table 4]. The median ICU length of stay was comparable. Similar to them4 19 30 (except Bagshaw study3), most ICU admissions for ≥80 year olds were emergency in nature and carried a higher hospital mortality. A study conducted by Bagshaw et al3 had a relatively higher proportion of elective cases (38%) and explains their apparently lower hospital mortality compared with others. It is difficult to compare disease severity across different studies as severity scoring systems are inconsistent. The performance of ICU for these groups of patients, however, can be assessed by the SMR that represents the ratio of observed versus expected mortality based on the severity score. An SMR of <1 indicates better-than-expected performance and >1 indicates suboptimal performance. Our SMR was slightly lower than other overseas studies and this might indicate a better outcome for those ≥80 years old. Another possible explanation for this phenomenon is that the severity scores adopted by other studies, namely SAPS II and APACHE II score, were developed in the 1990s and may not be appropriate to the modern ICU setting.31 32 33
 

Table 4. Comparison with overseas multicentre studies
 
The triage decision for ICU admission is always a difficult task for the critical care physician. The potential benefit of ICU care should be weighed against the multiple risks, namely iatrogenic complications from invasive monitoring and treatments, higher exposure to nosocomial infection and ICU delirium, in which the elderly patients are more vulnerable.34 35 36 We do not have any data from a randomised controlled trial that can advise whether we should place an upper age limit on ICU admission. Our study showed that more than 70% of critically ill patients aged ≥80 years could be discharged home and their 180-day survival rate was >60%. This is firm evidence to support ICU admission for those ≥80 years old. Post-discharge functional outcome is another valuable parameter and warrants consideration during triage decision. Such information, however, was not available in our study. The decision to discharge patients from ICU and hospital depends not only on clinical factors, but also on operational factors (eg bed occupancy and manpower issue). This may induce bias in assessment of patient outcome when using ICU or hospital mortality alone. Using 180-day mortality, as in our study, will resolve this problem.
 
Is it cost-effective to treat elderly patients in the ICU? It is difficult to conduct randomised study of this issue because of ethical considerations. An observational study by Edbrooke et al37 examined the cost-effectiveness of ICU admission by comparing patients who were accepted into ICU after ICU triage with those who were not, while attempting to adjust such comparison for confounding factors. Their study showed that ICU admission not only improved survival, but the cost per life saved decreased as severity of illness increased. The cost decreased substantially for patients with predicted mortality higher than 40%. The elderly patients have significant co-morbidities and higher disease severity that contributed to elevated predicted hospital mortality. Therefore, they may benefit more from ICU care at a lower cost. Chelluri et al38 investigated the relationship between age and hospital cost for those patients who received prolonged mechanical ventilation. Daily and total costs for hospitalisation were less for older patients than younger patients. One would think that the lower hospital cost was due to higher mortality and consequent shorter length of stay of elderly patients, but it is not the case. The relationship between age and costs was independent of hospital mortality, resuscitation status, and discharge location. More studies are required to clarify the potential health economic impact associated with increased ICU admission for these elderly patients.
 
Our study has several limitations. First, we have no information about the decision to limit or withdraw therapy. This may contribute to some of the differences between the oldest-old and other groups of patients. Second, the pre-ICU admission functional statuses and post-discharge quality-of-life assessment were not available. Functional status before ICU admission correlates with long-term outcome, and the absence of such information may have induced bias in this study.7 39 Many elderly patients deteriorate with critical illness that requires ICU care and improve after hospital discharge, although quality of life fails to return to the pre-admission level even after a prolonged period.40 41 Therefore, quality of life should be assigned the same weighting as mortality when determining a patient’s outcome. Third, other confounders such as smoking or nutritional status were not recorded and might have affected prognosis. Fourth, the follow-up duration was short and long-term outcome could not be assessed. Finally, this was a single-centre study and the findings may not be applicable to other institutions.
 
Conclusions
The proportion of critically ill patients aged ≥80 years increased over 5 years. Age, disease severity, and presence of co-morbidities independently predicted 180-day mortality. Despite having more significant co-morbidities, greater disease severity, and higher ICU/hospital/180-day mortality rate than those aged 60 to 79 years, 71.8% of those aged ≥80 years could be discharged home and 62.2% survived >180 days from ICU admission. This provides evidence to support ICU admission for those aged ≥80 years. We recommend further studies to explore the long-term functional outcome of these critically ill elderly patients and the potential health economic impact associated with increased ICU admission for those aged ≥80 years.
 
References
1. Hong Kong Population Projections 2012-2041. Available from: http://www.statistics.gov.hk/pub/B1120015052012XXXXB0100.pdf. Accessed Nov 2014.
2. Song X, MacKnight C, Latta R, Mitnitski AB, Rockwood K. Frailty and survival of rural and urban seniors: results from the Canadian Study of Health and Aging. Aging Clin Exp Res 2007;19:145-53. Crossref
3. Bagshaw SM, Webb SA, Delaney A, et al. Very old patients admitted to intensive care in Australia and New Zealand: a multi-centre cohort analysis. Crit Care 2009;13:R45. Crossref
4. Ihra GC, Lehberger J, Hochrieser H, et al. Development of demographics and outcome of very old critically ill patients admitted to intensive care units. Intensive Care Med 2012;38:620-6. Crossref
5. Garrouste-Orgeas M, Montuclard L, Timsit JF, Misset B, Christias M, Carlet J. Triaging patients to the ICU: a pilot study of factors influencing admission decisions and patient outcomes. Intensive Care Med 2003;29:774-81.
6. Dragsted L, Qvist J. Epidemiology of intensive care. Int J Technol Assess Health Care 1992;8:395-407. Crossref
7. de Rooij SE, Abu-Hanna A, Levi M, de Jonge E. Factors that predict outcome of intensive care treatment in very elderly patients: a review. Crit Care 2005;9:R307-14. Crossref
8. Fuchs L, Chronaki CE, Park S, et al. ICU admission characteristics and mortality rates among elderly and very elderly patients. Intensive Care Med 2012;38:1654-61. Crossref
9. Chelluri L, Pinsky MR, Donahoe MP, Grenvik A. Long-term outcome of critically ill elderly patients requiring intensive care. JAMA 1993;269:3119-23. Crossref
10. Kaarlola A, Tallgren M, Pettilä V. Long-term survival, quality of life, and quality-adjusted life-years among critically ill elderly patients. Crit Care Med 2006;34:2120-6. Crossref
11. Ip SP, Leung YF, Ip CY, Mak WP. Outcomes of critically ill elderly patients: is high-dependency care for geriatric patients worthwhile? Crit Care Med 1999;27:2351-7. Crossref
12. Definition of an older or elderly person. Available from: http://www.who.int/healthinfo/survey/ageingdefnolder/en/. Accessed 1 Oct 2014.
13. Zimmerman JE, Kramer AA, McNair DS, Malila FM. Acute Physiology and Chronic Health Evaluation (APACHE) IV: hospital mortality assessment for today’s critically ill patients. Crit Care Med 2006;34:1297-310. Crossref
14. Hong Kong Monthly Digest of Statistics. Census and Statistics Department, Hong Kong SAR; 2014: 5.
15. Hamel MB, Davis RB, Teno JM, et al. Older age, aggressiveness of care, and survival for seriously ill, hospitalized adults. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Ann Intern Med 1999;131:721-8. Crossref
16. Somme D, Maillet JM, Gisselbrecht M, Novara A, Ract C, Fagon JY. Critically ill old and the oldest-old patients in intensive care: short- and long-term outcomes. Intensive Care Med 2003;29:2137-43. Crossref
17. Boumendil A, Aegerter P, Guidet B; CUB-Rea Network. Treatment intensity and outcome of patients aged 80 and older in intensive care units: a multicenter matched-cohort study. J Am Geriatr Soc 2005;53:88-93. Crossref
18. Brandberg C, Blomqvist H, Jirwe M. What is the importance of age on treatment of the elderly in the intensive care unit? Acta Anaesthesiol Scand 2013;57:698-703. Crossref
19. Andersen FH, Kvåle R. Do elderly intensive care unit patients receive less intensive care treatment and have higher mortality? Acta Anaesthesiol Scand 2012;56:1298-305. Crossref
20. Nielsson MS, Christiansen CF, Johansen MB, Rasmussen BS, Tønnesen E, Nørgaard M. Mortality in elderly ICU patients: a cohort study. Acta Anaesthesiol Scand 2014;58:19-26. Crossref
21. Lerolle N, Trinquart L, Bornstain C, et al. Increased intensity of treatment and decreased mortality in elderly patients in an intensive care unit over a decade. Crit Care Med 2010;38:59-64. Crossref
22. Fuchs L, Novack V, McLennan S, et al. Trends in severity of illness on ICU admission and mortality among the elderly. PLoS One 2014;9:e93234. Crossref
23. Covinsky KE, Justice AC, Rosenthal GE, Palmer RM, Landefeld CS. Measuring prognosis and case mix in hospitalized elders. The importance of functional status. J Gen Intern Med 1997;12:203-8. Crossref
24. Inouye SK, Peduzzi PN, Robison JT, Hughes JS, Horwitz RI, Concato J. Importance of functional measures in predicting mortality among older hospitalized patients. JAMA 1998;279:1187-93. Crossref
25. Blot S, Cankurtaran M, Petrovic M, et al. Epidemiology and outcome of nosocomial bloodstream infection in elderly critically ill patients: a comparison between middle-aged, old, and very old patients. Crit Care Med 2009;37:1634-41. Crossref
26. Deiner S, Westlake B, Dutton RP. Patterns of surgical care and complications in elderly adults. J Am Geriatr Soc 2014;62:829-35. Crossref
27. Nin N, Lorente JA, De Paula M, et al. Aging increases the susceptibility to injurious mechanical ventilation. Intensive Care Med 2008;34:923-31. Crossref
28. Ely EW, Wheeler AP, Thompson BT, Ancukiewicz M, Steinberg KP, Bernard GR. Recovery rate and prognosis in older persons who develop acute lung injury and the acute respiratory distress syndrome. Ann Intern Med 2002;136:25-36.
29. Feng Y, Amoateng-Adjepong Y, Kaufman D, Gheorghe C, Manthous CA. Age, duration of mechanical ventilation, and outcomes of patients who are critically ill. Chest 2009;136:759-64. Crossref
30. Reinikainen M, Uusaro A, Niskanen M, Ruokonen E. Intensive care of the elderly in Finland. Acta Anaesthesiol Scand 2007;51:522-9. Crossref
31. Breslow MJ, Badawi O. Severity scoring in the critically ill: part 2: maximizing value from outcome prediction scoring systems. Chest 2012;141518-27. Crossref
32. Breslow MJ, Badawi O. Severity scoring in the critically ill: part 1—interpretation and accuracy of outcome prediction scoring systems. Chest 2012;141:245-52. Crossref
33. Juneja D, Singh O, Nasa P, Dang R. Comparison of newer scoring systems with the conventional scoring systems in general intensive care population. Minerva Anestesiol 2012;78:194-200.
34. Nguyen YL, Angus DC, Boumendil A, Guidet B. The challenge of admitting the very elderly to intensive care. Ann Intensive Care 2011;1:29. Crossref
35. Mercier E, Giraudeau B, Ginies G, Perrotin D, Dequin PF. Iatrogenic events contributing to ICU admission: a prospective study. Intensive Care Med 2010;36:1033-7. Crossref
36. Zhang Z, Pan L, Ni H. Impact of delirium on clinical outcome in critically ill patients: a meta-analysis. Gen Hosp Psychiatry 2013;35:105-11. Crossref
37. Edbrooke DL, Minelli C, Mills GH, et al. Implications of ICU triage decisions on patient mortality: a cost-effectiveness analysis. Crit Care 2011;15:R56. Crossref
38. Chelluri L, Mendelsohn AB, Belle SH, et al. Hospital costs in patients receiving prolonged mechanical ventilation: does age have an impact? Crit Care Med 2003;31:1746-51. Crossref
39. Boumendil A, Somme D, Garrouste-Orgeas M, Guidet B. Should elderly patients be admitted to the intensive care unit? Intensive Care Med 2007;33:1252-62. Crossref
40. Hennessy D, Juzwishin K, Yergens D, Noseworthy T, Doig C. Outcomes of elderly survivors of intensive care: a review of the literature. Chest 2005;127:1764-74. Crossref
41. Roch A, Wiramus S, Pauly V, et al. Long-term outcome in medical patients aged 80 or over following admission to an intensive care unit. Crit Care 2011;15:R36. Crossref

Intensive care unit family satisfaction survey

Hong Kong Med J 2015 Oct;21(5):435–43 | Epub 15 Sep 2015
DOI: 10.12809/hkmj144385
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE
Intensive care unit family satisfaction survey
SM Lam, MB, BS, FHKAM (Medicine)1; HM So, MN, MSc1; SK Fok, MN1; SC Li, RN, MN1; CP Ng, BSN1; WK Lui, RN1; DK Heyland, MSc, MD2; WW Yan, MB, BS, FHKAM (Medicine)1
1 Department of Intensive Care, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong
2 Department of Medicine, Queen’s University, Kingston, Ontario, Canada
Corresponding author: Dr SM Lam (lamsm2@ha.org.hk)
 
 Full paper in PDF
Abstract
Objectives: To examine the level of family satisfaction in a local intensive care unit and its performance in comparison with international standards, and to determine the factors independently associated with higher family satisfaction.
 
Design: Questionnaire survey.
 
Setting: A medical-surgical adult intensive care unit in a regional hospital in Hong Kong.
 
Participants: Adult family members of patients admitted to the intensive care unit for 48 hours or more between 15 June 2012 and 31 January 2014, and who had visited the patient at least once during their stay.
 
Results: Of the 961 eligible families, 736 questionnaires were returned (response rate, 76.6%). The mean (± standard deviation) total satisfaction score, and subscores on satisfaction with overall intensive care unit care and with decision-making were 78.1 ± 14.3, 78.0 ± 16.8, and 78.6 ± 13.6, respectively. When compared with a Canadian multicentre database with respective mean scores of 82.9 ± 14.8, 83.5 ± 15.4, and 82.6 ± 16.0 (P<0.001), there was still room for improvement. Independent factors associated with complete satisfaction with overall care were concern for patients and families, agitation management, frequency of communication by nurses, physician skill and competence, and the intensive care unit environment. A performance-importance plot identified the intensive care unit environment and agitation management as factors that required more urgent attention.
 
Conclusions: This is the first intensive care unit family satisfaction survey published in Hong Kong. Although comparable with published data from other parts of the world, the results indicate room for improvement when compared with a Canadian multicentre database. Future directions should focus on improving the intensive care unit environment, agitation management, and communication with families.
 
New knowledge added by this study
  • This study provides the first dataset on the level of family satisfaction with intensive care unit (ICU) care in Hong Kong.
  • Factors that independently affected family satisfaction include the ICU environment, agitation management, and communication between health care workers and families. These are all potentially amenable to improvement.
Implications for clinical practice or policy
  • Factors identified to be independently associated with higher family satisfaction will provide directions for future improvement.
  • Such baseline data will allow for assessment of the efficacy of future improvement initiatives.
 
 
Introduction
Providing professional care and establishing a good rapport with patients is the mission of all health care workers. This relationship building is part of the patient-centred health care delivery model that is currently being advocated over a clinician- or disease-centred model.1 It is associated with better clinical outcomes and may reduce potential complaints due to miscommunication.2 3 4 In the intensive care setting where patients often cannot make their own decisions, either due to their illness or to the effect of medications,5 building a good relationship with the patients’ family is especially important. Furthermore, it has been recognised that families of patients admitted to the intensive care unit (ICU) are at higher risk of developing anxiety, depression, and post-traumatic stress disorder.6 7 They are suddenly subjected to an uncertain outcome for their loved ones, with associated emotional, social and financial consequences, and in a strange environment packed with complex technological advancements. The long-term psychological impact on the family after an ICU encounter is now termed as post-intensive care syndrome–family (PICS-F).7 This adds to the society’s health care burden and reduces the family ability to provide care. Evidence suggests that the risk of developing PICS-F is affected by the manner in which health care workers interact with the family.8 For these reasons, ICU quality measurement should include the families’ perspective and their satisfaction with the care process.9 10
 
In early 2012, the Department of Intensive Care, Pamela Youde Nethersole Eastern Hospital, Hong Kong (PYNICU) initiated the Family Satisfaction Enhancement (FAME) programme that aimed to improve family satisfaction with ICU care. A regular satisfaction survey was performed that intended to identify problem areas and make subsequent improvements. The current study was part of the FAME programme that evaluated the level of family satisfaction in a local ICU and its performance in comparison with international standards, and determined factors that are independently associated with a higher family satisfaction and could be used to plan future initiatives.
 
Methods
This was a questionnaire survey carried out at PYNICU, which is a mixed medical-surgical 22-bed adult ICU in a regional hospital with 1633 beds in Hong Kong. It is a closed ICU with 24-hour intensivist coverage.
 
The Family Satisfaction in the ICU (FS-ICU) questionnaire is a patient family satisfaction questionnaire originally developed in 2003 by a group of health care professionals in Canada: the Canadian Researchers at the End of Life Network (CARENET).5 The questionnaire has been validated for use in North America and Europe,11 12 13 14 and has been translated into other languages including Chinese. The questionnaire is accessible online (http://www.thecarenet.ca). The questionnaire consists of 37 items in two parts: satisfaction with overall ICU care, and satisfaction with decision-making around the care of critically ill patients; and three open-ended questions. Respondents were asked to provide baseline data (sex, age, relationship with the patient, prior experience with ICU, and whether they lived together before admission) at the start of the questionnaire. Corresponding patient data were retrieved from the Clinical Management System, electronic Patient Record, and Clinical Data Analysis and Reporting System.
 
Patients who were admitted to the ICU for 48 hours or more between 15 June 2012 and 31 January 2014, and were visited by their next-of-kin (NOK; defined as the key contact person nominated by the family and documented on the nursing chart on admission) during their stay in the ICU were eligible. Once an eligible patient was nearing ICU discharge (defined as an expected date of ICU discharge within the next 5 days as judged each morning by a senior clinician or nurse consultant), or had passed away in the ICU, his/her NOK was invited by an independent research assistant not involved in clinical care to participate in the survey. A minimum stay of 48 hours was used as in previous studies to ensure an adequate exposure of families to the ICU.15 16 A copy of the questionnaire and an envelope were given to the NOK to be completed based on his/her opinion. He/she was asked to return the questionnaire in the envelope provided, which was opened only by researchers. Those who failed to return the questionnaire were contacted by phone within 2 months of ICU discharge or death, and the questionnaire was sent to them with a stamped addressed envelope if they agreed to participate. All respondents were ensured of the confidentiality and anonymity of their response. For patients who were admitted to the ICU more than once within the same hospitalisation, only the last was analysed.
 
The study protocol was reviewed by the Hong Kong East Cluster Ethics Committee and the need for consent was waived.
 
Statistical analyses
Items in the FS-ICU questionnaire were scored as previously described12: each item was recoded into a linear scale ranging from 0 to 100, with 0 as very poor or very dissatisfied, and 100 as excellent or completely satisfied. Three items (“received appropriate amount of information”, “had enough time to think in decision-making process”, and “adequate time to address concerns and answer questions”) were recoded into dichotomous variables, while two items (“involved at right time in decision-making process”, and “given right amount of hope patient would recover”) were recoded into a 3-point Likert scale.12 A mean (± standard deviation [SD]) score was computed for each item. Subscores for satisfaction with overall ICU care (FS-ICU/Care) and satisfaction with role in decision-making (FS-ICU/DM), and a total score (FS-ICU/Total) were generated by averaging available items, provided that the respondent answered 70% or more of the items in the respective sections.12
 
Results were compared using Mann-Whitney U test with those of a multicentre Canadian database (written communication, Daren Heyland, Feb 2014) that comprised data captured from 2003 to 2006 at 12 Canadian sites.
 
Univariate analyses of satisfaction with overall ICU care and satisfaction with role in decision-making were conducted. Variables included the baseline respondent’s and patient’s characteristics, as well as items of part 1 or part 2 of FS-ICU, respectively. Continuous variables were categorised using their median, and questionnaire items were categorised into “completely satisfied” and “less than completely satisfied”. Factors with a P value of ≤0.1 were entered into multivariable logistic regression using stepwise backward elimination to identify independent factors associated with complete family satisfaction with overall ICU care and role in decision-making.
 
The independent factors thus identified by multivariable logistic regression were used in the construction of performance-importance plots to identify those factors that deserve more urgent attention because of their higher importance (regression weights above the median) but lower performance (percentage of that item being rated as “excellent” being below the median).
 
By applying the rule of 10 on logistic regression analysis of family satisfaction with overall ICU care, a target sample size was estimated to be 725 with 29 covariates with an estimated 40% of respondents being “completely satisfied” with overall care. All tests were two-sided, and a P value of <0.05 was considered statistically significant. All data were analysed using the Statistical Package for the Social Sciences (Windows version 20; SPSS Inc, Chicago [IL], US).
 
Results
From 15 June 2012 to 31 January 2014, 961 patients were eligible and 822 families agreed to participate; 736 questionnaires were eventually returned, with a response rate of 76.6%. Excluding the three questions only applicable to families of patients who passed away in ICU and the three open-ended questions, 23 766 (95.0%) of the total 25 024 questions were completed. Baseline characteristics of the respondents and patients are shown in Table 1.
 

Table 1. Baseline characteristics of respondents and patients (n=736)
 
Our mean (± SD) FS-ICU/Total, FS-ICU/Care, and FS-ICU/DM scores were 78.1 ± 14.3, 78.0 ± 16.8, and 78.6 ± 13.6, respectively. Table 2 shows the percentage of responses and mean score for each questionnaire item.
 

Table 2. Family satisfaction with overall care and role in decision-making, and benchmarking with Canadian multicentre database
 
When results were compared with the Canadian data (written communication, Daren Heyland, Feb 2014), the latter had a higher mean FS-ICU/Total, FS-ICU/Care, and FS-ICU/DM score of 82.9 ± 14.8, 83.5 ± 15.4, and 82.6 ± 16.0, respectively (P<0.001 for all three scores when compared with PYNICU). Table 2 shows the result for each FS-ICU item; PYNICU achieved a significantly higher mean score for item “control over care”. There was no significant difference in scores between the two databases for items “frequency of communication by physicians”, “atmosphere of ICU waiting room”, “involved at the right time in decision-making”, “received appropriate amount of information”, and “given right amount of hope”. The Canadian sites achieved higher scores for the remaining items.
 
In the univariate analysis of satisfaction with overall ICU care, none of the patient’s or respondent’s characteristics had a P≤0.1. Items “spiritual support for family”, “support from social workers”, and “support from pastors” were excluded since more than 30% of the responses were either missing or deemed not applicable. Thus, a total of 14 covariates were analysed in the multivariable analysis. The independent factors identified were “concern and caring for patients”, “agitation management”, “concern and caring for family”, “frequency of communication by nurses”, “physician skill and competence”, “atmosphere of ICU”, and “atmosphere of ICU waiting room” (Table 3). In the multivariable analysis of satisfaction with role in decision-making, 16 covariates including “age of respondent”, “sex of respondent” (with P values of 0.005 and 0.08, respectively in the univariate analysis), and all items in part two of the questionnaire excluding item “given right amount of hope” (P=0.214 in univariate analysis) were tested. Independent factors identified were “honesty of information”, “completeness of information”, “control over care”, “agreement within family regarding care patient received”, “satisfaction with amount of health care”, and “age of respondent ≥47 years” (Table 3).
 

Table 3. Factors independently associated with complete satisfaction
 
Performance-importance plots identified the following items as being more important but performed less satisfactorily: “atmosphere of ICU waiting room”, “atmosphere of ICU”, “agitation management” (overall care), and “satisfaction with amount of health care” (decision-making) [Fig 1].
 

Figure 1. Performance-importance plots of satisfaction with (a) overall care and (b) role in decision-making
(a) Horizontal and vertical lines indicate the medians of regression weights (1.236) and performances (43.8), respectively
(b) Horizontal and vertical lines indicate the medians of regression weights (1.207) and performances (35.7), respectively
 
Discussion
This is the first ICU family satisfaction survey published in Hong Kong, and was conducted following implementation of the FAME programme in 2012. Following a small-scale survey carried out by PYNICU in 2010 (written communication, HL Wu, 2012), staff awareness about the importance of family satisfaction has increased. Family satisfaction was added to the regular agenda at our weekly business meetings, where comments and feedback from NOKs were discussed. These discussions led to various measures to improve communication (unsolicited nurses’ update during visiting hours), access to information (information booklets in waiting rooms and noticeboard displays for families), and facilities (chairs for families at bedside, televisions for awake patients, and refurbishment of the waiting rooms). This survey showed high satisfaction scores in 2012 to 2014 that were similar to figures reported around the world (Fig 2 16 17 18 as well as the multicentre Canadian database—a German study reported their mean FS-ICU/Total, FS-ICU/Care, and FS-ICU/DM as 78.3 ± 14.3, 78.6 ± 14.3, and 77.8 ± 15.616; a Swiss study reported scores of 78 ± 14, 79 ± 14, and 77 ± 1517; and an American study achieved scores of 76.6 ± 20.6, 77.7 ± 20.6, and 75.2 ± 22.6, respectively.18 Nonetheless the Canadian centres were able to achieve a significantly better result in most items and in the summary scores. This might be explained by cross-cultural (different expectations from families), as well as administrative differences (nurse-patient and doctor-patient ratios), but it may also indicate room for further improvement.
 

Figure 2. Comparison of mean total and subscores across centres 16 17 18
 
Independent factors that affected satisfaction with overall care and identified by this study can be grouped into: care of the patient and family (concern and caring for the patient and family; agitation management), professional care (frequency of communication by nurses; physician skill and competence), and the ICU environment (atmosphere of the ICU and its waiting room). Consistent with prior studies, none of the patient’s or respondent’s characteristics, including the ICU survival status, was found to be independently associated with satisfaction of overall care.16 19 Setting professional skills aside, the perceived physician competence and amount of concern and care shown to patients and their families were largely affected by the communication skill of the health care providers and their manner when interacting with patients and families. The importance of communication has been emphasised by numerous studies.20 21 22 23 24 25 One study found that longer periods of communication between health care providers and families was associated with reduced anxiety among family members of ICU patients.24 They reported a median (range) time of staff contact as 10 (1-60) minutes. In addition to the duration, a proactive, structured, and multidisciplinary communication strategy that incorporated the five objectives in the mnemonic “VALUE” (to Value and appreciate what the family members said, to Acknowledge the family members’ emotions, to Listen, to ask open-ended questions that would allow the caregiver to Understand who the patient was as a person, and to Elicit questions from family members) was shown to lessen symptoms of anxiety, depression, and post-traumatic stress disorder.25 Education and training in communication skills, especially the power of listening and to allow families more opportunity to speak during conferences also improved family satisfaction in the ICU.26 It is also essential to diagnose the root cause of any communication problem.15 Removing barriers in the health care system that discourage communication, for example heavy workload rendering insufficient time spent with families and restrictive visiting policies, would be beneficial.27
 
Factors in the left upper quadrant of the performance-importance plots (Fig 1) had greater regression weights but performed less satisfactorily, and therefore warrant more urgent attention. Among these were the ICU and waiting room environment. The questionnaire items do not specify the particular areas of concern that individual families had in mind, but responses to the three open-ended questions were illuminating. Comments related to the ICU environment focused on the availability of facilities for patients (visual and audio entertainment devices) and their families (chairs and toilet), ICU noise level, room temperature, space, and privacy. In fact, the ICU environment has been repeatedly identified as a factor that affects satisfaction.13 18 19 One study found that migration of an ICU with multiple beds in one ward to another with single-room design significantly improved family and patient satisfaction.13 These findings offer opportunities for improvement, and also provide valuable information for administrators when designing a new ICU.
 
Agitation management also warranted more urgent attention (Fig 1a). Although evidence supports maintenance of a light rather than deep level of sedation in adult critically ill patients to shorten duration of mechanical ventilation and ICU length of stay,28 29 a balance needs to be struck to prevent excessive pain, agitation, or adverse experiences that are associated with a higher incidence of post-traumatic stress disorder in ICU survivors and could negatively impact their families.30 The revised 2013 version of Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult ICU Patients has recommended routine monitoring of the depth of sedation and targeted titration of preferably non-benzodiazepine sedatives.31
 
Our subscore for decision-making was higher than that for overall care, in contrast to the overseas counterparts.16 17 18 We do not know if this is unique to the Chinese population since no other Chinese survey is available for comparison. One interesting finding was that younger respondents were less satisfied with their role in decision-making than older respondents. A similar observation has been made before.32 In this information explosion era where electronic data are easily available, it can be understood that the younger generation wants to play a greater role in making decisions for their sick family member. A paternalistic approach will be less appealing to our future generation, and a deliberative model should therefore be adopted, with an emphasis on provision of complete and honest information to increase their sense of control over the care of their family member.
 
There are limitations to our study. First, the reason for refusal to participate in the survey was not documented and therefore we cannot rule out a response bias, where dissatisfied families might have declined participation in the survey, thus overestimating satisfaction. The high return rate compared with other studies (76.6% vs 27.8-75.4%15 16 17) would have lessened any effect of a response bias. Second, social desirability bias cannot be ruled out as most respondents completed the questionnaire while their sick family member was still under our care. We tried to minimise this by reassuring families of the confidentiality of their response and providing an envelope in which to return the completed questionnaire that was only opened by researchers at a later time. Third, questionnaires completed before ICU discharge might not reflect the whole ICU experience. Recruiting NOKs when the patient was nearing ICU discharge reduced premature data capture and prevented the otherwise increased administrative cost, increased recall bias, and anticipated lower response rate that would be involved when tracing eligible NOKs following ICU discharge. Fourth, FS-ICU has not been validated in the Chinese language. The Chinese (Taiwan) version provided by CARENET was modified by the co-authors wherein Taiwanese terms were replaced by ones familiar to the Hong Kong people and questions on the respondent’s demographics were added as in the original English questionnaire. This modified version was circulated to and approved by all co-authors to ensure face validity. The high return rate of the questionnaire and the high response rate to questions (95.0%) indicated feasibility of this modified Chinese version.11 Last, this was a single-centre study and thus generalisability of the results to other settings may not be appropriate.
 
Conclusions
Family satisfaction is an important measure of ICU quality. We found that families were satisfied with the ICU care we provided and with their role in decision-making. Their satisfaction was comparable with most overseas centres. Nonetheless there remains room for improvement when compared with the Canadian database. Future initiatives will focus on improving the ICU environment, agitation management, and enhancing communication with families.
 
Acknowledgements
We wish to thank all members of the FAME team including Dr Arthur CW Lau, Ms Nora LP Kwok, Ms L Lau, Ms CH Lee, and Ms HY Wong for their administrative advice and contribution in data collection and entry, and Ms CH Li, Ms WY So, and Ms PS Chiu for subject recruitment. We also wish to thank the Canadian Researchers at the End of Life Network for sharing their FS-ICU database. Current versions of the FS-ICU questionnaire can be found on their website <www.thecarenet.ca/57-researchers/our-projects/family-satisfaction-survey>.
 
References
1. Davidson JE, Powers K, Hedayat KM, et al. Clinical practice guidelines for support of the family in the patient-centered intensive care unit: American College of Critical Care Medicine Task Force 2004-2005. Crit Care Med 2007;35:605-22. Crossref
2. Lewin SA, Skea ZC, Entwistle V, Zwarenstein M, Dick J. Interventions for providers to promote a patient-centred approach in clinical consultations. Cochrane Database Syst Rev 2001;(4):CD003267. Crossref
3. Roter DL, Hall JA, Kern DE, Barker LR, Cole KA, Roca RP. Improving physicians’ interviewing skills and reducing patients’ emotional distress. A randomized clinical trial. Arch Intern Med 1995;155:1877-84. Crossref
4. Stewart M, Brown JB, Donner A, et al. The impact of patient-centered care on outcomes. J Fam Pract 2000;49:796-804.
5. Heyland DK, Tranmer JE; Kingston General Hospital ICU Research Working Group. Measuring family satisfaction with care in the intensive care unit: the development of a questionnaire and preliminary results. J Crit Care 2001;16:142-9. Crossref
6. Sundararajan K, Martin M, Rajagopala S, Chapman MJ. Posttraumatic stress disorder in close relatives of intensive care unit patients’ evaluation (PRICE) study. Aust Crit Care 2014;27:183-7. Crossref
7. Schmidt M, Azoulay E. Having a loved one in the ICU: the forgotten family. Curr Opin Crit Care 2012;18:540-7. Crossref
8. Davidson JE, Jones C, Bienvenu J. Family response to critical illness: postintensive care syndrome-family. Crit Care Med 2012;40:618-24. Crossref
9. Flaatten H. The present use of quality indicators in the intensive care unit. Acta Anaesthesiol Scand 2012;56:1078-83. Crossref
10. de Vos M, Graafmans W, Keesman E, Westert G, van der Voort PH. Quality measurement at intensive care units: which indicators should we use? J Crit Care 2007;22:267-74. Crossref
11. Stricker KH, Niemann S, Bugnon S, Wurz J, Rohrer O, Rothen HU. Family satisfaction in the intensive care unit: cross-cultural adaptation of a questionnaire. J Crit Care 2007;22:204-11. Crossref
12. Wall RJ, Engelberg RA, Downey L, Heyland DK, Curtis JR. Refinement, scoring, and validation of the family satisfaction in the intensive care unit (FS-ICU) survey. Crit Care Med 2007;35:271-9. Crossref
13. Jongerden IP, Slooter AJ, Peelen LM, et al. Effect of intensive care environment on family and patient satisfaction: a before-after study. Intensive Care Med 2013;39:1626-34. Crossref
14. Tastan S, Iyigun E, Ayhan H, Kilickaya O, Yilmaz AA, Kurt E. Validity and reliability of Turkish version of family satisfaction in the intensive care unit. Int J Nurs Pract 2014;20:320-6. Crossref
15. Heyland DK, Rocker GM, Dodek PM, et al. Family satisfaction with care in the intensive care unit: results of a multiple center study. Crit Care Med 2002;30:1413-8. Crossref
16. Schwarzkopf D, Behrend S, Skupin H, et al. Family satisfaction in the intensive care unit: a quantitative and qualitative analysis. Intensive Care Med 2013;39:1071-9. Crossref
17. Stricker KH, Kimberger O, Schmidlin K, Zwahlen M, Mohr U, Rothen HU. Family satisfaction in the intensive care unit: what makes the difference? Intensive Care Med 2009;35:2051-9. Crossref
18. Osborn TR, Curtis JR, Nielsen EL, Back AL, Shannon SE, Engelberg RA. Identifying elements of ICU care that families report as important but unsatisfactory: decision-making, control, and ICU atmosphere. Chest 2012;142:1185-92. Crossref
19. Hunziker S, McHugh W, Sarnoff-Lee B, et al. Predictors and correlates of dissatisfaction with intensive care. Crit Care Med 2012;40:1554-61. Crossref
20. Scheunemann LP, McDevitt M, Carson SS, Hanson LC. Randomized, controlled trials of interventions to improve communication in intensive care: a systematic review. Chest 2011;139:543-54. Crossref
21. Kodali S, Stametz RA, Bengier AC, Clarke DN, Layon AJ, Darer JD. Family experience with intensive care unit care: association of self-reported family conferences and family satisfaction. J Crit Care 2014;29:641-4. Crossref
22. Lily CM, De Meo DL, Sonnar LA, et al. An intensive communication intervention for the critically ill. Am J Med 2000;109:469-75. Crossref
23. Shelton W, Moore CD, Socaris S, Gao J, Dowling J. The effect of a family support intervention on family satisfaction, length-of-stay, and cost of care in the intensive care unit. Crit Care Med 2010;38:1315-20. Crossref
24. Rusinova K, Kukal J, Simek J, Cerny V; DEPRESS study working group. Limited family members/staff communication in intensive care units in the Czech and Slovak Republics considerably increases anxiety in patients’ relatives—the DEPRESS study. BMC Psychiatry 2014;14:21. Crossref
25. Lautrette A, Darmon M, Megarbane B, et al. A communication strategy and brochure for relatives of patients dying in the ICU. N Engl J Med 2007;356:469-78. Crossref
26. McDonagh JR, Elliott TB, Engelberg RA, et al. Family satisfaction with family conferences about end-of-life care in the intensive care unit: increased proportion of family speech is associated with increased satisfaction. Crit Care Med 2004;32:1484-8. Crossref
27. Curtis JR, Patrick DL, Shannon SE, Treece PD, Engelberg RA, Rubenfeld GD. The family conference as a focus to improve communication about end-of-life care in the intensive care unit: opportunities for improvement. Crit Care Med 2001;29(2 Suppl):N26-33. Crossref
28. Kress JP, Pohlman AS, O’Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000;342:1471-7. Crossref
29. Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial. Lancet 2008;371:126-34. Crossref
30. Granja C, Gomes E, Amaro A, et al. Understanding posttraumatic stress disorder–related symptoms after critical care: the early illness amnesia hypothesis. Crit Care Med 2008;36:2801-9. Crossref
31. Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med 2013;41:263-306. Crossref
32. Crow R, Gage H, Hampson S, et al. The measurement of satisfaction with healthcare: implications for practice from a systematic review of the literature. Health Technol Assess 2002;6:1-244. Crossref

Endovascular stenting in the management of malignant superior vena cava obstruction: comparing safety, effectiveness, and outcomes between primary stenting and salvage stenting

Hong Kong Med J 2015 Oct;21(5):426–34 | Epub 3 Jul 2015
DOI: 10.12809/hkmj144363
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE
Endovascular stenting in the management of malignant superior vena cava obstruction: comparing safety, effectiveness, and outcomes between primary stenting and salvage stenting
ST Leung, MB, BS, FRCR; Tony HT Sung, FRCR, FHKAM (Radiology); Alvin YH Wan, FRCR, FHKAM (Radiology); KW Leung, FRCR, FHKAM (Radiology); WK Kan, FRCR, FHKAM (Radiology)
Department of Radiology, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong
 
Corresponding author: Dr ST Leung (baryleung@hotmail.com)
 
 Full paper in PDF
Abstract
Objective: To compare the safety, effectiveness, and outcomes of primary stenting and salvage stenting for malignant superior vena cava obstruction.
 
Design: Case series with internal comparison.
 
Setting: Regional hospital, Hong Kong.
 
Patients: A total of 56 patients with malignant superior vena cava obstruction underwent 59 stentings from 1 May 1999 to 31 January 2014. Patients’ characteristics, procedural details, and outcomes were retrospectively reviewed. Of the 56 patients, 33 had primary stenting before conventional therapy and 23 had salvage stenting after failure of conventional therapy. Statistical analyses were made by Fisher’s exact test and Mann-Whitney U test.
 
Results: Primary lung carcinoma was the most common cause of malignant superior vena cava obstruction (primary stenting, 22 patients; salvage stenting, 16 patients; P=0.768), followed by metastatic lymphadenopathy. Most patients had superior vena cava obstruction only (primary stenting, 16 patients; salvage stenting, 15 patients; P=0.633), followed by additional right brachiocephalic vein involvement. Wallstents (Boston Scientific, Natick [MA], US) were used in all patients. Technical success was achieved in all but two patients, one in each group (P=1.000). Only one stent placement was required in most patients (primary stenting, 28 patients; salvage stenting, 20 patients; P=0.726). Procedure time was comparable in both groups (mean time: primary stenting, 89 minutes; salvage stenting, 84 minutes; P=0.526). Symptomatic relief was achieved in most patients (primary stenting, 32 patients; salvage stenting, 23 patients; P=0.639). In-stent restenosis and bleeding were the commonest complications (primary stenting, 6 and 1 patients, respectively; salvage stenting, 2 and 2 patients, respectively). Nine patients required further treatment for symptom recurrence (primary stenting, 6 patients; salvage stenting, 3 patients; P=0.725).
 
Conclusion: Endovascular stenting is safe and effective for relieving malignant superior vena cava obstruction. No statistically significant differences in number of stents, success rates, procedure times, symptom relief rates, complication rates, and re-procedure rates were found between primary stenting and salvage stenting.
 
 
New knowledge added by this study
  • Endovascular stenting is safe and effective for relieving malignant superior vena cava obstruction (SVCO) in both primary stenting and salvage stenting settings.
  • Direct comparison between primary stenting and salvage stenting for safety, effectiveness, and outcomes of superior vena cava (SVC) stenting showed no significant differences in number of stents required, success rates, procedure times, symptom relief rates, complication rates, and re-procedure rates between the two groups.
Implications for clinical practice or policy
  • Primary SVC stenting should be considered for patients at their initial presentation with SVCO before conventional therapy by radiotherapy and/or chemotherapy.
  • Salvage SVC stenting remains a safe and effective treatment for patients with SVCO after failure of radiotherapy and/or chemotherapy.
 
 
Introduction
Superior vena cava (SVC) syndrome encompasses a constellation of symptoms and signs secondary to superior vena cava obstruction (SVCO). The syndrome frequently occurs secondary to extrinsic SVC compression, mostly from malignant causes, due to its low internal venous pressure and location within the rigid structures in the mediastinum. The resulting elevated venous pressure in the upper body causes oedema of the head, neck, and upper extremities. Oedema in the airway may cause life-threatening airway obstruction, and cerebral oedema may result in confusion and coma. There is also decreased venous return causing haemodynamic compromise. These all result in the significant morbidity and mortality associated with SVCO.1 2
 
Since its first description by Charnsangavej et al in 1986,3 SVC stenting has gained increasing popularity in the management of SVCO due to its rapid and effective relief of symptoms compared with conventional therapy by radiotherapy and chemotherapy. A systematic review by Rowell and Gleeson4 concluded that stenting is the most effective and rapid treatment for relieving SVCO symptoms, providing overall symptomatic relief in 95% of patients with an 11% symptom recurrence rate. Radiotherapy and chemotherapy, however, could only achieve symptomatic relief in 60% to 77% of patients, with 17% to 19% of patients having symptom recurrence.4
 
Stenting of SVC is traditionally offered as a salvage therapy after failure of conventional therapy. In recent years, an increasing number of hospitals have begun to consider primary stenting as a first-line treatment prior to conventional therapy due to its promising results.2 5 However, there is currently a lack of studies directly comparing the results of primary stenting before conventional therapy and salvage stenting after failure of conventional therapy. In addition, previous studies evaluating SVC stenting are often limited by a small sample size and lack of long-term follow-up. Only a few case series of more than 50 patients are currently available in the literature.6 7 8 9 10 11
 
With the aim of comparing the safety, effectiveness, and outcomes between patients undergoing primary stenting before conventional therapy and salvage stenting after failure of conventional therapy, we report our 15 years’ experience in the management of malignant SVCO with Wallstent endoprosthesis (Boston Scientific, Natick [MA], US).
 
Methods
A retrospective review of the indications, clinical characteristics, procedures, complications, and outcomes was performed for all patients with clinical symptoms of SVCO who underwent SVC stenting at a single hospital in Hong Kong from 1 May 1999 to 31 January 2014. Patients were identified from the departmental internal records and the radiology information system. All patients had computed tomography performed prior to stent placement, which revealed unresectable malignant SVCO. Patients’ medical and procedural records were retrospectively reviewed by a radiologist who was a Fellow of the Royal College of Radiologists with subspecialty training in interventional radiology, and who was blinded to whether the patient was receiving primary stenting or salvage stenting during the review of patients’ outcomes. The follow-up period was considered as being from the day of the procedure to the day of the latest information or death, with the end of data collection fixed on 1 May 2014. This study was approved by the local Institutional Review Board.
 
Patients were categorised into either the primary stenting group or the salvage stenting group. Patients in the primary stenting group had SVC stenting performed at initial presentation of SVCO before any radiotherapy and/or chemotherapy. Patients in the salvage stenting group had SVC stenting performed after failure of radiotherapy and/or chemotherapy, which was defined as newly developed or worsening SVCO symptoms despite the use of radiotherapy and/or chemotherapy. The primary stenting group comprised 33 patients with 35 SVC stentings done and the salvage stenting group comprised 23 patients with 24 SVC stentings performed.
 
Stent placement was performed under local anaesthesia in an angiography suite with cardiopulmonary monitoring for all patients after obtaining informed consent. Pre-procedure superior vena cavograms were performed for assessment of site, length, degree of stenosis, and planning of stent placement. Wallstent endoprostheses were used in all patients. Intravenous heparin was administered before stent placement.
 
The stenoses were first negotiated with a guidewire. Placements of Wallstents across the stenoses were then performed. Balloon angioplasty was performed before and/or after stent placement if considered necessary by the performing interventional radiologist. Stent position and patency were confirmed by post-procedural superior vena cavogram, which also excluded any venous rupture (Fig 1).
 

Figure 1. Superior vena cavograms showing superior vena cava (SVC) stenting of a 70-year-old woman who developed SVC obstruction complicating a primary lung carcinoma
(a) Superior vena cavogram performed via the right femoral approach shows a malignant stricture with shouldering at the upper SVC involving the left brachiocephalic vein (arrow); (b) measurements are being made for planning of stent placement in the SVC. The narrowest segment of the stricture measured 4.25 mm; (c) a 16 x 60-mm Wallstent endoprosthesis is deployed across the stricture with the cranial end at the left brachiocephalic vein and the caudal end at the lower SVC (arrows); (d) post-stenting superior vena cavogram shows moderate residual stricture with flow limitation (arrow). The narrowest segment of the stricture measured 4.41 mm after stent placement; (e) the stricture is subsequently dilated by balloon angioplasty (arrow); (f) post-angioplasty superior vena cavogram shows decreasing residual stricture and resolution of flow limitation (arrow). The narrowest segment of the stricture is enlarged to 7.50 mm after balloon angioplasty
 
Statistical analyses were performed by the Statistical Package for the Social Sciences (Windows version 19.0; SPSS Inc, Chicago [IL], US). P values were calculated by Fisher’s exact test and Mann-Whitney U test when appropriate, and a significance level of 0.05 was used.
 
Results
A total of 56 (40 male and 16 female) patients underwent 59 SVC stentings for malignant SVCO during the study period. All patients were included in the study and their mean age was 64 years (range, 48-83 years). There were no statistically significant differences in male-to-female ratio (P=0.797), patient age (P=0.548), and underlying causes between the primary and salvage stenting groups. The background demographics of the two groups of patients are summarised in Table 1.
 

Table 1. Patient characteristics by stenting group
 
Underlying cause
Primary lung carcinoma was the most common cause in both groups of patients, accounting for 67% (n=22) in the primary stenting group and 70% (n=16) in the salvage stenting group. No statistically significant difference was seen between the two groups (P=0.768).
 
Among the causes other than primary lung carcinoma, metastatic lymphadenopathy was the most common indication, which was seen in two patients in the primary stenting group and four in the salvage stenting group. Carcinoma of the breast was the most common primary site, accounting for three of the six patients. Other causes included lymphoma (n=1), malignant thymic tumour (n=1), and neuroendocrine tumour (n=1) [Table 1].
 
Site of obstruction
Among the 59 stenting procedures, obstruction at the level of SVC only was most commonly encountered, accounting for 46% (n=16) of cases in the primary stenting group and 63% (n=15) of cases in the salvage stenting group. Additional sites of obstruction were found at the right brachiocephalic vein, bilateral brachiocephalic veins, and left brachiocephalic vein. There were no statistically significant differences between the two groups (P=0.633) [Table 2].
 

Table 2. Procedure characteristics by stenting group
 
Procedures
Results of the procedures are summarised in Table 2. No statistically significant differences were seen between the two groups. The femoral approach was used for most patients: 86% (n=30) in the primary stenting group and 88% (n=21) in the salvage stenting group. The jugular and basilic approaches were used for the remaining patients.
 
Successful stent placement was achieved in all but two patients, with similar success rates in both groups of patients: 97% in the primary stenting group and 96% in the salvage stenting group (P=1.000). One failure occurred in the primary stenting group due to development of fatal haemopericardium during the procedure. Another failure occurred in the salvage stenting group due to failure of stent placement across the obstruction.
 
A single stent was sufficient to restore vessel patency in most patients, with the results comparable for both groups of patients: 82% (n=28) in the primary stenting group and 87% (n=20) in the salvage stenting group. No statistically significant differences were seen between the two groups (P=0.726). The remaining patients required placement of two to three stents to alleviate the obstruction. Anticoagulation following stent placement was recommended for prevention of in-stent thrombosis with the individual anticoagulation regimen decided by the senior physicians and oncologists.
 
The procedure times for the two groups of patients showed no statistically significant difference (P=0.526). The mean procedure time was 89 minutes (range, 45-205 minutes) in the primary stenting group, and 84 minutes (range, 40-240 minutes) in the salvage stenting group (Table 2).
 
Treatment outcome
Table 3 summarises the outcomes after SVC stenting. Resolution or improvement of symptoms within 72 hours post-stenting was demonstrated in most patients: 91% (n=32) in the primary stenting group and 96% (n=23) in the salvage stenting group (P=0.639). One patient in the primary stenting group had worsening symptoms after stenting due to development of in-stent thrombosis shortly after stent placement.
 

Table 3. Outcomes of procedures by stenting group
 
Complications
Procedure-related complications were uncommon and there were no statistically significant differences between the two groups of patients for complication rates: 9% (n=3) in the primary stenting group and 8% (n=2) in the salvage stenting group (P=1.000). The complications included haemopericardium (n=1), acute pulmonary oedema (n=1), and bleeding-related complications (groin haematoma, n=2; arterial injury, n=1). One periprocedural death occurred due to fatal haemopericardium and the overall mortality was 1.7%.
 
For stent-related complications, in-stent thrombosis was seen in 14% of patients: 17% (n=6) in the primary stenting group and 8% (n=2) in the salvage stenting group (P=0.453). No stent migration was identified.
 
Patient outcomes
Following successful stent placement, a minority of patients had recurrence of SVCO symptoms requiring further interventions, including further stenting, thrombolysis, and angioplasty (Fig 2). Comparable results were seen in the two groups of patients: 17% (n=6) in the primary stenting group and 13% (n=3) in the salvage stenting group (P=0.725).
 

Figure 2. Superior vena cavograms showing thrombolysis for in-stent thrombosis after superior vena cava (SVC) stenting of a 67-year-old man who developed superior vena cava obstruction (SVCO) complicating a primary lung carcinoma
(a) Superior vena cavogram performed via the right femoral approach shows marked eccentric stenosis at the SVC and left brachiocephalic vein (arrows); (b) SVC stenting is subsequently performed with stent placement in the SVC and left brachiocephalic vein. Venogram performed after stent placement shows a good angiographic result with a patent stent (arrows); (c) superior vena cavogram is performed 2 days after initial stenting due to worsening SVCO symptoms, and showed an occluded stent in the SVC and left brachiocephalic vein (arrow); (d) thrombolysis was done with recombinant tissue plasminogen activator. Venogram performed after the first infusion of recombinant tissue plasminogen activator shows only a small amount of contrast passage through the previously thrombosed stent (arrows); (e) further thrombolysis with additional recombinant tissue plasminogen activator infusions and balloon angioplasties are subsequently performed; (f) post-procedural venogram confirms a patent stent with absence of in-stent thrombosis
 
Patients in the primary stenting group had a statistically significant longer survival than patients in the salvage stenting group (P<0.05). The median survival was 64 (range, 5-1156) days for patients in the primary stenting group, and 62 (range, 2-710) days for patients in the salvage stenting group.
 
At the end of the data collection, one patient in the primary stenting group was alive 1849 days after stenting and two patients in the salvage stenting group were alive 110 days and 226 days after stenting, respectively. Two patients in the primary stenting group were lost to follow-up.
 
Discussion
Symptoms of SVCO usually develop over a period of 2 weeks in approximately one third of patients, and over a longer period in other patients. Oedema and distended veins are the most common symptoms and signs of SVCO of facial and arm oedema occurred in 82% and 46% of patients, respectively, and neck and chest vein distension occurred in 63% and 53% of patients, respectively.1 Respiratory symptoms and signs are common and include dyspnoea (54%), cough (54%), hoarseness (17%), and stridor (4%). Neurological symptoms and signs include syncope (10%), headaches (9%), dizziness (6%), confusion (4%), and visual symptoms (2%).1
 
Malignant conditions account for about 90% of cases of SVCO in previous studies.12 Non–small-cell lung cancer is the most common cause of malignant SVCO and accounts for 50% of cases, followed by small-cell lung cancer (22%), lymphoma (12%), metastatic cancer (9%, of which two thirds are breast cancer), germ-cell cancer (3%), thymoma (2%), and mesothelioma (1%).1 Non-malignant causes of SVCO have become more common in recent years, reflecting the increasing use of intravascular devices such as catheters and pacemakers.1 Ye et al13 have identified that most SVCOs of benign cause are related to haemodialysis catheter placement (70%). Other causes include hypercoagulability and mediastinal fibrosis.
 
The femoral vein is the classic route for stent insertion, and was used for most cases in the current series. Some authors have also suggested jugular vein, subclavian vein, or basilic vein access as possible options.5 9 14 In cases of bilateral brachiocephalic vein obstruction, some authors have proposed that it is sufficient to relieve the obstruction by stent placement in either the right or left brachiocephalic vein, with collaterals allowing drainage from both sides. It has been shown that this is as clinically effective as bilateral stent placement, while offering lower cost, easier placement, and lower rates of complications and recurrence.5 7 8 9
 
Previous studies have shown 87% to 100% effectiveness of primary stenting in relieving SVCO. Recurrence of SVCO is seen in up to 18% of patients.9 10 15 16 17 18 These figures are in keeping with that shown in this study. After successful stent placement, symptoms of SVCO usually resolve within 48 to 72 hours. This is compared with radiotherapy or chemotherapy which usually take weeks to have an effect.1 12 The rapid improvement of patient’s haemodynamic and performance status after primary stenting enables underlying aetiology-specific therapy to be initiated at a full dose and in a timely manner.2 In addition, primary SVC stenting can also be performed immediately after diagnosis in the absence of a histological diagnosis, which is required for deciding the optimal treatment protocol by conventional therapy with chemotherapy and/or radiotherapy.
 
In patients with tumour recurrence or progression despite conventional therapy, or in patients who are not fit for chemotherapy or radiotherapy due to poor performance status or concomitant illness, salvage SVC stenting provides good palliation of SVCO symptoms.19 Most studies for salvage SVC stenting after conventional therapy failure report effective relief of venous compression after cancer recurrence, ranging from 81% to 100%, which is similar to the findings in this study. Most studies report a recurrence rate of up to 25% but figures up to 33% to 41% have also been reported.2 20 21 22 23 24 25 26 27
 
A recent review article has studied complication rates after SVC stenting.2 In a total of 884 stent placements in 32 studies, the mortality was 2%, which is similar to that in this study. A total of 41% of the deaths were due to severe haemorrhage such as pulmonary or cerebral haemorrhage, and 23% were due to acute cardiac events, including arrhythmia, myocardial infarction, and cardiac tamponade. Other causes included respiratory failure (17%) and pulmonary embolism (6%).2 Cardiac tamponade following rupture of central veins, which was seen in this series, is rare, but can be rapidly fatal.28 For this reason, it has been suggested that facilities for pericardial drainage should be available in the room to allow emergent pericardiocentesis.12
 
Periprocedural and post-procedural complications are low and were found in up to 19% of patients in previous studies.12 Overall, these complications compare very favourably with those of chemotherapy and radiotherapy.4 The most common major complications are stent malposition or migration, accounting for 47% of all complications, followed by bleeding (21%), deep vein thrombosis (10%), pulmonary oedema (8%), arrhythmia (5%), infection (5%), and pulmonary embolism (3%).2
 
For stent-related complications, a series by Lanciego et al7 reviewed 149 patients with Wallstent placement for SVC syndrome, which demonstrated a 10.7% rate of stent occlusion (complete, 8%; partial, 2.7%), 2.7% stent thrombosis, 2.7% stent shortening, and 0.7% stent migration.
 
Although commonly given for patients after SVC stent placement, the effectiveness of anticoagulation has not been clearly proven. In general, anticoagulation is recommended at least for the first month after stent placement due to the high thrombogenic effect of the stent before neoendothelium covers the endovascular surface.7 A range of 1 to 9 months of anticoagulation has been proposed and no consensus is currently available.13
 
Patient survival is generally short and is related to the usual status of locally advanced or metastatic malignancy causing SVCO. As demonstrated in this study, survival was shorter in patients receiving salvage stenting after failure of conventional therapy (mean, 3.7 months) compared with that of patients receiving primary stenting before conventional therapy (mean, 8.7 months). This is likely due to the difference in underlying disease status between the two groups of patients. In a previous report, overall patient survival was approximately 6 months after SVC stenting,7 which is similar to the overall mean survival identified in this series (6.6 months).
 
There are a few limitations to this study. As a retrospective study, there was a lack of standardised selection criteria for the choice between primary SVC stenting and conventional therapy by radiotherapy and/or chemotherapy for patients presenting with SVCO. There was also a lack of standardised grading system of the degree of SVCO symptoms and follow-up protocol. The decisions for angioplasty before and after stent placement were made by the operating radiologists during the procedure, and the post-stenting anticoagulation regimen was also decided individually by the senior physicians and oncologists. The small sample size might have limited the power of the study. There are also possibilities of information bias during the review process. These should serve as future references for performing a prospective study with a standardised protocol to evaluate the results of SVC stenting in different groups of patients.
 
Conclusion
Stenting of SVC is a safe and effective means of alleviating SVCO symptoms both in patients undergoing primary stenting before conventional therapy and in those undergoing salvage stenting after failure of conventional therapy. The number of stents required, success rates, procedure times, symptom relief rates, complication rates, and re-procedure rates showed no statistically significant difference between these two groups of patients.
 
Declaration
All the authors have no potential conflict of interest to declare.
 
References
1. Wilson LD, Detterbeck FC, Yahalom J. Clinical practice. Superior vena cava syndrome with malignant causes. N Engl J Med 2007;356:1862-9. Crossref
2. Nguyen NP, Borok TL, Welsh J, Vinh-Hung V. Safety and effectiveness of vascular endoprosthesis for malignant superior vena cava syndrome. Thorax 2009;64:174-8. Crossref
3. Charnsangavej C, Carrasco CH, Wallace S, et al. Stenosis of the vena cava: preliminary assessment of treatment with expandable metallic stents. Radiology 1986;161:295-8. Crossref
4. Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review. Clin Oncol (R Coll Radiol) 2002;14:338-51. Crossref
5. Ganeshan A, Hon LQ, Warakaulle DR, Morgan R, Uberoi R. Superior vena caval stenting for SVC obstruction: current status. Eur J Radiol 2009;71:343-9. Crossref
6. Fagedet D, Thony F, Timsit JF, et al. Endovascular treatment of malignant superior vena cava syndrome: results and predictive factors of clinical efficacy. Cardiovasc Intervent Radiol 2013;36:140-9. Crossref
7. Lanciego C, Pangua C, Chacón JI, et al. Endovascular stenting as the first step in the overall management of malignant superior vena cava syndrome. AJR Am J Roentgenol 2009;193:549-58. Crossref
8. Dinkel HP, Mettke B, Schmid F, Baumgartner I, Triller J, Do DD. Endovascular treatment of malignant superior vena cava syndrome: is bilateral wallstent placement superior to unilateral placement? J Endovasc Ther 2003;10:788-97. Crossref
9. Lanciego C, Chacón JL, Julián A, et al. Stenting as first option for endovascular treatment of malignant superior vena cava syndrome. AJR Am J Roentgenol 2001;177:585-93. Crossref
10. Nagata T, Makutani S, Uchida H, et al. Follow-up results of 71 patients undergoing metallic stent placement for the treatment of a malignant obstruction of the superior vena cava. Cardiovasc Intervent Radiol 2007;30:959-67. Crossref
11. Nicholson AA, Ettles DF, Arnold A, Greenstone M, Dyet JF. Treatment of malignant superior vena cava obstruction: metal stents or radiation therapy. J Vasc Interv Radiol 1997;8:781-8. Crossref
12. Uberoi R. Quality assurance guidelines for superior vena cava stenting in malignant disease. Cardiovasc Intervent Radiol 2006;29:319-22. Crossref
13. Ye M, Shi YX, Huang XZ, Zhao YP, Zhang H, Zhang JW. Endovascular recanalization of superior vena cava, brachiocephalic, and subclavian venous occlusions caused by nonmalignant lesions. Chin Med J 2012;125:1767-71.
14. Miller JH, McBride K, Little F, Price A. Malignant superior vena cava obstruction: stent placement via the subclavian route. Cardiovasc Intervent Radiol 2000;23:155-8. Crossref
15. Chatziioannou A, Alexopoulos T, Mourikis D, et al. Stent therapy for malignant superior vena cava syndrome: should be first line therapy or simple adjunct to radiotherapy. Eur J Radiol 2003;47:247-50. Crossref
16. Bierdrager E, Lampmann LE, Lohle PN, et al. Endovascular stenting in neoplastic superior vena cava syndrome prior to chemotherapy or radiotherapy. Neth J Med 2005;63:20-3.
17. Gross CM, Krämer J, Waigand J, et al. Stent implantation in patients with the superior vena cava syndrome. AJR Am J Roentgenol 1997;169:429-32. Crossref
18. Chacón López-Muñiz JI, García García L, Lanciego Pérez C, et al. Treatment of superior and inferior vena cava syndromes of malignant cause with Wallstent catheter placed percutaneously. Am J Clin Oncol 1997;20:293-7. Crossref
19. Urruticoechea A, Mesia R, Dominguez J, et al. Treatment of malignant superior vena cava syndrome by endovascular stent insertion. Experience on 52 patients with lung cancer. Lung Cancer 2004;43:209-14. Crossref
20. Kee ST, Kinoshita L, Razavi MK, Nyman UR, Semba CP, Dake MD. Superior vena cava syndrome: treatment with catheter-directed thrombolysis and endovascular stent placement. Radiology 1998;206:187-93. Crossref
21. Marcy PY, Magné N, Bentolila F, Drouillard J, Bruneton JN, Descamps B. Superior vena cava obstruction: is stenting necessary? Support Care Cancer 2001;9:103-7. Crossref
22. Greillier L, Barlési F, Doddoli C, et al. Vascular stenting for palliation of superior vena cava obstruction in non-small-cell lung cancer patients: a future ‘standard’ procedure? Respiration 2004;71:178-83. Crossref
23. García Mónaco R, Bertoni H, Pallota G, et al. Use of self-expanding vascular endoprosthesis in superior vena cava syndrome. Eur J Cardiothorac Surg 2003;24:208-11. Crossref
24. Tanigawa N, Sawada S, Mishima K, et al. Clinical outcome of stenting in superior vena cava syndrome associated with malignant tumors. Comparison with conventional treatment. Acta Radiol 1998;39:669-74. Crossref
25. Courtheoux P, Alkofer B, Al Refaï M, Gervais R, Le Rochais JP, Icard P. Stent placement in superior vena cava syndrome. Ann Thorac Surg 2003;75:158-61. Crossref
26. Crowe MT, Davies CH, Gaines PA. Percutaneous management of superior vena cava occlusions. Cardiovasc Intervent Radiol 1995;18:367-72. Crossref
27. Furui S, Sawada S, Kuramoto K, et al. Gianturco stent placement in malignant caval obstruction: analysis of factors for predicting the outcome. Radiology 1995;195:147-52. Crossref
28. Ploegmakers MJ, Rutten MJ. Fatal pericardial tamponade after superior vena cava stenting. Cardiovasc Intervent Radiol 2009;32:585-9. Crossref

Patient acceptability, efficacy, and skin biophysiology of a cream and cleanser containing lipid complex with shea butter extract versus a ceramide product for eczema

Hong Kong Med J 2015 Oct;21(5):417–25 | Epub 28 Aug 2015
DOI: 10.12809/hkmj144472
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE
Patient acceptability, efficacy, and skin biophysiology of a cream and cleanser containing lipid complex with shea butter extract versus a ceramide product for eczema
KL Hon, MD, FCCM1; YC Tsang, BSc1; NH Pong, MPhil1; Vivian WY Lee, PharmD2; NM Luk, FRCP3; CM Chow, FRCPCH1; TF Leung, FRCPCH, FAAAAI1
1 Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong
2 School of Pharmacy, The Chinese University of Hong Kong, Shatin, Hong Kong
3 Hong Kong Dermatology Foundation, Hong Kong
Corresponding author: Prof KL Hon (ehon@hotmail.com)
 
 Full paper in PDF
Abstract
Objectives: To investigate patient acceptability, efficacy, and skin biophysiological effects of a cream/cleanser combination for childhood atopic dermatitis.
 
Design: Case series.
 
Setting: Paediatric dermatology clinic at a university teaching hospital in Hong Kong.
 
Patients: Consecutive paediatric patients with atopic dermatitis who were interested in trying a new moisturiser were recruited between 1 April 2013 and 31 March 2014. Swabs and cultures from the right antecubital fossa and the worst eczematous area, disease severity (SCORing Atopic Dermatitis index), skin hydration, and transepidermal water loss were obtained prior to and following 4-week usage of a cream/cleanser containing lipid complex with shea butter extract (Ezerra cream; Hoe Pharma, Petaling Jaya, Malaysia). Global or general acceptability of treatment was documented as ‘very good’, ‘good’, ‘fair’, or ‘poor’.
 
Results: A total of 34 patients with atopic dermatitis were recruited; 74% reported ‘very good’ or ‘good’, whereas 26% reported ‘fair’ or ‘poor’ general acceptability of treatment of the Ezerra cream; and 76% reported ‘very good’ or ‘good’, whereas 24% reported ‘fair’ or ‘poor’ general acceptability of treatment of the Ezerra cleanser. There were no intergroup differences in pre-usage clinical parameters of age, objective SCORing Atopic Dermatitis index, pruritus, sleep loss, skin hydration, transepidermal water loss, topical corticosteroid usage, oral antihistamine usage, or general acceptability of treatment of the prior emollient. Following use of the Ezerra cream, mean pruritus score decreased from 6.7 to 6.0 (P=0.036) and mean Children’s Dermatology Life Quality Index improved from 10.0 to 8.0 (P=0.021) in the ‘very good’/‘good’ group. There were no statistically significant differences in the acceptability of wash (P=0.526) and emollients (P=0.537) with pre-trial products. When compared with the data of another ceramide-precursor moisturiser in a previous study, there was no statistical difference in efficacy and acceptability between the two products.
 
Conclusions: The trial cream was acceptable in three quarters of patients with atopic dermatitis. Patients who accepted the cream had less pruritus and improved quality of life than the non-accepting patients following its usage. The cream containing shea butter extract did not differ in acceptability or efficacy from a ceramide-precursor product. Patient acceptability is an important factor for treatment efficacy. There is a general lack of published clinical trials to document the efficacy and skin biophysiological effects of many of the proprietary moisturisers.
 
New knowledge added by this study
  • Patient acceptability is an important factor for treatment efficacy.
Implications for clinical practice or policy
  • There is a general lack of published clinical trials to document the efficacy and skin biophysiological effects of many of the proprietary moisturisers.
 
 
Introduction
Eczema or atopic dermatitis (AD) is a chronically relapsing dermatosis associated with atopy, and characterised by reduced skin hydration (SH), impaired skin integrity (transepidermal water loss [TEWL]), and poor quality of life as a result of deficient ceramides in the epidermis.1 Regular application of a moisturiser is the key step in its management. Moisturiser therapy for AD is significantly complicated by the diversity of disease manifestations and by a variety of complex immune abnormalities.1 Filaggrin (filament-aggregating protein) and related moisturising factors have an important function in epidermal differentiation and barrier function, and null mutations within the filaggrin gene are major risk factors for developing AD.2 3 4 5 6 Ceramides and related lipid products are also important components in skin barrier function.7 Recent advances in the understanding of the pathophysiological process of AD have led to the production of new moisturisers targeted at correcting the reduced amount of ceramides and natural moisturising factors in the stratum corneum with ceramides, pseudoceramides, or natural moisturising factors.7 Many proprietary products claim to have these ingredients, but have no or limited studies to document their clinical efficacy. Our group previously tested a number of these commercial products and found patient preference and acceptability may influence outcomes of topical treatment independent of the ingredients in these products.8 The purposes of this study were to investigate patient acceptability of a cream/cleanser combination containing lipid complex and shea butter extract with claimed antihistaminergic properties, and evaluate its efficacy in improving the clinical and biophysiological properties of the skin in AD patients. A MEDLINE search was also performed to evaluate whether evidence of efficacy of many of the proprietary moisturisers exists.
 
Methods
Consecutive patients with AD who were interested in trying a new moisturiser were recruited from the paediatric dermatology clinic at a university teaching hospital in Hong Kong. Diagnosis of AD was based on the UK working group criteria.9 In this study, SH and TEWL in the right forearm (2 cm below the antecubital flexure), and disease severity (SCORing Atopic Dermatitis [SCORAD] index) were measured. We have previously described our method of standardising measurements of SH and TEWL.10 After acclimatisation in the consultation room with the patient sitting comfortably in a chair for 20 to 30 minutes, SH (in arbitrary units) and TEWL (in g/m2/h) were then measured according to the manufacturer’s instructions with the Mobile Skin Center MSC 100 equipped with a Corneometer CM 825 (Courage + Khazaka electronic GmbH, Cologne, Germany), and a Tewameter TM 210 probe (Courage + Khazaka electronic GmbH). We documented that a site 2 cm distal to the right antecubital flexure was optimal for standardisation. Oozing and infected areas were avoided by moving the probe slightly sideways.10 The clinical severity of AD was assessed with the SCORAD index.11 12 The SCORAD index also scores pruritus and sleep loss/disturbance on a scale of 0 to 10 (0 being not affected and 10 being most severely affected).
 
Patients were given a liberal supply of a trial cream containing lipid complex with shea butter extract for eczema (Ezerra [E]; Hoe Pharma, Petaling Jaya, Malaysia) and body wash (E, Hoe Pharma). The moisturiser contained STIMU-TEX AS (Centerchem Inc, Norwalk [CT], US) and saccharide isomerate. The wash contained STIMU-TEX AS and Amisoft (Amisoft Technologies Ltd, Brentwood, UK). The patients were instructed not to use any other moisturiser or topical treatment. Use of any medications such as topical corticosteroid or oral antihistamine was documented. Patients were encouraged to use the test moisturiser at least twice daily on the flexures and areas with eczema. In case the emollient effect was not satisfactory, they could use their usual emollient and medications, but the frequency of such use was to be reported and they must continue with the E moisturiser. The patients were reviewed at the end of 4 weeks. Measurements of SCORAD index, Children’s Dermatology Life Quality Index (CDLQI), SH, and TEWL were repeated. Patients’ global or general acceptability of treatment (GAT) was recorded as ‘very good’, ‘good’, ‘fair’, or ‘poor’.8 13 Approval was obtained from the Clinical Research Ethics Committee of the Chinese University of Hong Kong and written informed consents were obtained from the guardian and patient.
 
Continuous data were expressed as mean and standard deviation. Mann-Whitney U test was used for intergroup comparison and Wilcoxon signed rank test for within-group comparison as a small number of patients was included. Categorical data were presented in counts. Chi squared test or Fisher’s exact test where appropriate was used to compare intergroup categorical data, while McNemar’s test was used to compare within-group categorical data. Fisher’s exact test was used to determine the GAT of previously used proprietary products and E moisturiser and wash. All comparisons were two-tailed, and P values of <0.05 were considered to be statistically significant. The results were also compared with the data for an emollient (C) containing ceramide-precursor lipids and moisturising factors (n=24).14
 
Results
Between 1 April 2013 and 31 March 2014, 34 patients (56% boys; mean [± standard deviation] age, 12.1 ± 4.4 years) with AD were recruited and treated with applications of a moisturising cream (E). Compliance was good and patients generally managed to use the moisturiser daily. Among the patients, 74% reported ‘very good’ or ‘good’ acceptability, whereas 26% reported ‘fair’ or ‘poor’ acceptability of the moisturiser (Tables 1 and 2).
 

Table 1. Global acceptability of treatment (GAT) of cream/cleanser containing lipid complex (E)
 

Table 2. Acceptability and efficacy of Ezerra cream containing lipid complex
 
There were no intergroup differences in pre-usage clinical parameters of age, objective SCORAD index, pruritus, sleep loss, SH, TEWL, topical corticosteroid usage, oral antihistamine usage, or GAT of prior emollient (Table 2). Following use of the E cream, pruritus score and CDLQI were lower in the ‘very good’/‘good’ group than in the ‘fair’/‘poor’ group. Mean pruritus score decreased from 6.7 to 6.0 (P=0.036) and mean CDLQI improved from 10.0 to 8.0 (P=0.021) in the ‘very good’/‘good’ group (Table 2).
 
When analysed for the association of the rating of acceptability, the acceptability of E cleanser (P=0.526) and E cream (P=0.537) was not significantly associated with their respective pre-trial products (Table 1). Patients who preferred the trial moisturiser or wash might or might not have come from the group of poor/fair acceptability of their prior emollient or wash, and vice versa. Prior products included emulsifying ointment and various other proprietary products.
 
When compared historically with another product containing ceramide-precursor lipids (C) that we tested in a previous report,14 the present shea butter extract–containing cream showed similar efficacy and acceptability (Table 3). It appears that ceramide does not confer superiority in terms of acceptability and clinical efficacy.
 

Table 3. Comparative study of the cream containing lipid complex (E) with a proprietary emollient containing ceramide-precursor lipids (C)
 
A MEDLINE search was performed on selected common proprietary moisturisers/emollients for eczema using the following search terms in combinations: “eczema” OR “atopic dermatitis”, AND “emollient” OR “moisturizer” OR “barrier” OR “barrier repair” OR “natural moisturizing factor” OR “ceramide” OR “pseudoceramide”. We selected literature mainly from the past 10 years, but did not exclude commonly referenced and highly cited older articles. We included and described all randomised trials, case series, and bench studies in barrier repair therapy for eczema, with limits activated (Humans, Clinical Trial, Meta-Analysis, Randomized Controlled Trial, English, published in the past 10 years). Editorials, letters, practice guidelines, reviews, and animal studies were excluded. In addition, the bibliographies of the retrieved articles and our own research database were also hand searched. As of 23 April 2014, 18 articles were obtained (Table 413 27 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48). The common proprietary moisturisers were included. The publications generally provided limited evidence of efficacy and biophysical effects (such as SH and TEWL), but virtually no data on patient acceptability and effects on Staphylococcus aureus colonisation.
 

Table 4. Results of a MEDLINE search of studies of selected proprietary moisturisers13 27 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48
 
Discussion
Atopic dermatitis is a chronically relapsing dermatosis characterised by pruritus, skin dryness, inflammation, secondary bacterial infection by S aureus, and poor quality of life.1 15 16 17 The stratum corneum normally consists of fully differentiated corneocytes surrounded by natural moisturising factor and a lipid-rich matrix containing cholesterol, free fatty acids, and ceramide. In AD, metabolism of lipid and filaggrin protein is abnormal, causing a deficiency of ceramide and natural moisturising factors and impairment of epidermal barrier function that leads to increased TEWL and abnormal skin integrity.1 4 7 18 19 20 21 Moisturisers form the first-line therapy as maintenance and therapeutic management in childhood-onset AD.1 22 23 Hydration of the skin helps to improve dryness, reduce pruritus, and restore disturbed barrier function. Bathing without the use of moisturiser may compromise SH.24 25 26
 
In this study, we explored clinical efficacy and acceptability of a proprietary moisturiser (E) containing shea butter extract. The cream was acceptable as ‘very good’ or ‘good’ in about three quarters of patients with AD who tried the moisturiser, and ameliorated their pruritus and improved their quality of life.
 
Compliance or adherence to usage of the moisturising cream was reflected by the GAT and reported frequency of usage (times per day).27 We did not calculate the amount of moisturising cream used because many parents/patients have discarded the tubes or failed to bring them back for weighing in previous trials. Topical steroid usage is also an important confounding factor in this study. We standardise treatment for all our patients by not changing their existing topical steroid (mometasone furoate) and other medications (ie oral antihistamine, topical immunomodulant, and Chinese medicine). In previous studies, we found that documentation of the exact amount of steroid usage (weight or frequency of usage) was difficult for similar reasons as those for moisturisers.28 Most parents are still concerned about topical steroid usage and tend to use the minimal amount of steroid as far as possible.29
 
Alternative explanations for the modest within-group changes in pruritus and CDLQI (Table 2) include regression to the mean, detection bias, or confounding by co-treatment with topical corticosteroid or usual emollients. Our study did not demonstrate any reduction in clinical severity or S aureus colonisation. When compared historically with another product (C) containing ceramide-precursor lipids that we tested in a previous report,14 although different patients were involved and the E or C products were not received by patients in the same period, the present E cream showed similar efficacy and acceptability with the use of a similar study protocol as the previous study. It appears that specific ceramide-precursor lipids do not confer superiority in terms of acceptability and clinical efficacy.
 
Regarding intra-group comparisons, the C cream reduced objective SCORAD index (P=0.027) and increased SH (P=0.015), whereas the E cream reduced pruritus and improved CDLQI only in the ‘very good’/‘good’ group (Table 3). Regarding intergroup comparisons, overall there were no significant differences between the pretreatment and post-treatment parameters for the two moisturisers. We note that in the subgroup analysis, pruritus and CDLQI could be the possible contributing factors for the acceptability in the ‘very good’/‘good’ group for the E cream.
 
Many proprietary emollients/moisturisers are available in the market.7 22 30 31 Despite claims about their efficacy, little evidence has demonstrated the short- or long-term usefulness of many of these proprietary products. Ceramides, pseudoceramides, or filaggrin protein products have been studied and added to commercial moisturisers to mimic natural skin lipids and moisturising factors.32 Anxious parents often consult their physicians for recommendation as to the choice of an ideal or perfect moisturiser for their child with AD. Physicians need to have some evidence-based understanding about these moisturisers in order to address issues raised by the parents. We performed a MEDLINE search and found that only a few of these products have published clinical data (Table 413 27 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48). The majority either do not have patient acceptability or clinical efficacy data in the scientific literature. The efficacy of ceramides and natural moisturiser factors is generally not scientifically documented. Larger-scale, properly conducted randomised controlled trials with recruitment of more study participants may validate subtle differences in clinical efficacy between different emollients. It is likely that there will be similar outcomes in efficacy if the tested emollient is compared with any other traditional emollient such as aqueous cream or Vaseline (Unilever, London, England). Commercial pharmaceutical companies are often unwilling to supply free samples of their product to compare with an inexpensive product, even if more validated and conclusive results may be obtained by increasing the sample size in clinical trials. That is perhaps why there are so few comparative clinical studies in the medical literature.
 
In a wider context, AD is a complex multifactorial atopic disease. Monotherapy targeting merely at replacement of ceramides, pseudoceramides, or filaggrin degradation products at the epidermis is often suboptimal. In particular, colonisation with S aureus must be adequately treated before emollient treatment can be optimised.17
 
The major hindrance to the efficacy of a moisturiser is the patient’s perception as to what an ideal moisturiser should be.8 Indeed, it is often not the product, but the patient’s acceptability that determines whether it may be used consistently. Therefore, the physician caring for a patient with AD must educate and guide the parents and the patient to choose the most acceptable formulation to ensure optimal compliance.
 
This open-label series confirms our previous experience in emollient research. First, patient acceptance of the strengths, types, and formulations of any novel products need to be studied, preferably in randomised controlled trials. Second, holistic efficacy studies of all clinical parameters (namely severity scores, quality-of-life indices, SH, TEWL, S aureus colonisation, and patient acceptance) must be included. Third, as AD is not a simple epidermal skin disease but rather a complex atopic disease, emollient alone is bound to be suboptimal in efficacy.
 
Conclusions
Well-designed, large-scale, randomised, placebo-controlled trials to document therapeutic effects on disease severity, skin biophysiological parameters, quality of life, and patient acceptability are needed. Patient’s acceptability of a certain product is pivotal for compliance and clinical outcome. Only few of the many proprietary moisturisers for AD have undergone clinical trials to evaluate clinical efficacy and patient acceptability.
 
Declaration
Drs KL Hon and TF Leung have performed research on eczema therapeutics, and written about the subject matter of filaggrin, ceramides, and emollients.
 
Acknowledgements
We thank Hoe Pharma in Hong Kong for freely supplying the studied materials. The company, however, was not involved in the design or analysis of the research data. The products used in the present study could be examples of other similar products containing shea butter.
 
References
1. Leung AK, Hon KL, Robson WL. Atopic dermatitis. Adv Pediatr 2007;54:241-73. Crossref
2. Sandilands A, Terron-Kwiatkowski A, Hull PR, et al. Comprehensive analysis of the gene encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic eczema. Nat Genet 2007;39:650-4. Crossref
3. Sandilands A, Smith FJ, Irvine AD, McLean WH. Filaggrin’s fuller figure: a glimpse into the genetic architecture of atopic dermatitis. J Invest Dermatol 2007;127:1282-4. Crossref
4. Enomoto H, Hirata K, Otsuka K, et al. Filaggrin null mutations are associated with atopic dermatitis and elevated levels of IgE in the Japanese population: a family and case-control study. J Hum Genet 2008;53:615-21. Crossref
5. Chamlin SL, Kao J, Frieden IJ, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002;47:198-208. Crossref
6. Maintz L, Novak N. Getting more and more complex: the pathophysiology of atopic eczema. Eur J Dermatol 2007;17:267-83.
7. Hon KL, Leung AK. Use of ceramides and related products for childhood-onset eczema. Recent Pat Inflamm Allergy Drug Discov 2013;7:12-9. Crossref
8. Hon KL, Wang SS, Pong NH, Leung TF. The ideal moisturizer: a survey of parental expectations and practice in childhood-onset eczema. J Dermatolog Treat 2013;24:7-12. Crossref
9. Williams HC, Burney PG, Pembroke AC, Hay RJ. The U.K. Working Party’s Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. Br J Dermatol 1994;131:406-16. Crossref
10. Hon KL, Wong KY, Leung TF, Chow CM, Ng PC. Comparison of skin hydration evaluation sites and correlations among skin hydration, transepidermal water loss, SCORAD index, Nottingham Eczema Severity Score, and quality of life in patients with atopic dermatitis. Am J Clin Dermatol 2008;9:45-50. Crossref
11. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993;186:23-31. Crossref
12. Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997;195:10-9. Crossref
13. Hon KL, Wang SS, Lau Z, et al. Pseudoceramide for childhood eczema: does it work? Hong Kong Med J 2011;17:132-6.
14. Hon KL, Pong NH, Wang SS, Lee VW, Luk NM, Leung TF. Acceptability and efficacy of an emollient containing ceramide-precursor lipids and moisturizing factors for atopic dermatitis in pediatric patients. Drugs R D 2013;13:37-42. Crossref
15. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest 2004;113:651-7. Crossref
16. Hon KL, Lam MC, Leung TF, et al. Clinical features associated with nasal Staphylococcus aureus colonisation in Chinese children with moderate-to-severe atopic dermatitis. Ann Acad Med Singapore 2005;34:602-5.
17. Hon KL, Wang SS, Lee KK, Lee VW, Fan LT, Ip M. Combined antibiotic/corticosteroid cream in the empirical treatment of moderate to severe eczema: friend or foe? J Drugs Dermatol 2012;11:861-4.
18. Hanifin JM, Rajka RG. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980;2:44-7.
19. Hanifin JM. Atopic dermatitis. J Am Acad Dermatol 1982;6:1-13. Crossref
20. Candi E, Schmidt R, Melino G. The cornified envelope: a model of cell death in the skin. Nat Rev Mol Cell Biol 2005;6:328-40. Crossref
21. Leung DY, Nicklas RA, Li JT, et al. Disease management of atopic dermatitis: an updated practice parameter. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol 2004;93(3 Suppl 2):S1-21. Crossref
22. Hon KL, Leung AK, Barankin B. Barrier repair therapy in atopic dermatitis: an overview. Am J Clin Dermatol 2013;14:389-99. Crossref
23. Krakowski AC, Eichenfield LF, Dohil MA. Management of atopic dermatitis in the pediatric population. Pediatrics 2008;122:812-24. Crossref
24. Lancaster W. Atopic eczema in infants and children. Community Pract 2009;82:36-7.
25. Tarr A, Iheanacho I. Should we use bath emollients for atopic eczema? BMJ 2009;339:b4273. Crossref
26. Hon KL, Leung TF, Wong Y, So HK, Li AM, Fok TF. A survey of bathing and showering practices in children with atopic eczema. Clin Exp Dermatol 2005;30:351-4. Crossref
27. Hon KL, Ching GK, Leung TF, Choi CY, Lee KK, Ng PC. Estimating emollient usage in patients with eczema. Clin Exp Dermatol 2010;35:22-6. Crossref
28. Hon KL, Leung TF, Ng PC, et al. Efficacy and tolerability of a Chinese herbal medicine concoction for treatment of atopic dermatitis: a randomized, double-blind, placebo-controlled study. Br J Dermatol 2007;157:357-63. Crossref
29. Hon KL, Kam WY, Leung TF, et al. Steroid fears in children with eczema. Acta Paediatr 2006;95:1451-5. Crossref
30. Roos TC, Geuer S, Roos S, Brost H. Recent advances in treatment strategies for atopic dermatitis. Drugs 2004;64:2639-66. Crossref
31. Baumer JH. Atopic eczema in children, NICE. Arch Dis Child Educ Pract Ed 2008;93:93-7.
32. Park KY, Kim DH, Jeong MS, Li K, Seo SJ. Changes of antimicrobial peptides and transepidermal water loss after topical application of tacrolimus and ceramide-dominant emollient in patients with atopic dermatitis. J Korean Med Sci 2010;25:766-71. Crossref
33. Mohammed D, Matts PJ, Hadgraft J, Lane ME. Influence of Aqueous Cream BP on corneocyte size, maturity, skin protease activity, protein content and transepidermal water loss. Br J Dermatol 2011;164:1304-10. Crossref
34. Tsang M, Guy RH. Effect of Aqueous Cream BP on human stratum corneum in vivo. Br J Dermatol 2010;163:954-8. Crossref
35. Simpson E, Böhling A, Bielfeldt S, Bosc C, Kerrouche N. Improvement of skin barrier function in atopic dermatitis patients with a new moisturizer containing a ceramide precursor. J Dermatolog Treat 2013;24:122-5. Crossref
36. Laquieze S, Czernielewski J, Baltas E. Beneficial use of Cetaphil moisturizing cream as part of a daily skin care regimen for individuals with rosacea. J Dermatolog Treat 2007;18:158-62. Crossref
37. Simpson E, Trookman NS, Rizer RL, et al. Safety and tolerability of a body wash and moisturizer when applied to infants and toddlers with a history of atopic dermatitis: results from an open-label study. Pediatr Dermatol 2012;29:590-7. Crossref
38. Miller MA, Borys D, Riggins M, Masneri DC, Levsky ME. Two cases of contact dermatitis resulting from use of body wash as a skin moisturizer. Am J Emerg Med 2008;26:246.e1-2.
39. Miller DW, Koch SB, Yentzer BA, et al. An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial. J Drugs Dermatol 2011;10:531-7.
40. Draelos ZD. The effect of ceramide-containing skin care products on eczema resolution duration. Cutis 2008;81:87-91.
41. Madaan A. Epiceram for the treatment of atopic dermatitis. Drugs Today (Barc) 2008;44:751-5. Crossref
42. Palatty PL, Azmidah A, Rao S, et al. Topical application of sandal wood oil and turmeric based cream prevents radiodermatitis in head and neck cancer patients undergoing external beam radiotherapy: a pilot study. Br J Radiol 2014;87:20130490. Crossref
43. Wang S, Kislalioglu MS, Breuer M. The effect of rheological properties of experimental moisturizing creams/lotions on their efficacy and perceptual attributes. Int J Cosmet Sci 1999;21:167-88. Crossref
44. Boffa MJ, Beck MH. Allergic contact dermatitis from quaternium 15 in Oilatum cream. Contact Dermatitis 1996;35:45-6. Crossref
45. Garfield SS. The beneficial effects of oilatum cream on hyperhydrosis. J Am Podiatry Assoc 1966;56:22-4. Crossref
46. Yilmaz E, Borchert HH. Effect of lipid-containing, positively charged nanoemulsions on skin hydration, elasticity and erythema—an in vivo study. Int J Pharm 2006;307:232-8. Crossref
47. Kemeny L, Koreck A, Kis K, et al. Endogenous phospholipid metabolite containing topical product inhibits ultraviolet light–induced inflammation and DNA damage in human skin. Skin Pharmacol Physiol 2007;20:155-61. Crossref
48. Dizon MV, Galzote C, Estanislao R, Mathew N, Sarkar R. Tolerance of baby cleansers in infants: a randomized controlled trial. Indian Pediatr 2010;47:959-63. Crossref

Corticosteroid adulteration in proprietary Chinese medicines: a recurring problem

Hong Kong Med J 2015 Oct;21(5):411–6 | Epub 28 Aug 2015
DOI: 10.12809/hkmj154542
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE
Corticosteroid adulteration in proprietary Chinese medicines: a recurring problem
YK Chong, MB, BS; CK Ching, FRCPA, FHKAM (Pathology); SW Ng, MPhil; Tony WL Mak, FRCPath, FHKAM (Pathology)
Hospital Authority Toxicology Reference Laboratory, Princess Margaret Hospital, Laichikok, Hong Kong
Corresponding author: Dr Tony WL Mak (makwl@ha.org.hk)
 
 Full paper in PDF
Abstract
Objectives: To investigate adulteration of proprietary Chinese medicines with corticosteroids in Hong Kong.
 
Design: Case series with cross-sectional analysis.
 
Setting: A tertiary clinical toxicology laboratory in Hong Kong.
 
Patients: All patients using proprietary Chinese medicines adulterated with corticosteroids and referred to the authors’ centre from 1 January 2008 to 31 December 2012.
 
Main outcome measures: Patients’ demographic data, clinical presentation, medical history, drug history, laboratory investigations, and analytical findings of the proprietary Chinese medicines were analysed.
 
Results: The records of 61 patients who consumed corticosteroid-adulterated proprietary Chinese medicines were reviewed. The most common corticosteroid implicated was dexamethasone. Co-adulterants such as non-steroidal anti-inflammatory drugs and histamine H1-receptor antagonists were detected in the proprietary Chinese medicine specimens. Among the patients, seven (11.5%) required intensive care, two (3.3%) died within 30 days of presentation, and 38 (62.3%) had one or more complications that were potentially attributable to exogenous corticosteroids. Of 22 (36.1%) patients who had provocative adrenal function testing performed, 17 (77.3% of those tested) had adrenal insufficiency.
 
Conclusion: The present case series is the largest series of patients taking proprietary Chinese medicines adulterated with corticosteroids. Patients taking these illicit products are at risk of severe adverse effects, including potentially fatal complications. Adrenal insufficiency was very common in this series of patients. Assessment of adrenal function in these patients, however, has been inadequate and routine rather than discretionary testing of adrenal function is indicated in this group of patients. The continuing emergence of proprietary Chinese medicines adulterated with western medication indicates a persistent threat to public health.
 
 
New knowledge added by this study
  • Adulteration of proprietary Chinese medicines (pCMs) with corticosteroids is a significant yet underrecognised phenomenon. Co-adulteration with non-steroidal anti-inflammatory drugs and histamine H1-receptor antagonists is often seen.
  • Adrenal insufficiency is a common complication in patients who have consumed pCMs adulterated with corticosteroids.
Implications for clinical practice or policy
  • Adrenal function testing is essential for patients suspected to have taken corticosteroid-adulterated pCMs.
  • Public health education on the danger of taking pCMs of dubious sources and implementation of effective regulatory measures are important to address the problem of corticosteroid-adulterated pCMs.
 
 
Introduction
Proprietary Chinese medicines (pCMs) are products claimed to be made of Chinese medicines and formulated in a finished dosage form. As with traditional Chinese medicine, pCMs are generally regarded by the public as benign and non-toxic, as compared with western medications.
 
Undeclared corticosteroids, among other adulterants, have been reported to be added to pCMs, Ayurvedic medicine, and homeopathic medicine.1 2 3 4 5 There are multiple incentives for adding corticosteroids: they have powerful analgesic and anti-inflammatory actions, making these proprietary products effective against various allergic, autoimmune, dermatological, and musculoskeletal pain disorders.
 
From 2008 to 2012, the Hospital Authority Toxicology Reference Laboratory, the only tertiary referral centre for clinical toxicological analysis in Hong Kong, confirmed 61 cases of corticosteroid-adulterated pCMs. We report these cases to highlight the severity and danger of using such adulterated medications.
 
Methods
From 1 January 2008 to 31 December 2012, all cases referred to the Hospital Authority Toxicology Reference Laboratory that involved the use of pCMs, which were subsequently found to contain corticosteroids, were retrospectively reviewed.
 
Clinical data were obtained by reviewing the laboratory database as well as the patients’ electronic and, where necessary, paper health records. Demographic data, clinical presentation, medical history, drug history, laboratory investigations, radiological investigations, and analytical findings of the pCMs were reviewed. For the evaluation of adrenocortical function, due to the heterogeneity of patient population and the nature of the retrospective case series for the present study, both low-dose short synacthen test (LDSST) and short synacthen test (SST) have been used for the diagnosis of adrenal insufficiency. We adopted a cutoff of 550 nmol/L, which has been traditionally used for SST, and previously validated in the local population for LDSST.6
 
The presumed causal relationship between the clinical features or complications or both of the patients and the adulterants was evaluated based on the temporal sequence, the known adverse effects of the detected drugs, and the presence of underlying diseases.
 
The presence of corticosteroids was analysed qualitatively by liquid chromatography–tandem mass spectrometry (LC-MS/MS) with a linear ion trap instrument. The presence of other co-adulterants was analysed qualitatively by high-performance liquid chromatography with diode-array detection. Confirmations by LC-MS/MS or gas chromatography–mass spectrometry were performed as required.
 
This study was approved by the Hong Kong Hospital Authority Kowloon West Cluster Research Ethics Committee (approval number KW/EX-13-121). The Committee exempted the study group from obtaining patient consent because the presented data were anonymised, and the risk of identification was low.
 
Results
A total of 61 patients involving the use of 61 corticosteroid-adulterated pCMs were referred to the Hospital Authority Toxicology Reference Laboratory in Hong Kong. There were 30 men and 31 women, with an age range of 1 to 91 years (median, 65 years). Seven (11.5%) patients were younger than 18 years. The usage duration ranged from 3 days to 10 years, with a median of 4 months.
 
Most (n=47, 77.0%) patients obtained the corticosteroid-adulterated pCMs over-the-counter and 13 (21.3%) obtained the steroid-adulterated pCMs from Chinese medicine practitioners. The source for one case remained unknown. Among the 47 patients who obtained their pCMs over-the-counter, 38 (80.9%) obtained the pCMs in the Mainland China, seven (14.9%) obtained the pCMs in Hong Kong, and the remaining two patients (each accounting for 2.1%) obtained the pCMs from Taiwan and Malaysia. For patients who obtained their pCMs from Chinese medicine practitioners (n=13), the practitioners were located in Hong Kong in nine (69.2%), Mainland China in two (15.4%), and Macau in two (15.4%) cases.
 
The three most common indications for the use of pCMs were musculoskeletal pain (n=36; 59.0%), skin disorders such as eczema and psoriasis (n=13; 21.3%), and airway problems such as asthma, bronchiectasis, and chronic obstructive airway disease (n=8; 13.1%). The indications for all seven (11.5%) paediatric patients were for skin disorders.
 
Dexamethasone, present in 29 (47.5%) pCMs, and prednisone, present in 21 (34.4%) pCMs, were the most common corticosteroid adulterants among the pCMs submitted for analysis. Details of the corticosteroid adulteration are listed in Table 1.
 

Table 1. Corticosteroids used to adulterate the proprietary Chinese medicines (pCMs) taken by patients in this study (n=61)
 
Other than steroids, co-adulterants were also detected in 53 (86.9%) pCMs. The most common co-adulterants were non-steroidal anti-inflammatory drugs (NSAIDs; present in 33 [54.1%] pCMs) and histamine H1-receptor antagonists (present in 20 [32.8%] pCMs). The co-adulterants are listed in Table 2.
 

Table 2. Co-adulterants in the proprietary Chinese medicines taken by patients in this study (n=61)
 
Overall, 38 (62.3%) patients had one or more complications that were either attributable or potentially attributable to the use of exogenous corticosteroids: 18 (29.5%) were documented to have clinical Cushing’s syndrome; eight (13.1%) had endoscopic-proven gastritis or peptic ulcer disease, of whom six (9.8%) were proven to be Helicobacter pylori–negative; five (8.2%) had sepsis at presentation; three (4.9%) had hepatitis B exacerbation; and two (3.3%) had tuberculosis. Other clinical presentations included hepatitis C reactivation, transient diabetes that resolved after discontinuation of corticosteroids, and cataract occurring in a paediatric patient. Overall, 22 (36.1%) patients had adrenal function testing performed, and among them 17 (77.3%) had biochemically confirmed adrenal insufficiency.
 
For the subgroup in whom Cushing’s syndrome was not identified (n=43; 70.5%), LDSST/SST were performed in 11 (25.6%), and among those, seven (63.6%) had biochemically confirmed adrenal insufficiency.
 
Seven (11.5%) patients in this series required intensive care, and two (3.3%) died within 1 month of initial presentation. Among the patients who had consumed pCMs adulterated with corticosteroids and required intensive care unit admission, the clinical presentations of two patients may have been related to the use of corticosteroids, which are described below.
 
Case 1
The patient was a 67-year-old man who had a history of psoriasis, diabetes, hypertension, and chronic renal impairment. He presented in 2012 with fever, decreased urine output, and gastro-intestinal upset. He reported a 2-month history of using a pCM for psoriasis, and his skin condition dramatically improved. He was in shock on admission, with acute renal failure and respiratory distress. He was admitted to the intensive care unit where he stayed for 7 days. He required inotropic support and mechanical ventilation. Computed tomography revealed a large lung abscess and blood culture showed Pseudomonas species. During his hospitalisation, SST was performed, and the results were adequate (cortisol level of 944 nmol/L at 30 minutes after synacthen injection).
 
In the pCM submitted for analysis, prednisone acetate was detected, among other herbal markers. His condition improved with drainage of the abscess and prolonged intravenous antibiotics, including cefoperazone and sulbactam (1 g and later 2 g every 12 hours intravenously [IV] for 39 days) as well as imipenem and cilastatin (500 mg every 8 hours IV for 51 days). He was discharged after a long rehabilitation programme, 3 months after the initial admission.
 
Case 2
The patient was a 61-year-old man. He presented in 2009 with a history of asthma, and was a chronic smoker. He initially presented with low back pain after slipping and falling. He, however, was noted to have bilateral apical opacities on chest radiograph, and was found to have smear-positive, open pulmonary tuberculosis.
 
He was put on piperacillin (4 g every 6 hours IV), augmentin (1.2 g every 8 hours IV), clarithromycin (500 mg twice a day orally), isoniazid (300 mg daily orally), rifampicin (450 mg daily orally), and ethambutol (700 mg daily orally) initially while he was intubated, ventilated, and admitted to intensive care unit for respiratory failure. During his initial improvement in the intensive care unit, he reported the use of a kind of herbal powder, which he took to alleviate his airway condition. In the herbal powder, opium alkaloids (morphine, codeine), oxytetracycline, diazepam, clenbuterol, and prednisone were detected, among other herbal markers.
 
His condition later deteriorated and he went into respiratory failure and required intubation. Subsequently, he died of ventilator-associated Escherichia coli pneumonia. In this patient, adrenal function testing with LDSST/SST was not performed.
 
Discussion
Corticosteroids are notorious for causing side-effects such as Cushing’s syndrome, adrenal insufficiency, cataracts, peptic ulcer disease, osteoporosis, and decreased immune response, particularly when used for a protracted period of time in high doses. The latest Endocrine Society guidelines on the diagnosis of Cushing’s syndrome has also stressed obtaining a thorough history to exclude excessive exogenous glucocorticoid exposure leading to iatrogenic Cushing’s syndrome.7 The continuing emergence of corticosteroid-adulterated pCMs indicates that iatrogenic Cushing’s syndrome is a persistent problem with public health implications.
 
The incentive behind adulteration of pCMs is easily understandable. Most of the pCMs involved suggest that they are useful for the treatment of pain, skin problems, or respiratory ailments. Steroids, notwithstanding their many adverse effects, are effective therapy for pain, inflammatory disorders, allergic skin problems, and respiratory disorders such as asthma and chronic obstructive airway disease.
 
Although the side-effects of corticosteroids have been extensively described over the past century, many of these effects are multifactorial in their pathophysiology, and the effect of corticosteroids is difficult to quantitate in isolation. For example, Cushing’s syndrome and adrenal insufficiency as adverse drug reactions associated with the use of corticosteroid-adulterated pCMs are less likely to be disputed, for example H pylori–negative peptic ulcer disease can be due to stress, alcoholism, use of NSAIDs, and other concomitant illnesses.
 
Despite the presence of confounding factors, the adverse effects of corticosteroid use are suspected in many of the patients who use corticosteroid-containing pCMs: for example, the deep-seated infection in patient 1 and open tuberculosis in patient 2 could well be a result of immunosuppression due to the use of corticosteroids. For the paediatric patient with cataract on presentation, given that the patient had no other clinical features to suggest a metabolic or exogenous cause for the cataract, it is more likely that the presence of the cataract was due to the use of corticosteroids. The authors considered all cases of Cushing’s syndrome, adrenal insufficiency, and cataract occurring in paediatric patients to be attributable to the use of exogenous steroids. The prevalence of these conditions in this case series and other conditions that are potentially attributable to the use of exogenous corticosteroids are listed in Table 3.
 

Table 3. Complications attributable to exogenous corticosteroids in the proprietary Chinese medicines (pCMs) taken by patients in this study (n=61)
 
The presence of co-adulterants in steroid-adulterated pCMs appears to be the rule rather than the exception. It cannot be overstressed that co-adulterants present in pCMs are equally dangerous, even when compared with corticosteroids, for example, the presence of multiple NSAIDs together with steroids puts patients at high risk for complications (such as acute kidney injury and peptic ulcer disease), and opiates (such as codeine and morphine) present in pCMs indicated for respiratory conditions puts patients, who most likely have asthma or chronic obstructive airway disease, at high risk for respiratory depression and carbon dioxide narcosis. While effective at ameliorating symptoms, these drugs delay the clinical presentation and hence the opportunity to treat the disease at an early stage.
 
Many therapeutically irrelevant medications were also found in the pCMs. Examples include histamine H1-receptor antagonists found in adulterated pCMs that are intended to treat bone pain, and the presence of tadalafil (a drug used to treat erectile dysfunction) found in an adulterated pCM that is supposed to treat diabetes.
 
It is difficult to comprehend the reason behind the addition of such co-adulterants, although contamination due to poor pharmaceutical manufacturing practice is likely a contributing factor, if not the sole reason.
 
For the diagnosis of exogenous corticosteroid intake, maintaining a high index of suspicion is of utmost importance. The classical feature of Cushing’s syndrome was present in less than 30% of patients in this series. This indicates that a large proportion of cases would likely be missed if biochemical testing was only performed following demonstration of classical features of exogenous steroid intake. This experience indicates that it is often worthwhile testing patients who improve dramatically with the use of pCMs from dubious sources, especially when the treatment claims to be effective for treating pain, airway diseases, and childhood eczema. In these cases, a detailed drug history, and laboratory analysis of suspicious pCMs can help to confirm the diagnosis.
 
The management of these patients starts with termination of exposure to the adulterated pCMs, and treatment of the complications that have already occurred. It is prudent to provide corticosteroid replacement therapy pending dynamic function test for adrenal function. For patients with underlying inflammatory or autoimmune disorders such as gouty arthritis, psoriasis, and eczema, abrupt discontinuation of corticosteroid medications may trigger an exacerbation of disease. In these groups of patients, slow, gradual tapering should be considered.
 
A worrying observation in the present series is the occurrence of adrenal insufficiency, as well as the lack of investigations thereof. Patients who were exposed to pCMs adulterated with corticosteroids were clearly at risk of adrenal insufficiency due to suppression of adrenocorticotropic hormone secretion and the resultant adrenocortical atrophy.
 
In this series, LDSST/SST was only performed in 36.1% of the patients, and in those patients in whom the tests were performed, 77.3% were inadequate. It is clear that, among the patients who were not tested, some were likely to have undiagnosed adrenal insufficiency. As undiagnosed adrenal insufficiency carries a high risk of morbidity and mortality, the authors believe that LDSST should be performed on all patients who have significant exposure to pCMs adulterated with corticosteroids, even if they have no signs of Cushing’s syndrome.
 
While spot cortisol obtained in the morning is diagnostic if it is <100 nmol/L or >420 nmol/L as verified locally by Choi et al,6 we recommend LDSST as the test for adrenal function; LDSST (1 µg) is preferred over the standard (250 µg) SST because studies indicate that LDSST may be more sensitive in detecting partial adrenal insufficiency.8 9 The authors further recommend that a sensitive cutoff of 550 nmol/L at 30 minutes be used for the purpose of diagnosing adrenal insufficiency in this group of patients. Our recommendation for use of provocative adrenal testing and a sensitive cutoff level is based on the high probability of adrenal insufficiency in this group of patients.
 
Prevention is always better than cure, and this is especially true for public health issues. While analytical and clinical toxicologists are well aware of the situation, it is important to bring this matter to the other stakeholders in society, namely, policy-makers, frontline clinicians, and the general public, with communication tailored to the recipients.
 
For the general public, a simple rule can be taught: if it sounds too good to be true, it probably is; and this is especially so for pCMs that claim to treat certain conditions in which western-drug adulteration is common, for example, weight reduction and diabetes, as previously reported by our unit,10 11 and pain, respiratory conditions, and skin problems, as reported in the present study. It is prudent to consider brands and retailers that are trustworthy and, in case of doubt, patients should seek opinion from their primary care doctors.
 
For frontline clinicians, we wish to bring to their attention that this adulteration issue is common, recurring, and worthy of consideration, and that patients who have a history of using such corticosteroid-adulterated pCMs should have their adrenal function tested. It is also important that iatrogenic Cushing’s syndrome subsequent to the use of corticosteroids that are from a source of adulteration be reported to the relevant authorities. It is the opinion of the authors that liberal, but careful, reporting would contribute to better understanding of this problem, further the prosecution of those behind steroid-adulteration of pCMs, and help to ameliorate this public health problem.
 
As for legislation and policies, consideration of fraudulent prescription contrary to the expectation of patients, who would expect traditional Chinese medicine rather than the inappropriate use of corticosteroids seen in many of these cases, by the legislators, judiciary, and relevant councils and constituents, rather than focusing on the possession and unlawful sale of the relevant compounds, would be a great deterrent to these illicit practices.
 
Conclusion
The present case series is the largest series of patients using pCMs adulterated with corticosteroids. The continuing emergence of pCMs adulterated with western medications indicates a persistent threat to public health. It is thus important that the risk be communicated not only to the medical profession, but also to the public, and effective regulatory measures to combat these illicit pCMs should be in place.
 
References
1. Ahmed S, Riaz M. Quantitation of cortico-steroids as common adulterants in local drugs by HPLC. Chromatographia 1991;31:67-70. Crossref
2. Hon KL, Leung TF, Yau HC, Chan T. Paradoxical use of oral and topical steroids in steroid-phobic patients resorting to traditional Chinese medicines. World J Pediatr 2012;8:263-7. Crossref
3. Ku Y, Wen K, Ho L, Chang YS. Solid-phase extraction and high performance liquid chromatographic determination of steroids adulterated in traditional Chinese medicines. J Food Drug Anal 1999;7:123-30.
4. Morice A. Adulteration of homoeopathic remedies. Lancet 1987;329:635. Crossref
5. Savaliya AA, Prasad B, Raijada DK, Singh S. Detection and characterization of synthetic steroidal and non-steroidal anti-inflammatory drugs in Indian ayurvedic/herbal products using LC-MS/TOF. Drug Test Anal 2009;1:372-81. Crossref
6. Choi CH, Tiu SC, Shek CC, Choi KL, Chan FK, Kong PS. Use of the low-dose corticotropin stimulation test for the diagnosis of secondary adrenocortical insufficiency. Hong Kong Med J 2002;8:427-34.
7. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008;93:1526-40. Crossref
8. Broide J, Soferman R, Kivity S, et al. Low-dose adrenocorticotropin test reveals impaired adrenal function in patients taking inhaled corticosteroids. J Clin Endocrinol Metab 1995;80:1243-6. Crossref
9. Streeten DH, Anderson GH Jr, Bonaventura MM. The potential for serious consequences from misinterpreting normal responses to the rapid adrenocorticotropin test. J Clin Endocrinol Metab 1996;81:285-90. Crossref
10. Ching CK, Lam YH, Chan AY, Mak TW. Adulteration of herbal antidiabetic products with undeclared pharmaceuticals: a case series in Hong Kong. Br J Clin Pharmacol 2012;73:795-800. Crossref
11. Tang MH, Chen SP, Ng SW, Chan AY, Mak TW. Case series on a diversity of illicit weight-reducing agents: from the well known to the unexpected. Br J Clin Pharmacol 2011;71:250-3. Crossref

Is locking plate fixation a better option than casting for distal radius fracture in elderly people?

Hong Kong Med J 2015 Oct;21(5):407–10 | Epub 3 Jul 2015
DOI: 10.12809/hkmj144440
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE
Is locking plate fixation a better option than casting for distal radius fracture in elderly people?
LP Hung, MRCSEd1; YF Leung, FHKAM (Orthopaedic Surgery)1; WY Ip, MS, FHKAM (Orthopaedic Surgery)2; YL Lee, FHKAM (Orthopaedic Surgery)1
1 Department of Orthopaedics and Traumatology, Tseung Kwan O Hospital, Tseung Kwan O, Hong Kong
2 Department of Orthopaedics and Traumatology, Queen Mary Hospital, Pokfulam, Hong Kong
Corresponding author: Dr LP Hung (joshua.hlp@gmail.com)
 
 Full paper in PDF
Abstract
Objectives: To compare the outcomes of locking plate fixation versus casting for displaced distal radius fracture with unstable fracture pattern in active Chinese elderly people.
 
Design: Historical cohort study.
 
Setting: Orthopaedic ward and clinic at Tseung Kwan O Hospital, Hong Kong.
 
Patients: Between 1 May 2010 and 31 October 2013, 57 Chinese elderly people aged 61 to 80 years were treated either operatively with locking plate fixation (n=26) or conservatively with cast immobilisation (n=31) for unstable displaced distal radius fracture.
 
Main outcome measures: Clinical, radiological, and functional outcomes were assessed at 9 to 12 months after treatment.
 
Results: The functional outcome (based on the quick Disabilities of the Arm, Shoulder and Hand score) was significantly better in the locking plate fixation group than in the cast immobilisation group, while clinical and radiological outcomes were comparable with those in other similar studies.
 
Conclusions: Locking plate fixation resulted in better functional outcome for displaced distal radius fracture with unstable fracture pattern in active Chinese elderly people aged 61 to 80 years. Further prospective study with long-term follow-up is recommended.
 
 
New knowledge added by this study
  • In active Chinese elderly people aged 61 to 80 years, apart from better clinical and radiological outcomes than cast immobilisation, locking plate fixation for displaced distal radius fracture with unstable fracture pattern also improves functional outcome.
Implications for clinical practice or policy
  • We advise management of displaced distal radius fracture with unstable fracture pattern with locking plate fixation in active Chinese elderly people aged 61 to 80 years.
 
 
Introduction
Since the introduction of locking plate fixation, there has been a tendency to manage distal radius fracture in elderly people with plate fixation over cast fixation. In the US, the rate of plate fixation in elderly people increased 5-fold from 3% in 1996 to 16% by 2005.1
 
Only a few recent studies have compared conservative versus operative management of distal radius fracture in elderly people. Some authors have concluded that, while grip strength was significantly better after operation, functional outcome did not improve.2 3
 
In Hong Kong, Chinese elderly people tend to have poorer bone quality than western people of the same age.4 Life expectancies in Hong Kong, however, are one of the longest in the world, at 80.9 years for men and 86.6 years for women in 2013.5 Moreover, an increasing number of people older than 60 years are still working and therefore the expectation for clinical outcomes after distal radius fracture will be higher than that in the past. As a result, it is imperative to investigate whether locking plate fixation is a good option in treating distal radius fracture in Chinese elderly people. The aim of this study was to compare the outcomes between locking plate fixation and cast immobilisation as treatment for displaced distal radius fracture with unstable fracture pattern in Chinese elderly people.
 
Methods
The hospital database was reviewed for elderly patients with distal radius fracture from 1 May 2010 to 31 October 2013. The study was approved by the Research Ethics Committee of the Hospital Authority, Hong Kong.
 
The operation rate for distal radius fracture decreased with age and elderly patients (>70 years) tended to prefer conservative management. The oldest patient who underwent locking plate fixation was 77 years. As a result, our inclusion criteria were: Chinese patients, aged 61 to 80 years, having displaced distal radius fracture with unstable fracture pattern (defined as having at least three out of five criteria of: initial dorsal angulation >20°, initial shortening >5 mm, >50% dorsal comminution, intra-articular fracture, and ulnar fracture6), and completion of a rehabilitation programme after either operative or conservative management.
 
The exclusion criteria were: operative management other than 2.4- or 3.5-mm locking compression plates (eg K-wire fixation, non-locking plate fixation, or external fixation), open fracture or neurovascular deficits requiring immediate operative management, concomitant same-side upper limb injury (eg elbow dislocation, shoulder dislocation, or humeral fracture) that affected the overall functional outcome, and a history of medical illness (eg stroke or dementia) that hindered the rehabilitation results.
 
A total of 57 patients were identified. All of the patients were active, independent in activities of daily living, and otherwise healthy. The patients were admitted to orthopaedic ward at Tseung Kwan O Hospital, Hong Kong from the Accident and Emergency Department. Initial closed reduction of distal radius fracture under local anaesthesia and immobilisation with a backslab were performed. Options of conservative management with cast immobilisation or operative management with locking plate fixation and the associated risks and complications were discussed with the patients. The patient made the final decision with written consent for either treatment.
 
For patients who opted for cast immobilisation, the reduced fracture was immobilised with a short arm cast for 6 weeks, followed by mobilisation and strengthening exercises. For patients who opted for locking plate fixation, the operation was done under general anaesthesia with an arm tourniquet. The modified Henry approach was used and the fracture was fixed with a 2.4- or 3.5-mm locking compression plate, followed by immediate mobilisation and then strengthening exercises. All patients were reviewed regularly in the orthopaedic out-patient clinic, with serial radiographs and rehabilitation until they reached the maximal improvement in range of motion and grip strength.
 
At the beginning of this retrospective study, the majority of the patients had been discharged from the clinic. In view of the technical difficulty of calling back elderly patients for physical assessment, the clinical parameters recorded in the last section of the rehabilitation programme were collected and the last radiographs taken in the clinic were retrieved for measurement. The duration from treatment to the last section of the rehabilitation programme averaged 10 months (range, 6-12 months) and the duration from treatment to the last radiographs averaged 9 months (range, 6-14 months).
 
Clinical parameters, including range of motion and grip strength of both hands, were measured by physiotherapists and occupational therapists not involved in this study. Radiographic parameters—including volar tilt, radial inclination, radial length, and ulnar variance—were measured by one of the investigators.
 
Functional outcome was assessed using the quick Disabilities of the Arm, Shoulder and Hand questionnaire (DASH) score at a mean of 12 months (range, 6-24 months) after treatment; DASH score is a measure of a patient’s perceived disability. The quick DASH was chosen instead of the full DASH because the elderly patients generally had a low educational background, making completion of a comprehensive questionnaire difficult. The 11-question evaluation was completed by means of an interview in the clinic, a telephone interview, or answers to a mailed questionnaire. In summary, clinical, radiological, and functional outcomes were assessed at 9 to 12 months after treatment.
 
Data were assessed with different statistical tests. For categorical variables, Chi squared test (for sex and side of injury) and analysis of variance (for Orthopaedic Trauma Association classification) were used. For continuous variables, independent sample t test was used for normally distributed data (including grip strength and radiographic parameters) and Mann-Whitney U test for non-normally distributed data (including age, range of motion, and quick DASH score). A P value of ≤0.05 was considered statistically significant.
 
Results
Of 57 patients enrolled in this study, 26 were treated with locking plate fixation and 31 were treated with cast immobilisation. The number of patients in the cast immobilisation group was low because many of them were either excluded due to stable fracture pattern (n=31) or were lost to follow-up in the rehabilitation programme (n=49). There were no statistically significant differences in characteristics between the two groups (Table 1).
 

Table 1. Patient characteristics
 
Clinical outcomes are shown in Table 2. Grip strength was presented in the form of fraction of grip strength in the non-injured side as the denominator. The operative group did not achieve significantly better range of motion when compared with the cast immobilisation group, but grip strength was significantly better. Only one complication was documented, which was carpal tunnel syndrome after cast immobilisation. There was a statistically significant improvement in the radiographic parameters (except for radial length) after anatomical reduction in the operative group (Table 3). Regarding functional outcome, the operative group perceived significantly less disability than the cast immobilisation group (Table 4).
 

Table 2. Clinical outcomes
 

Table 3. Radiographic variables
 

Table 4. Functional outcome
 
Discussion
This study found that locking plate fixation for displaced, unstable distal radius fracture achieved significantly better grip strength, radiographic parameters, and functional outcome when compared with cast immobilisation in elderly people aged 61 to 80 years.
 
Whether anatomical reduction results in better functional outcome in elderly people with displaced distal radius fracture of unstable fracture pattern is still a controversial topic. Some authors have reported satisfactory functional outcome after cast immobilisation for displaced distal radius fracture in low-demand elderly people, regardless of the radiographic result.7 8 In the younger age-group, reconstruction of articular congruity of displaced intra-articular distal radius fractures by means of internal fixation and/or external fixation have long been known to improve functional outcome.9 Only a few studies in the literature have investigated this correlation in elderly patients.
 
One historical cohort study compared the outcomes of 90 patients older than 65 years who were treated either operatively with plate-and-screw fixation or external fixation, or conservatively with cast immobilisation.3 Grip strength and radiographic parameters were superior in the operative group, but there was no difference in other outcomes including DASH score.3 In one prospective randomised trial, 73 patients aged 65 years or older were randomised to receive open reduction internal fixation with volar locking plate or closed reduction and cast immobilisation.2 Similar results were reported. Lastly, in one diagnostic study examining 53 patients older than 55 years, operative intervention was found to have no influence on functional outcome.10
 
Our study has a discrepancy for functional outcome, although clinical and radiological outcomes were consistent with the previous studies. Our opinion is that the previous studies included some patients older than 80 years, for whom operation might not be suitable due to poorer premorbid status and lower functional demand than those aged 61 to 80 years. Therefore, the overall functional outcome did not improve after operation. We believe that locking plate fixation for active Chinese elderly people aged up to 80 years could achieve good clinical, radiological, and functional outcomes. However, the decision should not only be determined by chronological age but also be balanced with functional age and medical condition.
 
There are some limitations to this study. Since it is a non-randomised study, there might have been bias during discussion of the treatment options with the patients. Moreover, the two groups of patients were not blinded (and could not be blinded) to the therapists and investigator in assessing the clinical and radiological outcomes, which might have resulted in information bias. A substantial number of eligible patients defaulted the rehabilitation programme (four in the operative group, 49 in the cast immobilisation group) and were counted as loss to follow-up. Therefore, there was a possibility of self-selection bias among the remaining patients, who had better motivation for rehabilitation and regaining functions. Other confounding factors, such as differences in background characteristics and expectations of outcome, might have made the two groups of patients non-comparable. The follow-up duration was relatively short due to limitations of human resources. The times for assessing outcomes were not standardised due to the retrospective nature of this study. The sample size was relatively small due to the strict inclusion and exclusion criteria, especially after exclusion of patients older than 80 years, but this resulted in significantly better functional outcome. Lastly, the quick DASH score might have been affected by previous injury or degenerative arthritis of the same upper limb. Using a wrist-specific score such as the Mayo wrist score or Patient-Rated Wrist Evaluation, however, could not reflect how the whole upper limb compensates for the wrist function in elderly patients after distal radius fracture.
 
Conclusions
We advise operation with locking plate fixation for displaced distal radius fracture with unstable fracture pattern in active Chinese elderly patients aged 61 to 80 years. Nevertheless, further prospective study such as a randomised controlled trial is needed to resolve this controversy.
 
Acknowledgements
Special thanks to the many dedicated colleagues from the Physiotherapy and Occupational Therapy Departments of Tseung Kwan O Hospital.
 
References
1. Chung KC, Shauver MJ, Birkmeyer JD. Trends in the United States in the treatment of distal radial fractures in the elderly. J Bone Joint Surg Am 2009;91:1868-73. Crossref
2. Arora R, Lutz M, Deml C, Krappinger D, Haug L, Gabl M. A prospective randomized trial comparing nonoperative treatment with volar locking plate fixation for displaced and unstable distal radial fractures in patients sixty-five years of age and older. J Bone Joint Surg Am 2011;93:2146-53. Crossref
3. Egol KA, Walsh M, Romo-Cardoso S, Dorsky S, Paksima N. Distal radial fractures in the elderly: operative compared with nonoperative treatment. J Bone Joint Surg Am 2010;92:1851-7. Crossref
4. Lau EM, Lynn H, Woo J, Melton LJ 3rd. Areal and volumetric bone density in Hong Kong Chinese: a comparison with Caucasians living in the United States. Osteoporos Int 2003;14:583-8. Crossref
5. Stoker S, editor. Hong Kong 2013. Information Services Department, Hong Kong Special Administrative Region Government; 2013.
6. Lafontaine M, Hardy D, Delince P. Stability assessment of distal radius fractures. Injury 1989;20:208-10. Crossref
7. Anzarut A, Johnson JA, Rowe BH, Lambert RG, Blitz S, Majumdar SR. Radiologic and patient-reported functional outcomes in an elderly cohort with conservatively treated distal radius fractures. J Hand Surg Am 2004;29:1121-7. Crossref
8. Young BT, Rayan GM. Outcome following nonoperative treatment of displaced distal radius fractures in low-demand patients older than 60 years. J Hand Surg Am 2000;25:19-28. Crossref
9. Trumble TE, Schmitt SR, Vedder NB. Factors affecting functional outcome of displaced intra-articular distal radius fractures. J Hand Surg Am 1994;19:325-40. Crossref
10. Synn AJ, Makhni EC, Makhni MC, Rozental TD, Day CS. Distal radius fractures in older patients: is anatomic reduction necessary? Clin Orthop Relat Res 2009;467:1612-20. Crossref

Angiographic factors associated with haemorrhagic presentation of brain arteriovenous malformation in a Chinese paediatric population

Hong Kong Med J 2015 Oct;21(5):401–6 | Epub 31 Jul 2015
DOI: 10.12809/hkmj144339
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE
Angiographic factors associated with haemorrhagic presentation of brain arteriovenous malformation in a Chinese paediatric population
Elaine WS Fok, FRCR, FHKCR1; WL Poon, FRCR, FHKAM (Radiology)1; KS Tse, FRCR, FHKAM (Radiology)1; HY Lau, FRCR, FHKAM (Radiology)1; CH Chan, MB, BS, FRCR2; NY Pan#, FRCR, FHKAM (Radiology)2; HY Cho, FRCR, FHKAM (Radiology)2; TW Yeung, FRCR, FHKCR3; YC Wong, FRCR, FHKAM (Radiology)3; KW Leung, FRCR, FHKAM (Radiology)4; Jennifer LS Khoo, FRCR, FHKAM (Radiology)4; KW Tang, FRCR, FHKAM (Radiology)1
1 Department of Radiology and Imaging, Queen Elizabeth Hospital, Jordan, Hong Kong
2 Department of Radiology, Kwong Wah Hospital, Yaumatei, Hong Kong
3 Department of Radiology and Nuclear Medicine, Tuen Mun Hospital, Tuen Mun, Hong Kong
4 Department of Radiology, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong
# Currently at Department of Radiology, Princess Margaret Hospital, Laichikok, Hong Kong
Corresponding author: Dr Elaine WS Fok (elainefokws@gmail.com)
 
 Full paper in PDF
Abstract
Objective: To identify specific angiographic factors associated with haemorrhagic presentation of brain arteriovenous malformation in Chinese paediatric patients.
 
Design: Retrospective cross-sectional observational study.
 
Setting: Four locoregional tertiary neurosurgical centres in Hong Kong: Queen Elizabeth Hospital, Tuen Mun Hospital, Kwong Wah Hospital, and Pamela Youde Nethersole Eastern Hospital.
 
Patients: Patients aged 18 years or younger who underwent pretreatment digital subtraction angiography for brain arteriovenous malformation between 1 January 2005 and 31 July 2013 were included. Patients were divided into haemorrhagic and non-haemorrhagic groups based on the initial presentation. Pretreatment digital subtraction angiographies were independently reviewed by two experienced neuroradiologists.
 
Main outcome measures: The following parameters were evaluated for their association with haemorrhagic presentation by univariate and multivariate analyses: nidus location, nidus size, nidus morphology (diffuse or compact); origin and number of arterial feeders; venous drainage; number of draining veins; presence of aneurysms, venous varices, and venous stenosis.
 
Results: A total of 67 children and adolescents (28 male, 39 female) with a mean age of 12 years were included. Of them, 52 (78%) presented with haemorrhage. Arteriovenous malformation size (P=0.004) and morphology (P=0.05) were found to be associated with haemorrhagic presentation by univariate analysis. Small arteriovenous malformation nidus size and diffuse nidal morphology were identified as independent risk factors for haemorrhage by multivariate analysis.
 
Conclusion: Smaller arteriovenous malformation size and diffuse nidal morphology are angiographic factors independently associated with haemorrhagic presentation. Bleeding risk is important in determining the therapeutic approach (aggressive vs conservative) and timeframe, particularly in paediatric patients.
 
 
New knowledge added by this study
  • Studies on paediatric arteriovenous malformation (AVM) are scarce and mostly based in Caucasian populations. This multicentre study involving Chinese paediatric patients found that small AVM nidus size and diffuse nidal morphology are independent risk factors for haemorrhage.
Implications for clinical practice or policy
  • These two angiographic features associated with haemorrhagic presentation can help local clinicians to assess bleeding risk and determine the therapeutic approach (aggressive vs conservative) and treatment timeframe in paediatric patients with cerebral AVM.
 
 
Introduction
Brain arteriovenous malformation (AVM) is a vascular abnormality that consists of multiple fistulous connections between arteries and veins without a normal intervening capillary bed. It is believed to be congenital in nature, and commonly presents in early adulthood.1 The usual clinical presentations of brain AVM include haemorrhage, seizures, headache, and progressive neurological deficit. About 52% to 77% of patients with AVM have initial haemorrhagic presentation,2 3 4 which is also associated with poorer prognosis. Various studies evaluating the history of AVM record an annual haemorrhage rate of about 2% to 4%.1 5
 
Computed tomography (CT) is the initial screening tool for identifying haemorrhage and demonstrating the location of the AVM. Subsequent angiographic evaluation is required for virtually all patients with suspected AVM, with digital subtraction angiography (DSA) being accepted as the gold standard for characterisation and grading. The information obtained from the angiogram is crucial in treatment decision-making and prognostication.
 
Brain AVM is an important cause of haemorrhagic stroke in children.6 7 8 Studies in adults have identified radiological features that are associated with haemorrhagic presentation and future haemorrhage.9 10 11 Similar studies on AVM in children are, however, scarce and mostly based on studies from Europe and North America.12 13 Whether those angiographic features that predict haemorrhage in Caucasian children with AVM similarly predict haemorrhage in Chinese children with AVM is unknown.
 
The objective of this multicentre study was to determine specific angiographic factors associated with haemorrhagic presentation in brain AVM in the Hong Kong Chinese paediatric population, with a view to assisting clinical decision-making regarding the optimal timing and type of treatment.
 
Methods
This was a multicentre retrospective cross-sectional observational study. We included patients aged 18 years or younger (at time of diagnosis) who underwent pretreatment cerebral DSA for a principal diagnosis of brain AVM from 1 January 2005 to 31 July 2013.
 
Patients were recruited from four locoregional tertiary neurosurgical centres in Hong Kong: Queen Elizabeth Hospital, Tuen Mun Hospital, Kwong Wah Hospital, and Pamela Youde Nethersole Eastern Hospital. These are the major acute hospitals belonging to the catchment areas of Kowloon Central, New Territories West, Kowloon West, and Hong Kong East clusters, respectively, according to the geographical cluster designation by the Hospital Authority. These clusters serve approximately 4 million Hong Kong inhabitants. Consecutive patients were retrieved from the Clinical Data Analysis and Reporting System by entering the targeted date range (01 January 2005 to 31 July 2013, inclusive) and the following search parameters: age range (0-18 years); International Classification of Diseases, 9th Revision, diagnostic code (747.81, AVM); and procedure code (88.41, arteriography of cerebral arteries). Exclusion criteria included a lack of accessible pretreatment DSA, other angiographic diagnoses (eg spinal AVM, vein of Galen aneurysmal malformation, dural arteriovenous fistulae), and non-Chinese ethnicity based on data extracted from the electronic Patient Record (ePR) and radiology reports. Approval was obtained from the institutional ethics committee and patient consent was waived for this retrospective study.
 
Basic demographic factors, including age at presentation and clinical symptoms, were obtained from the ePR. Patients were divided into a haemorrhagic group (those presenting with intracranial haemorrhage) and a non-haemorrhagic group based on the CT of the brain at presentation. Pretreatment DSAs were independently reviewed by two experienced interventional neuroradiologists (with 7 years and 15 years of experience) who were blinded to the clinical presentation and provided with the same demographic data. Each brain AVM was evaluated for the following parameters: nidus location (deep: thalamus, basal ganglia, corpus callosum, or brain stem vs hemispheric: cerebral or cerebellar lobes), nidus size (small <3 cm vs medium 3-6 cm vs large >6 cm), nidus morphology (compact: little or no intervening brain within the nidus vs diffuse: presence of significant intervening brain within the nidus) [Figs 1 and 2], origin of arterial feeders (cortical vs deep), number of arterial feeders (single vs multiple), presence of either flow-related or intranidal aneurysms (yes vs no), venous drainage destination (superficial vs deep), number of draining veins (single vs multiple), presence of venous varices (yes vs no), and presence of venous stenosis (yes vs no). Any discrepancy in reviews between the two neuroradiologists was resolved by mutual consensus.
 

Figure 1. Left occipital arteriovenous malformation, supplied solely by the posterior circulation via branches of the left posterior cerebral artery (solid arrow) and with deep venous drainage into the sigmoid sinus (dashed arrow)
The nidus (arrowhead) is compact (nodular or mass-like) and small, measuring 1.5 cm
 

Figure 2. (a) Anterior and (b) lateral views of an arteriovenous malformation in the splenium of the corpus callosum, with arterial supply from the splenial branch of the left posterior cerebral artery (solid arrows) and deep venous drainage into the great vein of Galen (dashed arrow). The nidus (arrowheads) is small (measuring <3 cm) and diffuse in morphology
 
Association between the angiographic features and haemorrhage was analysed using Chi squared test and Fisher’s exact test for categorical variables, and Student’s t test for numerical variables in univariate analysis. Logistic regression (with “enter” strategy) was carried out for covariates with a P value of <0.15. All statistical calculations were performed using the Statistical Package for the Social Sciences (Windows version 16.0; SPSS Inc, Chicago [IL], US).
 
Results
The sample included 67 children and adolescents who were eligible for inclusion, of which 28 (42%) were boys and 39 (58%) were girls. Among the patients, 52 (78%) were in the haemorrhagic group and 15 (22%) were in the non-haemorrhagic group. The mean age at presentation was 12 years (range, 2-18 years). No significant differences in age (P=0.15) or sex (P=0.88) were demonstrated between the haemorrhagic and non-haemorrhagic groups. Of the 67 patients, one in the haemorrhagic group was known to have idiopathic thrombocytopenic purpura. The remaining 66 patients had no known medical condition predisposing to intracranial haemorrhage.
 
Of the 67 children, 25 (37%) presented with headache, 12 (18%) with hemiplegia, 11 (16%) with convulsion, seven (10%) with collapse, three (4%) with loss of consciousness, one (1%) with cerebellar signs, and eight (12%) had other features, including confusion, decreased responsiveness, numbness, and restricted ocular motion. There were more asymptomatic patients in the non-haemorrhagic group (Fig 3). Three patients, all of whom were in the non-haemorrhagic group, were diagnosed incidentally with AVM during examination for precocious puberty, scalp haemangioma, and suspected neurofibromatosis type 1.
 

Figure 3. Presenting symptoms in the haemorrhagic and non-haemorrhagic groups
 
The frequency of haemorrhage of the 67 patients as a function of angioarchitectural features is shown in Table 1.
 

Table 1. Frequency of haemorrhage as a function of angioarchitectural features in paediatric brain arteriovenous malformation (n=67)
 
After univariate analysis, AVM size (P=0.004) and morphology (P=0.05) were the two factors found to be significantly associated with haemorrhagic presentation (Table 2). After multivariate analysis, small AVM size and diffuse nidal morphology were identified as independent risk factors for haemorrhage (Table 3). The odds of haemorrhagic presentation in patients with small AVM was about 9 times that of patients with medium-size AVM, whereas the odds for haemorrhagic presentation in patients with diffuse nidal morphology was approximately 12 times that of patients with compact AVM morphology. Factors found not to be statistically significantly associated with haemorrhagic presentation included location, origin of arterial feeders, number of arterial feeders, presence of related aneurysms, venous drainage, number of draining veins, presence of venous varices, and presence of venous stenosis.
 

Table 2. Univariate analysis of the angiographic features associated with haemorrhagic presentation
 

Table 3. Multivariate analysis of the angiographic features associated with haemorrhagic presentation
 
Discussion
To date, DSA remains the gold standard for evaluating brain AVM owing to its superior temporal and spatial resolution, with the ability to provide dynamic information and allow accurate identification of supplying arteries and draining veins. Generally CT and magnetic resonance angiography studies do not provide important dynamic information on the arterial supply and venous drainage.
 
Current treatment approaches for brain AVM include microsurgical resection, stereotactic radiosurgery, embolisation, a combination of these methods, and watchful waiting. As each patient with AVM is different, there is no universal algorithm or protocol to be followed. The management of brain AVM is highly individualised, requiring careful consideration of multiple factors, including lesion-related factors (eg size, location, and configuration) which can be obtained from cerebral angiogram; patient-related factors (eg life expectancy, general health, and lifestyle); and treatment-related risks. Children with AVM pose a particular problem in that they have a high cumulative bleeding risk due to their young age at presentation, and any insult to the developing brain (either spontaneous haemorrhage or treatment-related morbidity) may have lifelong and profound sequelae.14
 
To the best of our knowledge, our study is the first to evaluate the risk factors for brain AVM haemorrhage in Chinese paediatric patients. Ethnic differences exist in the incidence and haemorrhagic risk of AVM, and data from western populations are not routinely generalisable to the Chinese population. A cohort study of 1028 adult patients with AVM in the US has established a role of ethnic differences in brain AVM, with excess incidence in Asians, blacks, and Hispanics compared with Caucasians.15 The analysis reveals a statistically significant increased risk for subsequent AVM haemorrhage among Hispanics compared with Caucasians, and an insignificant trend for blacks and Asians.
 
Studies in adults have identified specific angiographic features of AVM that are associated with haemorrhagic presentation and future bleeding, including small size (<3 cm), deep location, deep venous drainage, single draining vein, intranidal aneurysms, and associated venous ectasia or stenosis.5 14 16 17
 
Our study identified small AVM size (<3 cm) to be an independent risk factor for haemorrhage. Small AVM size has been identified as a risk factor for haemorrhage in multiple adult studies,5 18 19 20 which is also demonstrated in a western paediatric population.12 Although the underlying pathophysiological mechanism is uncertain, some authors have postulated a relationship between AVM size and feeding artery pressures.8 12 Spetzler et al17 found a higher rate of haemorrhagic presentation among smaller AVMs and noted that smaller AVMs were associated with higher feeding artery pressures at the time of surgical management as well as larger haematoma sizes.
 
Diffuse AVM nidal morphology was identified as another independent risk factor for haemorrhage in our study. Although a similar relationship between morphology and haemorrhage was not demonstrated in a Caucasian paediatric population,12 diffuse AVM nidal morphology has been demonstrated in adults as a risk factor for haemorrhage.21 The underlying pathophysiological mechanism is uncertain. More information is needed to determine whether diffuse morphology is associated with haemodynamic aberrations such as increased pressure in the feeding artery or draining vein to account for the observed increased risk of haemorrhage.
 
Our study has several limitations. First, owing to the retrospective nature of this study, AVM patients with poorer clinical presentation who are unfit for DSA were not included. Second, although this is a multicentre study, the sample size was relatively small owing to the small number of paediatric patients undergoing DSA for AVM. Our study has also underestimated the haemorrhagic proportion of the study population, thus any potential associations between other angiographic features with haemorrhagic presentation that are more subtle to detect would remain undetected. Third, variations exist in the quality and amount of available angiographic images, as well as in the level of experience of the angiographers among the various centres; these may affect the radiological interpretation. Presence of intracranial haemorrhage can be inferred from the pretreatment DSA due to presence of blood vessel displacement, which is an inherent limitation of this study. Fourth, as presence of haemorrhage may render an originally compact nidus into a diffuse morphology, this is a limiting factor in determining the association between diffuse morphology and haemorrhagic presentation. Fifth, we were unable to control for the timing of DSA following the onset of presentation owing to the retrospective nature of this study. Lastly, the extent to which certain angiographic risk factors existent at the time of haemorrhagic presentation can be extrapolated as predictors of future haemorrhage in AVM is controversial. In other words, factors present at the time of presentation are not necessarily accurate predictors of future risk. For instance, several adult-based studies have identified a higher incidence of haemorrhagic presentation in small AVMs, but failed to find an association between AVM size and future haemorrhage.22 23
 
Unlike in adults, large-scale prospective studies aiming to study the natural course of paediatric AVMs are unlikely to take place owing to the relatively strong argument against conservative treatment, according to the prevailing view that ruptured paediatric AVMs should be treated aggressively owing to the significant risk of recurrent haemorrhage and subsequent morbidity and mortality.12 24 The recent controversial ARUBA (A Randomised trial of Unruptured Brain Arteriovenous malformations) in adults has demonstrated that medical management alone is superior in patients with unruptured AVMs,25 but there is insufficient scientific evidence to justify extrapolation of these results to a paediatric population. Moreover, while it has been shown that paediatric AVMs with haemorrhagic presentation do not necessarily have a higher risk of future haemorrhage nor a higher annualised bleeding risk than adults,26 their greater cumulative risk given their longer remaining life expectancy may be an argument for more aggressive treatment of paediatric AVMs. Choice of treatment for a small, unruptured paediatric AVM is therefore complex and should involve thorough consideration of other angioarchitectural factors on a case-by-case basis.
 
Despite these limitations, our study provides useful initial insights to the angiographic features associated with haemorrhagic presentation of AVMs in Chinese paediatric patients from multiple locoregional neurosurgical centres. These features may assist in stratifying risk of haemorrhage and assign priority for intervention, although data from future larger-scale studies may be needed before such features can be robustly applied as haemorrhagic risk predictors in Chinese children with AVM.
 
References
1. Ondra SL, Troupp H, George ED, Schwab K. The natural history of symptomatic arteriovenous malformations of the brain: a 24-year follow-up assessment. J Neurosurg 1990;73:387-91. Crossref
2. Choi JH, Mohr JP. Brain arteriovenous malformations in adults. Lancet Neurol 2005;4:299-308. Crossref
3. Freidlander RM. Clinical practice. Arteriovenous malformations of the brain. N Engl J Med 2007;356:2704-12. Crossref
4. Hofmeister C, Stapf C, Hartmann A, et al. Demographic, morphological, and clinical characteristics of 1289 patients with brain arteriovenous malformation. Stroke 2000;31:1307-10. Crossref
5. Graf CJ, Perret GE, Torner JC. Bleeding from cerebral arteriovenous malformations as part of their clinical history. J Neurosurg 1983;58:331-7. Crossref
6. Jordan LC, Hillis AE. Hemorrhagic stroke in children. Pediatr Neurol 2007;36:73-80. Crossref
7. Meyer-Heim AD, Boltshauser E. Spontaneous intracranial haemorrhage in children: aetiology, presentation and outcome. Brain Dev 2003;25:416-21. Crossref
8. Giroud M, Lemesle M, Madinier G, Manceau E, Osseby GV, Dumas R. Stroke in children under 16 years of age. Clinical and etiological difference with adults. Acta Neurol Scand 1997;96:401-6. Crossref
9. Stefani MA, Porter PJ, terBrugge KG, Montanera W, Willinsky RA, Wallace MC. Angioarchitectural factors present in brain arteriovenous malformations associated with hemorrhagic presentation. Stroke 2002;33:920-4. Crossref
10. Turjman F, Massoud TF, Viñuela F, Sayre JW, Guglielmi G, Duckwiler G. Correlation of the angioarchitectural features of cerebral arteriovenous malformations with clinical presentation of hemorrhage. Neurosurgery 1995;37:856-60; discussion 860-2. Crossref
11. Nataf F, Meder JF, Roux FX, et al. Angioarchitecture associated with haemorrhage in cerebral arteriovenous malformations: a prognostic statistical model. Neuroradiology 1997;39:52-8. Crossref
12. Ellis MJ, Armstrong D, Vachhrajani S, et al. Angioarchitectural features associated with hemorrhagic presentation in pediatric cerebral arteriovenous malformations. J Neurointerv Surg 2013;5:191-5. Crossref
13. Di Rocco C, Tamburrini G, Rollo M. Cerebral arteriovenous malformations in children. Acta Neurochir (Wien) 2000;142:145-56; discussion 156-8. Crossref
14. Fleetwood IG, Steinberg GK. Arteriovenous malformations. Lancet 2002;359:863-73. Crossref
15. Kim H, Stephen S, McChulloch, et al. Racial/ethnic differences in longitudinal risk of intracranial hemorrhage in brain arteriovenous malformation patients. Stroke 2007;38:2430-7. Crossref
16. Farhat HI. Cerebral arteriovenous malformations. Dis Mon 2011;57:625-37. Crossref
17. Spetzler RF, Hargraves RW, McCormick PW, Zabramski JM, Flom RA, Zimmerman RS. Relationship of perfusion pressure and size to risk of hemorrhage from arteriovenous malformations. J Neurosurg 1992;76:918-23. Crossref
18. Crawford PM, West CR, Chadwick DW, Shaw MD. Arteriovenous malformations of the brain: natural history in unoperated patients. J Neurol Neurosurg Psychiatry 1986;49:1-10. Crossref
19. Guidetti B, Delitala A. Intracranial arteriovenous malformations. Conservative and surgical treatment. J Neurosurg 1980;53:149-52. Crossref
20. Itoyama Y, Uemura S, Ushio Y, et al. Natural course of unoperated intracranial arteriovenous malformations: study of 50 cases. J Neurosurg 1989;71:805-9. Crossref
21. Pollock BE, Flickinger JC, Lunsford LD, Bissonette DJ, Kondziolka D. Factors that predict the bleeding risk of cerebral arteriovenous malformations. Stroke 1996;27:1-6. Crossref
22. da Costa L, Wallace MC, Ter Brugge KG, O’Kelly C, Willinsky RA, Tymianski M. The natural history and predictive features of hemorrhage from brain arteriovenous malformations. Stroke 2009;40:100-5. Crossref
23. Stapf C, Mast H, Sciacca RR, et al. Predictors of hemorrhage in patients with untreated brain arteriovenous malformation. Neurology 2006;66:1350-5. Crossref
24. Blauwblomme T, Bourgeois M, Meyer P, et al. Long-term outcome of 106 consecutive pediatric ruptured brain arteriovenous malformations after combined treatment. Stroke 2014;45:1664-71. Crossref
25. Mohr JP, Parides MK, Stapf C, et al. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial. Lancet 2014;383:614-21. Crossref
26. Fullerton HJ, Achrol AS, Johnston SC, et al. Long-term hemorrhage risk in children versus adults with brain arteriovenous malformations. Stroke 2005;36:2099-104. Crossref

Clinical value of transforaminal epidural steroid injection in lumbar radiculopathy

Hong Kong Med J 2015 Oct;21(5):394–400 | Epub 14 Aug 2015
DOI: 10.12809/hkmj144310
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE
Clinical value of transforaminal epidural steroid injection in lumbar radiculopathy
SM Leung, MMed(Pain Mgt)(Syd), FHKAM (Orthopaedic Surgery)1,2; WW Chau, MSc (Epi & Biostat)3; SW Law, MOM, FHKAM (Orthopaedic Surgery)1,2,4; KY Fung, MB, BS, FHKAM (Orthopaedic Surgery)1,2,4
1 Department of Orthopaedics and Traumatology, Alice Ho Miu Ling Nethersole Hospital, Tai Po, Hong Kong
2 Department of Orthopaedic Rehabilitation, Tai Po Hospital, Tai Po, Hong Kong
3 Department of Orthopaedics and Traumatology, The Chinese University of Hong Kong, Shatin, Hong Kong
4 Department of Orthopaedics and Traumatology, Prince of Wales Hospital, Shatin, Hong Kong
Corresponding author: Dr SM Leung (lsm457@ha.org.hk)
 
 Full paper in PDF
 
Abstract
Objectives: To identify the diagnostic, therapeutic, and prognostic values of transforaminal epidural steroid injection as interventional rehabilitation for lumbar radiculopathy.
 
Design: Case series.
 
Setting: Regional hospital, Hong Kong.
 
Patients: A total of 232 Chinese patients with lumbar radiculopathy attributed to disc herniation or spinal stenosis received transforaminal epidural steroid injection between 1 January 2007 and 31 December 2011.
 
Interventions: Transforaminal epidural steroid injection.
 
Main outcome measures: Patients’ immediate response, response duration, proportion of patients requiring surgery, and risk factors affecting the responses to transforaminal epidural steroid injection for lumbar radiculopathy.
 
Results: Of the 232 patients, 218 (94.0%) had a single level of radiculopathy and 14 (6.0%) had multiple levels. L5 was the most commonly affected level. The immediate response rate to transforaminal epidural steroid injection was 80.2% in 186 patients with clinically diagnosed lumbar radiculopathy and magnetic resonance imaging of the lumbar spine suggesting nerve root compression. Of patients with single-level radiculopathy and multiple-level radiculopathy, 175 (80.3%) and 11 (78.6%) expressed an immediate response to transforaminal epidural steroid injection, respectively. The analgesic effect lasted for 1 to <3 weeks in 35 (15.1%) patients, for 3 to 12 weeks in 37 (15.9%) patients, and for more than 12 weeks in 92 (39.7%) patients. Of the 232 patients, 106 (45.7%) were offered surgery, with 65 (61.3%) undergoing operation, and with 42 (64.6%) requiring spinal fusion in addition to decompression surgery. Symptom chronicity was associated with poor immediate response to transforaminal epidural steroid injection, but not with duration of pain reduction. Poor response to transforaminal epidural steroid injection was not associated with a preceding industrial injury.
 
Conclusions: The immediate response to transforaminal epidural steroid injection was approximately 80%. Transforaminal epidural steroid injection is a useful diagnostic, prognostic, and short-term therapeutic tool for lumbar radiculopathy. Although transforaminal epidural steroid injection cannot alter the need for surgery in the long term, it is a reasonably safe procedure to provide short-term pain relief and as a preoperative assessment tool.
 
 
New knowledge added by this study
  • This is the first local study to evaluate the clinical value of transforaminal epidural steroid injection (TFESI) as an alternative to or antecedent procedure for definitive spinal surgery.
Implications for clinical practice or policy
  • TFESI is a reasonably safe diagnostic and therapeutic option as interventional rehabilitation for lumbar radiculopathy.
 
 
Introduction
Lumbar radiculopathy can be well-managed conservatively in the primary health care setting, but many patients with persistent disabling radicular pain need attention in a specialty clinic. The majority of patients first attend a public specialty clinic in Hong Kong with pain chronicity of more than 12 months, as they have had no significant clinical response to conservative management in primary health care, private medical specialists, traditional Chinese medicine, or alternative medicine, and they anticipate a long waiting time in a public hospital. Epidural steroid injection is commonly practised by orthopaedic surgeons, neurosurgeons, rehabilitation specialists, pain specialists, and interventional radiologists worldwide. The thresholds for offering epidural steroid injection by clinicians and acceptance by patients are variable, however.
 
Transforaminal epidural steroid injection (TFESI) is one of the more common approaches of epidural steroid injection, along with the interlaminar and caudal approaches. The technique is target-specific and the best route for delivering medication to the ventral epidural space (Fig 1a) and dorsal root ganglion,1 where most pathological changes occur.2 3 The least amount of drug with a relatively higher drug concentration is required to reach the primary site of pathology compared with interlaminar and caudal epidural steroid injections.4
 

Figure 1. Epidural flow of water-soluble non-ionic contrast to reach ventral epidural space as shown in (a) lateral and (b) anteroposterior views; (c) the L4 exiting nerve root is well-outlined by the contrast (arrows)
 
Transforaminal epidural steroid injection is a useful procedure for lumbar radiculopathy.5 The technique provides neural blockade to anaesthetise the target nerve root for diagnostic purposes, and interrupts nociceptive input and self-sustaining activity of the neurons. Steroid provides anti-inflammatory effect (inhibition of pro-inflammatory synthesis and release of mediators) and produces longer-term pain relief, primarily for radiculopathy. The prognostic value of TFESI for surgical outcomes has been reported, with better surgical outcome in TFESI responders with chronic lumbar radiculopathy than in non-responders.6 The technique, however, does not alter the ultimate need for surgery.7
 
Underlying sepsis, malignant disease, and coagulopathy are considered to be contra-indications for spinal injection. The perceived benefits and threshold of offering TFESI as an adjunct to conservative treatment for patients with lumbar radiculopathy attributed to disc herniation or spinal stenosis are variable among orthopaedic surgeons, rehabilitation specialists, and pain specialists. The objective of this study was to identify the diagnostic, therapeutic, and prognostic values of TFESI for lumbar radiculopathy in Chinese patients in Hong Kong.
 
Methods
Procedural steps for transforaminal epidural steroid injection
Patients were placed in the prone position on a radiolucent operating table. A 22-G spinal needle was inserted into the target neuroforamen with fluoroscopic image guidance. The target nerve root and its epidural space were outlined by water-soluble non-ionic contrast, ensuring epidural flow of contrast with no intravascular, intradural, or subcutaneous infiltration (Fig 1). A mixture of 1-mL methylprednisolone acetate 40 mg and 1-mL bupivacaine 0.5% was injected. Finally, the intact spinal needle was removed.
 
Data collection and analysis
All patients who received TFESI for lumbar radiculopathy at Alice Ho Miu Ling Nethersole Hospital, Hong Kong from 1 January 2007 to 31 December 2011 (5 years) were identified by the electronic medical record system in the hospital. Retrospective review of all the medical records identified patients with numeric pain rating scale score (NPRS) of 4 to 7 (out of 10) who took less than three types of analgesics for at least 8 weeks as conservative treatment, or patients with persistent disabling pain with NPRS of >7 despite taking more than three types of analgesics for at least 1 week as conservative treatment. Patients with NPRS of <4, missing record of post-procedure response, or who had received previous lumbar spinal injection and lumbar spinal surgery were excluded.
 
The first part of the study assessed the response rate to diagnostic block by the local anaesthetic effect of TFESI for all patients with a clinical diagnosis of lumbar radiculopathy attributed to disc herniation or spinal stenosis, with compatible magnetic resonance imaging (MRI) findings of laterality and affected level. The second part of the study assessed the therapeutic and prognostic values of the steroid effect of TFESI as an adjunct to conservative treatment prior to assessment of surgical need.
 
The threshold for surgery for patients with lumbar radiculopathy attributed to prolapsed intervertebral disc (PID) and spinal stenosis, in general, considered factors of disabling pain resulting in inability to meet activity demands, clinical MRI findings compatible for laterality and site of compression, and medical fitness for general anaesthesia and major spinal surgery. Spinal fusion might be considered for patients with concomitant spondylolisthesis with instability or anticipated instability resulting from optimal surgical decompression in the lateral recess or foraminal stenosis and concomitant disabling discogenic low back pain that has not responded to conservative treatment.
 
An immediate response on the procedure day was considered to have a positive diagnostic value. Patients who reported pain reduction of greater than 50% at the first follow-up visit 4 weeks after TFESI were considered to have a positive therapeutic response to the steroid effects. The response duration, proportion of patients finally requiring surgery, whether decompression alone or spinal fusion besides decompression was needed, and risk factors that affected the response to TFESI were retrospectively reviewed.
 
Comparisons were carried out for all patients, as well as patients with PID or spinal stenosis only. Associations between responses to TFESI and risk factors for symptom chronicity and industrial injury were done by Fisher’s exact test or Mann-Whitney U test where appropriate. Non-parametric tests were done because some continuous variables were not normally distributed. The Statistical Package for the Social Sciences Windows version 20.0 (SPSS Inc, Chicago [IL], US) was used for all statistical analysis. A two-sided P value of ≤0.05 was considered statistically significant.
 
Results
A total of 241 patients were recruited into this study. Nine patients were excluded for the following reasons: TFESI responders with PID and L5 radiculopathy had had symptom duration of less than 1 week and TFESI was not considered to be adequate first-line conservative treatment (n=3); and TFESI immediate responders did not return for first follow-up (n=2) and TFESI responses were not documented in the medical records (n=4) so the response durations for these six patients could not be verified. Therefore, the total number of eligible participants was 232 (110 men and 122 women; mean age ± standard deviation [SD]: 55.6 ± 14.3 years). The mean age of patients with PID and spinal stenosis were 37.4 ± 7.5 years and 60.3 ± 11.7 years, respectively. The symptom chronicity ranged from 8 days to 23 years with a median of 12.0 months, as well as 25th, 75th, and 90th percentiles being 7.0, 36.0, and 60.0 months, respectively in patients with lumbar radiculopathy. No statistically significant difference (P=0.402) in symptom chronicity between the PID and spinal stenosis groups was noted (median [interquartile range] duration: PID group 12.0 [8.0-24.0] months vs spinal stenosis group 12.0 [6.0-36.0] months). Fewer PID patients (n=48; 20.7%) needed TFESI than spinal stenosis patients (n=184; 79.3%) with lumbar radiculopathy in the study period.
 
L5 was the most commonly affected level of radiculopathy (n=150; 64.7%) regardless of whether a patient had single or multiple levels or underlying pathology of PID or spinal stenosis (Table 1). Therefore, post-ganglionic block of the L5 nerve root by L5-S1 TFESI was most commonly done.
 

Table 1. Level of radiculopathy
 
Diagnostic value of transforaminal epidural steroid injection
The immediate response rate to TFESI was 80.2% in 186 patients with clinically diagnosed lumbar radiculopathy and MRI of the lumbar spine suggesting nerve root compression. Overall, 218 (94.0%) patients were affected at a single level and 14 (6.0%) were affected at multiple levels (Table 1). The immediate response rates to TFESI were 175 (80.3%) in the single-level radiculopathy group and 11 (78.6%) in the multiple-level radiculopathy group. There was no statistically significant difference in the immediate responder rate between patients with PID or spinal stenosis (P=0.877). No complications were reported.
 
Predictive value for final need for surgery
The final need for surgery of TFESI immediate responders was noted in 10/39 (25.6%) patients in the PID group and 43/147 (29.3%) patients in the spinal stenosis group (Table 2).
 

Table 2. Proportion of patients requiring surgery in different response and pathology groups (n=232)
 
Of the 232 patients, 106 (45.7%) were offered surgery, of whom 65 (61.3%) accepted surgery. The mean time from TFESI to uptake of surgery was 7.9 months. There was a statistically significant shorter median time to definitive surgery in the PID group (10.0 months) than in the spinal stenosis group (19.2 months) [P<0.01]. This reflects the fact that PID patients with failed first-line conservative treatment who needed TFESI for lumbar radiculopathy were likely to accept surgery earlier than patients with spinal stenosis. Patients with PID were younger (mean age, 37.0 years) than spinal stenosis patients (mean age, 59.2 years) undergoing surgery, which might be related to less daily activity demand, higher perceived operative risks, and older people being more psychologically reluctant to undergo surgery.
 
Of the 65 surgical patients, 23 (35.4%) underwent decompression surgery alone, with a mean time from TFESI of 5.45 months (SD, 5.25 months; median, 3.6 months; range, 8 days to 17.63 months). The remaining 42 (64.6%) patients required spinal fusion in addition to decompression surgery, with a mean time from TFESI of 9.37 months (SD, 7.23 months; median, 7.22 months; range, 14 days to 25.33 months). The difference in time to surgery for these two groups was statistically significant (P=0.012). More patients with a short-term response to TFESI underwent surgery (Fig 2) and TFESI was commonly used as a preoperative assessment tool.
 

Figure 2. Response duration according to the final surgery rate
 
Association between response to transforaminal epidural steroid injection and duration of pain relief
The analgesic effect of TFESI lasted for less than 1 week (poor response) in 68 (29.3%) patients, for 1 to <3 weeks (short term) in 35 (15.1%) patients, for 3 to 12 weeks (intermediate) in 37 (15.9%) patients, and for more than 12 weeks (long term) in 92 (39.7%) patients. More patients with spinal stenosis underwent surgery in the short-term pain reduction group (1-<3 weeks), and the association between response to TFESI and surgery for spinal stenosis was significant (P<0.01), but no significance was noted for PID patients (P=0.067) [Table 3].
 

Table 3. Association between response to TFESI, pain relief duration, and final surgery
 
Association between poor response to transforaminal epidural steroid injection and chronicity of symptoms and industrial injury
Poor response (mean, 34.3 ± 50.9 months) to TFESI (no immediate response and pain reduction duration of <1 week) was significantly associated with chronicity of symptoms (vs 23.1 ± 28.3 months in patients with positive response) [P=0.047]. Pain reduction duration had no significant association with symptom chronicity for pain reduction of less than 3 months and 3 months or more in the PID (P=0.225) and spinal stenosis (P=0.250) groups (Table 4).
 

Table 4. Association between symptom chronicity and TFESI response pattern in PID and spinal stenosis groups
 
There was no association between response to TFESI and industrial injury for all eligible patients (P=0.138) and no significant association according to the underlying cause of PID (P=0.359) and spinal stenosis (P=0.469) [Table 5].
 

Table 5. Association between the response to TFESI and industrial injury
 
Discussion
The decision by clinicians to offer a treatment and by patients to accept it is often determined by the perceived benefits, likelihood of success, and the cost (eg risks, time cost, labour cost, and financial cost) of the treatment. In real-world clinical practice, there are large variations in the perceived benefits and likelihood of success of TFESI among clinicians despite its relatively fewer risks and lower cost than spinal surgery. This retrospective case review attempted to show real-life practice in a local unit during a fixed period to evaluate the diagnostic, prognostic, and therapeutic values.
 
Lumbar radiculopathy can be well managed conservatively, but many patients still have persistent disabling radicular pain needing attention in a specialty clinic. Most patients first attended a public specialty clinic with chronicity of more than 12 months because of no significant clinical response to conservative management. Most patients receiving spinal injection have had a lengthy period of trying various modalities of conservative treatments, reflected by a median time of 12 months of symptom chronicity for patients receiving TFESI.
 
The threshold of offering TFESI as a diagnostic tool and/or a therapeutic adjunct to conservative treatment is variable among clinicians, reflected by the wide variation of symptom chronicity from 8 days to 23 years among the 232 patients receiving TFESI in this study. Other factors affecting the threshold of offering TFESI include severe neuropathic pain not controlled by more than three kinds of high-dose analgesic combinations that act on different pain pathways, and the diagnostic need for doubtful clinical MRI correlations, especially among patients contemplating surgery or who are undergoing a pain relief procedure while waiting for definitive surgery in a local public hospital.
 
L5 radiculopathy was the most commonly affected level, regardless of whether single or multiple levels were affected, in patients with PID or spinal stenosis in this series. Post-ganglionic block of the L5 nerve root by L5-S1 TFESI was commonly performed.
 
The clinical presentation of lumbar radiculopathy without significant neurocompression on MRI scan might be related to chemical irritation by local inflammation from an annular tear rather than significant mechanical compression to the nerve root. These patients can be treated conservatively or by TFESI. Sometimes, dynamic spinal stenosis as a result of an incompetent degenerative disc with loss of disc height and its support of the spinal load or spondylolisthesis with spinal instability might be worsened in the upright posture, and might not be well demonstrated in MRI of the lumbar spine taken in the supine position. The technique of TFESI is a target-specific diagnostic tool to the affected nerve root. The procedure increases the diagnostic confidence of clinical lumbar radiculopathy before both the patient and surgeon commit to more invasive surgical interventions, especially for a clinical diagnosis of lumbar radiculopathy with doubtful correlation to MRI findings.
 
As demonstrated in this study, TFESI is a target-specific diagnostic tool with up to 80% immediate response for lumbar radiculopathy. An immediate pain response is expected to be related to the local anaesthetic effect acting on the affected nerve root and its dorsal root ganglion, washout effects of injectates on the chemical irritation of the local inflammatory mediators or, occasionally, on the loose extraforaminal sequestrated disc material. The pain reduction duration is expected to be related to the anti-inflammatory effect of steroid. However, it is not expected to change the anatomy, which is due to significant mechanical compression to the affected nerve root. This often needs to be managed surgically so the results of TFESI cannot alter the final need for surgery.
 
Patients commonly enquire whether TFESI is an alternative or antecedent procedure to definitive spinal surgery. There is strong evidence to support the use of lumbar TFESI in patients with acute-to-subacute unilateral radicular pain caused by herniated nucleus pulposus or spinal stenosis.8 9 Nonetheless, there is no relief of pain in patients with chronic failed back surgery syndrome and documented fibrosis of the nerves.2
 
Chronic pain and industrial injury generally have less favourable responses to many treatments. This study showed significant differences in symptom chronicity and poor immediate response rate to TFESI (P=0.047), but failed to show a statistically significant association between symptom chronicity and TFESI response duration in lumbar radiculopathy attributed to PID (P=0.225) or spinal stenosis (P=0.250) [Table 4]. The diagnostic value of TFESI is more prominent than the therapeutic value in chronic lumbar radiculopathy in both the PID and spinal stenosis groups. A preceding history of industrial injury was not associated with TFESI response difference in lumbar radiculopathy attributed to PID (P=0.359) or spinal stenosis (P=0.469) [Table 5]. Therefore, industrial injury is not a limitation in consideration of offering TFESI.
 
As demonstrated in this study, most patients (80.2%) with lumbar radiculopathy attributed to PID or spinal stenosis were managed by non-surgical treatments. Less than one-half of patients (45.7%, 106/232) were offered surgery and only 65 (61.3%) of 106 patients accepted surgery. The technique of TFESI is a reasonable therapeutic trial as an alternative procedure, especially in older frail patients with multiple medical co-morbidities and high peri-operative risks. There were no complications related to the injected medication or needle placement in this series. The technique is a reasonable, safe procedure provided that there is radiographic verification of epidural flow of water-soluble non-ionic contrast with no intravascular, intradural, or subcutaneous infiltration.10
 
Nonetheless, there was still a sizable proportion of patients (45.6%) who underwent surgery for persistent disabling pain when there was clinical MRI–compatible neurocompression. The mean time to surgery from TFESI was 7.9 months. The technique of TFESI helps give time for better quality of pain relief, but it does not affect the ultimate need of surgery, especially for patients who require spinal fusion for spinal instability, either anticipated preoperatively or after surgical decompression. Among the 186 immediate responders, up to 10 (25.6%) of 39 in the PID group and 43 (29.3%) of 147 in the spinal stenosis group required surgery (Table 2). Although TFESI is unable to correct structural pathology, it is a reasonable antecedent procedure to definitive surgical decompression. The technique provides 80.2% immediate response, thus increasing the diagnostic confidence and providing short-term pain reduction enabling patients to remain active with reduced analgesic consumption and associated systemic side-effects while awaiting definitive spinal surgery. In addition, TFESI provides a better quality of pain relief to help maintain functional independence and to reduce hospital stay. The procedure has a reasonably good diagnostic utility and cost-effectiveness in patients considered for lumbar decompression surgery.11
 
A limitation of this retrospective case review is that the results were based on subjective self-reported pain response, because a more objective functional assessment was not always available in the patients’ medical records. A prospective controlled trial is warranted in the future to obtain more comprehensive information about the change in patients’ daily function in relation to pain reduction.
 
Conclusions
L5 radiculopathy is the most commonly affected level of lumbar radiculopathy. The local anaesthetic effect of TFESI is a useful diagnostic adjunct, with up to 80.2% immediate response in patients with lumbar radiculopathy. Although TFESI cannot alter the need for spinal surgery, it is a reasonably safe procedure to provide short-term pain relief to allow patients to stay active with reduced analgesic consumption and associated systemic side-effects while awaiting surgery.
 
Declaration
The authors do not have any conflicts of interest to declare.
 
References
1. Bhargava A, DePalma MJ, Ludwig S, Gelb D, Slipman CW. Injection therapy for lumbar radiculopathy. Curr Opin Orthop 2005;16:152-7. Crossref
2. Rho ME, Tang CT. The efficacy of lumbar epidural steroid injections: transforaminal, interlaminar, and caudal approaches. Phys Med Rehabil Clin N Am 2011;22:139-48. Crossref
3. Roberts ST, Willick SE, Rho ME, Rittenberg JD. Efficacy of lumbosacral transforaminal epidural steroid injections: a systematic review. PM R 2009;1:657-68. Crossref
4. Abdi S, Datta S, Trescot AM, et al. Epidural steroids in the management of chronic spinal pain: a systematic review. Pain Physician 2007;10:185-212.
5. Botwin KP, Gruber RD, Bouchlas CG, et al. Fluoroscopically guided lumbar transformational epidural steroid injections in degenerative lumbar stenosis: an outcome study. Am J Phys Med Rehabil 2002;81:898-905. Crossref
6. Derby R, Kine G, Saal JA, et al. Response to steroid and duration of radicular pain as predictors of surgical outcome. Spine (Phila Pa 1976) 1992;17(6 Suppl):S176-83. Crossref
7. Wilson-MacDonald J, Burt G, Griffin D, Glynn C. Epidural steroid injection for nerve root compression. A randomised, controlled trial. J Bone Joint Surg Br 2005;87:352-5. Crossref
8. Karppinen J, Malmivaara A, Kurunlahti M, et al. Periradicular infiltration for sciatica: a randomized controlled trial. Spine (Phila Pa 1976) 2001;26:1059-67. Crossref
9. Ng L, Chaudhary N, Sell P. The efficacy of corticosteroids in periradicular infiltration for chronic radicular pain: a randomized, double blind, controlled trial. Spine 2005;30:857-62. Crossref
10. Ptaszynski A, Huntoon M. Complications of spinal injections. Tech Reg Anesth Pain Manag 2007;11:122-32. Crossref
11. Beynon R, Hawkins J, Laing R, Higgins N, Whiting P. The diagnostic utility and cost-effectiveness of selective nerve root blocks in patients considered for lumbar decompression surgery: a systematic review and economic model. Health Technol Assess 2013;17:88. Crossref

Paracetamol overdose in Hong Kong: is the 150-treatment line good enough to cover patients with paracetamol-induced liver injury?

Hong Kong Med J 2015 Oct;21(5):389–93 | Epub 31 Jul 2015
DOI: 10.12809/hkmj144481
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE    CME
Paracetamol overdose in Hong Kong: is the 150-treatment line good enough to cover patients with paracetamol-induced liver injury?
Simon TB Chan, MB, BS1; CK Chan, Dip Clin Tox, FHKAM (Emergency Medicine)2; ML Tse, FHKCEM, FHKAM (Emergency Medicine)2
1 Department of Accident and Emergency, United Christian Hospital, Kwun Tong, Hong Kong
2 Hong Kong Poison Information Centre, United Christian Hospital, Kwun Tong, Hong Kong
Corresponding author: Dr Simon TB Chan (ctb021@ha.org.hk)
 
 Full paper in PDF
Abstract
Objectives: To evaluate the failure rate of the 150-treatment line for paracetamol overdose in Hong Kong, and the impact if the treatment threshold was lowered.
 
Design: Case series.
 
Setting: Public hospitals, Hong Kong.
 
Patients: All patients with acute paracetamol overdose reported to the Hong Kong Poison Information Centre from 1 January 2011 to 31 December 2013 were studied and analysed for the timed serum paracetamol concentration and their relationship to different treatment lines. Presence of significant liver injury following paracetamol overdose was documented. The potential financial burden of different treatment lines implemented locally was estimated.
 
Results: Of 893 patients, 187 (20.9%) had serum paracetamol concentration above the 150-treatment line, 112 (12.5%) had serum paracetamol concentration between the 100- and 150-treatment lines, and 594 (66.5%) had serum paracetamol level below the 100-treatment line. Of the 25 (2.8%) patients who developed significant liver injury, two were between the 100- and 150-treatment lines, and the other two were below the 100-treatment line. The failure rate of the 150-treatment line was 0.45%. Lowering the treatment threshold to the 100-treatment line might lower the failure rate of the treatment nomogram to 0.22% but approximately 37 more patients per year would need to be treated. It would incur an additional annual cost of HK$189 131 (US$24 248), and an additional 1.83 anaphylactoid reactions per year. The number needed-to-treat to potentially reduce one significant liver injury is 112.
 
Conclusions: Lowering the treatment threshold of paracetamol overdose may reduce the treatment-line failure rate. Nonetheless such a decision must be balanced against the excess in treatment complications and health care resources.
 
 
New knowledge added by this study
  • For paracetamol overdose in Hong Kong, the failure rate of the 150-treatment line is 0.45%. Lowering the treatment threshold to 100-treatment line may lower the failure rate to 0.22%.
  • Implementing the 100-treatment line in Hong Kong would incur an annual cost of HK$189 131 (US$24 248), 37 more patients per year needing treatment, and an additional 1.83 anaphylactoid reactions per year. The number needed-to-treat to potentially reduce one significant liver injury is 112.
Implications for clinical practice or policy
  • Clinicians should be aware of the chance of treatment-line failure in patients with acute paracetamol overdose.
  • Recommendations for the treatment threshold for acute paracetamol overdose may be evaluated together with the clinical and financial impacts described in this study.
 
 
Introduction
Paracetamol is a common analgesic and antipyretic, and is currently the most commonly overdosed therapeutic agent in Hong Kong, accounting for 8.4% of all poisoning cases.1 After the first human case report of paracetamol-induced liver injury in 1966,2 paracetamol overdose remains an important cause of acute liver failure with mortalities worldwide. The efficacy of N-acetylcysteine (NAC) in the treatment and prevention of paracetamol-induced liver injury has been established over the last decades.3 4 In acute paracetamol overdose, serum paracetamol concentration measured at 4 to 24 hours post-ingestion (timed serum paracetamol concentration) is plotted on the Rumack-Matthew nomogram. Treatment with NAC should be initiated if the serum paracetamol concentration is plotted on or above the treatment line.5 Different treatment lines exist, however, and there is no worldwide consensus on the safest serum paracetamol concentration at which to initiate NAC treatment.
 
In the United States, the timed serum paracetamol concentration is plotted against a single treatment line starting at 150 mg/L at 4 hours post-ingestion (150-treatment line).6 Patients with serum paracetamol concentration above this line are treated with NAC. This line was imposed by the United States Food and Drug Administration with a 25% safety margin based on the work of Rumack in 1975,5 and was also adopted in Australia and New Zealand.7
 
Previously in the United Kingdom, two different treatment lines were used. Patients were categorised into ‘normal risk’ or ‘high risk’ according to their medical and behavioural background. Those patients with possible glutathione depletion, for example with malnutrition or chronic heavy alcoholism, were considered ‘high risk’ while the remaining patients were considered ‘normal risk’. Treatment lines starting at 200 mg/L (200-treatment line) and 100 mg/L (100-treatment line) at 4 hours post-ingestion were used in patients with ‘normal risk’ and ‘high risk’, respectively.
 
The Medicines and Healthcare products Regulatory Agency of the United Kingdom lowered the threshold of NAC treatment in 2012,8 following a series of patients with severe liver injury and several mortalities after paracetamol overdose were reported to have a serum paracetamol concentration below the level dictated by the previous treatment protocol.9 All patients in the United Kingdom with serum paracetamol concentration over the 100-treatment line are now prescribed NAC treatment.
 
The Hong Kong Poison Information Centre (HKPIC) currently recommends intravenous NAC treatment in patients with serum paracetamol concentration above the 150-treatment line. One course of NAC treatment typically takes 21 hours of intravenous infusion in hospital under close observation. In this study, we examined a series of non-staggered acute paracetamol overdose cases in Hong Kong to determine how well the current 150-treatment line can cover patients with paracetamol-induced liver injury and the impact on the local health care system if the treatment threshold is changed.
 
Methods
We performed a retrospective observational study by reviewing patients with acute paracetamol overdose who presented to 16 emergency departments (EDs) in public hospitals in Hong Kong between 1 January 2011 and 31 December 2013. Data were retrieved from the electronic database of the HKPIC and electronic Patient Record of the Hospital Authority. All patients aged 12 years or above with acute paracetamol overdose were included.
 
In this study, acute paracetamol overdose was defined as ingestion of paracetamol or paracetamol-containing medications in a single attempt. As some patients intentionally took a large number of tablets, we allowed a maximum duration of ingestion process for up to 1 hour. When the ingestion process occurred over 1 hour, the overdose was considered to be staggered and such patients were excluded from the study. Patients were also excluded if time of ingestion was undetermined, no serum paracetamol concentration was available within 4 to 24 hours post-ingestion, or patients presented to EDs more than 24 hours post-ingestion.
 
The following data were collected: clinical profile including age, sex, first serum paracetamol concentration between 4 and 24 hours post-ingestion, treatment given, and the presence of significant liver injury during the episode. Significant liver injury was defined as serum alanine aminotransferase (ALT) level of ≥1000 IU/L in the absence of a known history of deranged liver function.
 
Results
There were a total of 1243 patients with acute paracetamol overdose within the study period. Exclusions included 73 patients with staggered overdose, 137 patients with undetermined time of paracetamol ingestion, 100 patients with no serum paracetamol concentration available within 4 to 24 hours of ingestion, and 40 patients who presented to the EDs of >24 hours post-ingestion. Data on 893 patients who fulfilled the inclusion criteria were analysed. The clinical data of the studied patients are presented in Table 1.
 

Table 1. Clinical data of patients with acute paracetamol overdose (n=893)
 
No deaths occurred in the study population and no patient required liver transplantation. There were 187 (20.9%) patients with a serum paracetamol concentration above the 150-treatment line, 112 (12.5%) patients had a serum paracetamol concentration between the 100- and 150-treatment lines, and the remaining 594 (66.5%) patients had serum paracetamol concentration below the 100-treatment line.
 
Significant liver injury occurred in 25 patients within the study period, giving an overall incidence of 2.8% following acute paracetamol overdose (Table 2). Four patients with serum paracetamol concentration below the 150-treatment line developed significant liver injury. The failure rate of the 150-treatment line was 0.45% (4/893). If 100-treatment line is applied instead of 150-treatment line, two patients with serum paracetamol concentration below the 100-treatment line developed significant liver injury. The failure rate of the 100-treatment line would thus be 0.22% (2/893).
 

Table 2. Serum paracetamol concentration and the incidence of significant liver injury
 
Discussion
Paracetamol overdose is a commonly encountered problem in Hong Kong, and is the single most common cause of poisoning. According to the Rumack-Matthew nomogram, a serum paracetamol concentration starting from 200 mg/L at 4 hours is associated with an increased risk of liver injury and death.10 The clinical decision to commence treatment with NAC is dictated by the timed serum paracetamol concentration plotted against the nomogram with a treatment line. If the timed serum paracetamol concentration is above the treatment line, NAC treatment is indicated. Based on different considerations, for example the accuracy of clinical history and individual susceptibility, different treatment lines are applied by different countries or centres to guide initiation of NAC treatment.
 
Since the United Kingdom lowered the NAC treatment threshold to the 100-treatment line,8 there has been discussion in Hong Kong about the benefit of changing local recommendations. Nonetheless, it is unknown whether the reasons for changing the recommendation in the United Kingdom apply to the Hong Kong population. This study serves to provide more information for further discussion and consideration.
 
We were most interested to identify patients who developed significant liver injury following paracetamol overdose in which the serum paracetamol concentration was lower than the treatment line. In the 3-year study period, four patients with a paracetamol concentration below the 150-treatment line developed significant liver injury. These cases are discussed in detail below and summarised in Table 3.
 

Table 3. Details of patients with significant liver injury below the 150-treatment line
 
Case 1
A 36-year-old woman with known depressive disorder attended the ED 20.5 hours following ingestion of 100 tablets of paracetamol. She had abdominal pain afterwards. On presentation, the paracetamol concentration was 43 µmol/L (6.5 mg/L). This level falls between the 100- and 150-treatment lines. The level of ALT was 53 IU/L and international normalised ratio (INR) was 1.03. She was admitted to the medical ward. Although her serum paracetamol concentration plotted below the 150-treatment line, NAC treatment was given soon after admission based on the clinical features of hepatitis. Her liver enzyme level started to elevate the next day with clinical jaundice, and on day 2 of admission her ALT level peaked at 3232 IU/L, and INR at 1.43 with bilirubin level of 45 µmol/L. She was treated conservatively and liver function gradually improved. She was discharged on day 6 of admission.
 
Case 2
A 31-year-old woman attempted suicide by ingesting around 50 tablets of over-the-counter drugs. She was brought to the ED 3 hours afterwards and complained of mild dizziness and nausea. Activated charcoal 50 g was given and she was admitted to the Intensive Care Unit (ICU). Serum paracetamol concentration taken at 7 hours post-ingestion was 418 µmol/L (63.3 mg/L), between the 100- and 150-treatment lines. The patient was treated supportively in the ICU for the first day. At 24-hour post-ingestion her ALT level was 48 IU/L, INR was 1.3, and at 29 hours post-ingestion the ALT level elevated to 73 IU/L, with INR of 1.4. Intravenous NAC treatment was commenced 30 hours post-ingestion. Liver function continued to deteriorate: ALT level peaked at 4655 IU/L and INR peaked at 1.5 on day 3 of admission. The serum bilirubin level was 67 µmol/L. She had clinical jaundice and vomiting. On day 4, NAC infusion was stopped. She had full recovery of liver function at 1-month follow-up.
 
Case 3
An 18-year-old man ingested around 50 tablets of paracetamol in a suicide attempt. He attended the ED 5 hours later. He was asymptomatic on presentation. Serum paracetamol concentration at 5 hours post-ingestion was 330 µmol/L (49.8 mg/L), below the 100-treatment line. At presentation his ALT level was 64 IU/L and INR was 1.06. Liver function tests repeated at 7 hours post-ingestion showed ALT level was increased to 98 IU/L and INR was 1.3. Intravenous NAC was started. The liver function deterioration peaked at day 3 of admission with ALT level of 2172 IU/L and INR of 1.53 and the patient complained of abdominal pain; NAC infusion was continued until day 5 of admission. His liver function improved and he was transferred to the psychiatric ward for management of depression on day 6. He had full recovery of his liver function.
 
Case 4
A 50-year-old man had flu-like symptoms and fever for 5 days. He ingested 60 tablets of paracetamol in a suicide attempt related to financial stress and physical discomfort. At 20 hours after ingestion, he attended the ED for recurring fever. On presentation his body temperature was 40.2°C. Blood tests revealed ALT level of 511 IU/L, INR of 1.1, and serum paracetamol concentration of 28 µmol/L (4.2 mg/L), below the 100-treatment line at 20.5 hours; NAC treatment was given based on the clinical features of chemical hepatitis. His liver markers peaked the next day with ALT level of 1162 IU/L, INR of 1.2, and with abdominal pain. His fever and respiratory symptoms subsided with a course of intravenous antibiotics. His liver function gradually improved and he was transferred to the psychiatric ward on day 6 after admission.
 
All four patients were considered ‘normal risk’ according to the old United Kingdom classification of treatment line options.
 
Analysis of these four cases revealed that if the NAC treatment threshold had been lowered from the 150-treatment line to 100-treatment line, the treatment line would have covered the first two cases but not the last two. The treatment-line failure rate would thus be reduced by half to 0.22%. A lower failure rate of the treatment line implies that people who will develop liver injury following paracetamol overdose are more likely to receive early treatment with NAC. Although not proven in this study, this should prevent a small number of cases of significant morbidity related to severe paracetamol poisoning.
 
Giving intravenous NAC is not without risk, however. If the 100-treatment line had been applied instead of the 150-treatment line, the number of patients in this study in whom NAC treatment would have been indicated would increase from 187 (20.9%) to 299 (33.5%)—an additional 112 courses of NAC over 3 years. In addition, since 4.9% of the patients given NAC in this study developed an anaphylactoid reaction, there would also have been an additional 5.49 anaphylactoid reactions (1.83 patients/year).
 
The financial burden of treating additional patients with NAC courses can be estimated by additional cost of hospital stay11 and drug cost of NAC, approximately HK$5066 (US$650) per standard 21-hour intravenous NAC administration. This is similar to the estimated cost of a standard NAC course in a United Kingdom study.12 An additional 112 courses of NAC would cost HK$567 392 (US$72 743) within the study period of 3 years with an average of HK$189 131 (US$24 248) per year. The calculations are shown in Table 4. On rare occasions NAC treatment may be extended over 21 hours and result in a further increase in the actual cost.
 

Table 4. Estimation of financial burden for different treatment lines
 
The liver injury in case 2 was judged to have been preventable by timely NAC treatment in nomogram perspective. Thus, we would need to administer NAC to an additional 112 patients to achieve potential benefit in one patient. The number needed-to-treat of lowering 150-treatment line to 100-treatment line to potentially prevent one case of paracetamol-induced liver injury is 112.
 
Despite these data, the clinical decision to initiate NAC treatment may not depend solely on the timed serum paracetamol concentration. As illustrated in case 1, NAC treatments were occasionally initiated based on the patient’s presentation and doctor’s clinical judgement. In our study, 23 of 112 patients with serum paracetamol concentration plotted between 100- and 150-treatment lines were prescribed NAC for similar reasons. Thus if the 100-treatment line is used instead of the 150-treatment line, the actual number of additional NAC treatment that would have been needed is 89 (ie 112-23 cases).
 
Limitations
In the clinical management of paracetamol overdose in Hong Kong, patients may be discharged if their serum paracetamol level is below the treatment line and there are no active clinical symptoms. Although no patient in this study was readmitted for hepatitis, there may have been others who developed chemical hepatitis and who were not brought to our attention. Thus the incidence of liver injury will have been underestimated.
 
Conclusions
Neither the 150- nor 100-treatment line can fully cover all patients who develop significant liver injury following paracetamol overdose. The failure rate of the treatment lines and potential financial burden were studied. This serves as the basis for future considerations of treatment in Hong Kong for paracetamol overdose.
 
References
1. Chan YC, Tse ML, Lau FL. Hong Kong Poison Information Centre: Annual Report 2012. Hong Kong J Emerg Med 2013;20:371-81.
2. Davidson DG, Eastham WN. Acute liver necrosis following overdose of paracetamol. Br Med J 1966;2:497-9. Crossref
3. Prescott LF, Illingworth RN, Critchley JA, Stewart MJ, Adam RD, Proudfoot AT. Intravenous N-acetylcysteine: the treatment of choice for paracetamol poisoning. BMJ 1979;2:1097-100. Crossref
4. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med 1988;319:1557-62. Crossref
5. Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol 2002;40:3-20. Crossref
6. Rowden AK, Norvell J, Eldridge DL, Kirk MA. Updates on acetaminophen toxicity. Med Clin North Am 2005;89:1145-59. Crossref
7. Daly FF, Fountain JS, Murray L, Graudins A, Buckley NA; Panel of Australian and New Zealand clinical toxicologists. Guidelines for the management of paracetamol poisoning in Australia and New Zealand—explanation and elaboration. A consensus statement from clinical toxicologists consulting to the Australasian poisons information centres. Med J Aust 2008;188:296-301.
8. Paracetamol overdose: new guidance on use of intravenous acetylcysteine. Commission on Human Medicines, United Kingdom. Available from: https://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAttachment.aspx?Attachment_id=101488. Accessed 7 Jul 2015.
9. Beer C, Pakravan N, Hudson M, et al. Liver unit admission following paracetamol overdose with concentrations below current UK treatment thresholds. QJM 2007;100:93-6. Crossref
10. Rumack BH, Matthew H. Acetaminophen poisoning and toxicity. Pediatrics 1975;55:871-6.
11. Head 140, Expenditure estimates, The 2014-15 Budget, Hong Kong Special Administrative Region, People’s Republic of China. Available from: http://www.budget.gov.hk/2014/eng/pdf/head140.pdf. Accessed 19 Nov 2014.
12. McQuade DJ, Dargan PI, Keep J, Wood DM. Paracetamol toxicity: What would be the implications of a change in UK treatment guidelines? Eur J Clin Pharmacol 2012;68:1541-7. Crossref

Dental luxation and avulsion injuries in Hong Kong primary school children

Hong Kong Med J 2015 Aug;21(4):339–44 | Epub 17 Jul 2015
DOI: 10.12809/hkmj144433
© Hong Kong Academy of Medicine. CC BY-NC-ND 4.0
 
ORIGINAL ARTICLE
Dental luxation and avulsion injuries in Hong Kong primary school children
SY Cho, MDS (Otago), FHKAM (Dental Surgery)
MacLehose Dental Centre, G/F, 286 Queen’s Road East, Wanchai, Hong Kong
Corresponding author: Dr SY Cho (rony_cho@dh.gov.hk)
 
 Full paper in PDF
 
Abstract
Objectives: To identify the major causes and types of dental luxation and avulsion injuries, and their associated factors in primary school children in Hong Kong.
 
Design: Case series.
 
Setting: School dental clinic, New Territories, Hong Kong.
 
Patients: The dental records of children with a history of dental luxation and/or avulsion injury between November 2005 and October 2012 were reviewed. Objective clinical and radiographical findings at the time of injury and at follow-up examinations were recorded using a standardised form. Data analysis was carried out using the Chi squared test and multinomial logistic regression.
 
Results: A total of 220 children with 355 teeth of dental luxation or avulsion injury were recorded. Their age ranged from 6 to 14 years and the female-to-male ratio was 1:1.8. The peak occurrence was at the age of 9 years. Subluxation was the most common type of injury, followed by concussion. Maxillary central incisors were the most commonly affected teeth. The predominant cause was fall and most injuries occurred at school. Incisor relationship was registered in 199 cases: most of them were Class I. Comparison of the incisor relationship in study children and the general Chinese population in another study revealed a higher proportion of Class II and fewer Class III occlusions in the trauma group (P<0.0001).
 
Conclusion: Most dental luxation and avulsion injuries in Hong Kong primary school children are caused by fall. Boys are more commonly affected than girls, and a Class II incisor relationship is a significant risk factor.
 
 
New knowledge added by this study
  • This is the first epidemiological study of traumatic dental injury in children residing in Hong Kong. The present findings provide an important baseline for future comparison.
Implications for clinical practice or policy
  • As most injuries occur at school, it may be beneficial to educate primary school teachers about emergency care of children with dental trauma.
 
 
Introduction
Childhood injury is a major cause of death and disability in many countries, including Hong Kong.1 Although previous studies have reviewed general childhood injuries in Hong Kong children,1 2 dental injuries have not been specifically studied and reported. The oral region comprises 1% of the total body area, yet a population-based study in Sweden showed that it accounts for 5% of all body injuries at all ages.3 A recent study conducted by the Department of Health showed that injuries to orofacial areas accounted for 1.7% of all body injuries in children aged 14 years or below.1
 
Dental luxation and avulsion injuries account for 15% to 61% of all dental traumas to permanent teeth.4 It is an important public health concern as the treatment of such injuries is often complicated and requires specialist care.5 6 It also tends to occur at a young age during which growth and development take place and so long-term follow-up is needed.5 6 7 The average number of dental visits because of trauma to a permanent tooth during 1 year has been shown to be much higher than that required for a bodily injury.6 Information on how and where dental trauma occurs, and the associated risk factors are important data that can be used to plan a preventive strategy. There is, however, little information about the epidemiology of dental trauma in children residing in Hong Kong. The aims of this retrospective study were to identify the major causes and types of dental luxation and avulsion injuries, and their associated factors in primary school children attending a school dental clinic in Hong Kong.
 
Methods
This retrospective study was carried out at Fanling School Dental Clinic that provides care for approximately 30 000 primary school children in the Hong Kong New Territories East region. The study materials comprised dental records of patients with a history of dental luxation and/or avulsion injury between November 2005 and October 2012. All dental luxation and avulsion injuries were logged in the electronic records using specific codes: an electronic search of records was performed using the same dental condition codes (DC=concussion, DS=subluxation, DE=extrusion, DN=intrusion, DL=lateral luxation, and DA=avulsion). All cases were examined clinically by at least one of the three attending paediatric dentists at the clinic who were experienced in treating children with dental trauma. All records were reviewed by one single examiner, the paediatric dentist in-charge of the clinic. Information was recorded in Microsoft Excel and data analysis was carried out using the Chi squared test and multinomial logistic regression with PASW Statistics 18 software (SPSS Inc, Chicago [IL], US). The level of significance was set at P<0.05. To evaluate intra-examiner reliability, all selected records were reviewed by the same author 1 month after the original analysis and the findings of the two examinations compared for discrepancies.
 
Clinical examinations
Since November 2005, a standardised dental trauma form has been used in the clinic to facilitate follow-up care. The following parameters were recorded for patients who presented with dental luxation or avulsion injuries: date and time of injury, place where the injury occurred, cause of trauma, presence of other orofacial soft tissue injury, and the incisor relationship according to the British Standard Incisor Classification.8 The type of injury was classified according to the Andreasen modification of the World Health Organization classification,9 and included six types of injury to periodontal tissues (Table 1).
 

Table 1. Indices used in the present study
 
The adjacent apparently unaffected teeth on both sides were also included in the examination. For each tooth, objective clinical findings from the initial and follow-up examinations were recorded using the same standardised format and included the following: pulp sensitivity test; percussion tone; tenderness to percussion; tooth mobility; tooth colour; periodontal probing depths; and the presence of concomitant crown fractures and pulp exposure.
 
Radiographic examinations
An anterior occlusal radiograph together with periapical radiographs of the affected teeth were taken at the initial examination. At each follow-up appointment, periapical radiographs were repeated for the affected teeth. All periapical radiographs were taken using a standard film holder (Dentsply Rinn, Elgin [IL], US).
 
Follow-up examinations
All cases were followed up at regular intervals: 3 weeks, 6 to 8 weeks, 6 months, and then annually from the time of injury. Patients with dental avulsion were also seen on days 7 to 10 for splint removal and root canal treatment if indicated.
 
Results
A total of 220 children with 355 teeth of dental luxation or avulsion injury were recorded during the study period. Their ages ranged from 6 to 14 years (mean age, 9.2 years; standard deviation, 1.7 years). To assess whether age was an important factor, children were divided into two age-groups: 58% (n=128) were aged 6 to 9 years and 42% (n=92) were 10 to 14 years at the time of injury. The male-to-female ratio was 1.8:1, with 141 boys and 79 girls. The gender difference in prevalence was more prominent in children aged 9 years or above. The peak occurrence was seen at the age of 9 years (n=46), followed by the age of 8 years (n=44) and 10 years (n=38). Only one tooth was traumatised in 117 (53%) children. The predominant traumatic dental injury was subluxation, followed by concussion (Table 2). Over 65% of teeth with concussion or subluxation also had crown fractures. Maxillary central incisors (295 teeth) were the most commonly affected, followed by maxillary lateral incisors (38 teeth) and mandibular incisors (20 teeth). The cause of injury was recorded in 219 cases (Table 3). Fall (62%) was the predominant cause in both genders and age-groups, followed by collision (18%) and cycling (15%). There were no incidents of injury caused by motor vehicle accidents or fights. Statistical analysis using Chi squared test showed no significant difference in the cause of injury between genders (P=0.108) or between the two age-groups (P=0.193). The place where the injury occurred was recorded in 217 cases: most occurred at school (Table 4). Statistical analysis using Chi squared test showed a significant difference in the place of occurrence between genders (Chi squared=15.6, degrees of freedom=6, P<0.05), but no significant difference between the two age-groups (P=0.078). Multivariate analysis using multinomial logistic regression was then performed with gender and age-group as independent variables and place of injury as a dependent variable. Because of the relatively small number of cases, injuries that occurred in the playground, street, swimming pool, and other places were grouped into one category named as other places in the analysis. Injury occurring at school was then compared with injuries that occurred at home, on a cycling path, or in other places. School was chosen as the reference because (1) it was the most common place where injury occurred; and (2) univariate analysis of individual places of injury using the Fisher’s exact test showed no significant difference between genders regarding injuries at school whereas there were significant gender differences in injuries that occurred at home and on a cycling path (P<0.05). The results of the regression showed that boys were more commonly affected than girls (P<0.05; odds ratio [OR]=2.97; 95% confidence interval [CI], 1.05-8.43) for injuries that occurred on a cycling path in comparison with injuries at school. In the same model, younger children were significantly less commonly affected than older children (P<0.05; OR=0.42; 95% CI, 0.21-0.85) for injuries that occurred in other places compared with injuries at school.
 

Table 2. Types of dental luxation and avulsion injuries
 

Table 3. Causes of dental luxation and avulsion injuries in relation to age and gender
 

Table 4. Places where dental luxation and avulsion injuries occurred in relation to age and gender
 
Incisor relationship was registered in 199 cases: most were Class I (63%) [Table 5]. Since such information was not available for the whole study, it was decided to use data from a previous study of the general Chinese population of children as a retrospective comparison group.10 Comparison of these two studies showed that there was a higher proportion of Class II and fewer Class III occlusions in the trauma group than in the general Chinese population. Statistical analysis showed a significant difference between the two population groups (Chi squared=36.1, degrees of freedom=2, P<0.0001). Soft tissue injury occurred in the orofacial region in 87 children, and lips were involved in most instances (82%). Intra-examiner reliability was evaluated and complete concordance of all data and parameters was found between the two evaluations that were 1 month apart.
 

Table 5. The distribution of incisor relationship in this study compared with a previous study of the general Chinese children population10
 
Discussion
The difference in the proportion of causes of traumatic dental injury depends on various factors including culture, age-group, and population.11 12 In some developing countries, the most common cause of dental injury in children is violence.9 In this study, fall against a hard object such as the ground was the cause in over 60% of cases. This finding is in agreement with most other studies of traumatic dental injury in children.7 11 12 13 14 15 16 17 18 19 20 In a study of New Zealand children, fall was the most common cause in children aged 5 to 7 years, but collision became more common in the 8- to 10-year-old group.21 Nonetheless, such a trend was not observed in this study. Although dental injury due to cycling accidents was not uncommon in this study, this finding may be confounded by the fact that New Territories East has one of the busiest cycling path networks in Hong Kong.2 The use of helmets offers little protection to the lower face and jaw.9 It has been suggested that modification of the helmet design to cover the lower face may be beneficial. There were few sports-related injuries observed in this study. This may be because high-risk contact sports, such as rugby and ice hockey,5 are not very popular among Hong Kong primary school children. Compulsory use of mouth guards in those who participate in such activities may also be a contributing factor. There was no case of trauma due to a road traffic accident; this may reflect the legal requirement in Hong Kong for all passengers to wear a car seatbelt.
 
In this study more boys than girls had dental luxation and avulsion injuries in accordance with the findings of most other studies.7 13 14 15 16 17 18 19 22 23 24 One probable reason for the gender difference is that boys take more risks and participate more in sports activities. Nonetheless this gender difference has narrowed in recent studies, possibly due to an increased interest in sports among girls, especially in western societies.5 11 21 In this study, a greater gender discrepancy in frequency of dental injury was observed in the older age-group, in accordance with the findings of Kania et al’s study of elementary school children in the US.24
 
Previous studies of dental trauma in children have shown that most injuries occur between the age of 6 and 12 years.7 16 17 18 The present study population comprised primary school children attending a regional school dental clinic. The age of most primary school children in Hong Kong falls within the range of 6 to 12 years, and so most of the dental injuries for this group of children could be registered in this study. The peak occurrence of injury was seen in 9-year-olds, again in agreement with previous studies where the highest frequency of trauma to permanent dentition was observed in 9- to 10-year-olds.12 19 Nonetheless in studies from New Zealand21 and Iraq,14 the highest frequency of dental injury occurred in 5- to 7-year-olds. Glendor et al9 observed a marked increase in the incidence of dental injury in boys aged 8 to 10 years, with the incidence rather stable in girls. The same trend was also seen in this study. This may reflect the more vigorous play characteristics of boys in this age-group than girls.9
 
The majority of dental injuries involve the anterior teeth, especially the maxillary central incisors. The maxillary lateral and mandibular incisors are affected less frequently.5 9 Similar findings were also observed in the present study. The more prominent position of the maxillary central incisors makes them more vulnerable to injury. In addition, Kania et al24 opined that maxillary incisors are more prone to injury than their mandibular counterparts because of the mandible’s non-rigid connection to the cranial base. Most of the children in this study experienced trauma to only one tooth. This concurs with the findings from previous studies of dental injury in children.9 11 14 23 24 Noori and Al-Obaidi14 opined that when one tooth is traumatised, the majority of the force is dispersed and so no more teeth will be injured.14 It has been suggested that multiple tooth injuries are seen more often in more serious accidents such as motor vehicle accidents and violence.8 9 24 Concussion and subluxation together accounted for 85% of the cases in this study, in accordance with the findings of most previous studies on luxation and avulsion injuries in children.7 16 17 19 21 As the force and direction of impact determines the resultant type of injury, the findings from this study seem to suggest that most periodontal tissue injuries in Hong Kong primary school children are caused by more trivial incidents.9 Increased overjet and consequent incompetent lip closure is a significant risk factor to traumatic dental injury.7 9 13 14 15 22 23 24 In a study conducted in Iraq, 70% of children who had a dental injury had increased overjet.14 In many other studies, most children who sustained a dental injury had normal overjet, yet the percentage of children with increased overjet was significantly higher in children with dental trauma than in the general population.7 9 13 22 23 24 Similar findings were also observed in the present study. The more prominent tooth position and the lack of a cushioning effect from the upper lip in Class II malocclusion make the maxillary incisors more prone to injury.14
 
In many previous studies, the predominant place of injury occurrence in school-aged children was home, followed by school and other public places.9 13 21 22 In the present study, most injuries occurred at school. The second and third most common places of occurrence were home and cycling paths, respectively. This finding was in agreement with the population bodily injury survey of children aged 14 years or below in Hong Kong.1 One probable reason is that school children in Hong Kong have relatively more play-time at school than at home. In this study, 40% of children with a traumatic dental injury also suffered soft tissue injury in the orofacial region. This percentage was of similar magnitude to another study that involved a large proportion of children with dental luxation and avulsion injuries,17 but higher than a study with a high proportion of minor dental trauma such as simple fracture.12 This discrepancy may be because incidents that resulted in dental luxation or avulsion were usually more severe and could lead to more soft tissue damage.
 
One of the limitations of this study is its retrospective design. It is, however, extremely difficult to perform prospective trauma studies on a population basis.25 ‘Grab’ sampling was employed in this retrospective study, ie all patients treated in one clinic for dental luxation and/or avulsion injury were used in the sample. The conclusions from this study may therefore not be applicable to other parts of Hong Kong. To avoid inter-examiner error, all the records were reviewed by the most senior paediatric dentist in the clinic. The use of a standardised trauma form helps improve the accuracy of data collected during treatment.25 With the aid of a standardised form, the cause of dental injury was recorded in all but one case, and the place of trauma in all but three. This illustrates the importance of a standardised registry of dental traumatology.
 
This is the first epidemiological study of traumatic dental injury in children resident in Hong Kong and our data provide an important baseline for future comparison. Very often, school teachers are often the first to deal with an acute dental injury and it may be beneficial to educate them about the emergency care of children with dental trauma. For example, with avulsion injuries, where immediate management is critical for optimal healing, the teachers should be taught how to replant the tooth on site. If that could not be done, they should know how to store the avulsed tooth in an appropriate medium to prevent damage to the periodontal tissue. The effects of various factors on healing will be investigated and reported in a subsequent paper.
 
Dental traumas have social and economic impacts with regard to the treatment required but it is difficult to prevent dental injuries that are not sports-related.6 21 One option is to improve environmental factors to prevent falling at school and at home. Environmental and behavioural factors, however, were not included in this study so it is difficult to make conclusive suggestions in this regard. Further studies are warranted.
 
Conclusion
The causes and types of dental luxation and avulsion injuries in this group of Hong Kong children were similar to those of other studies, except that more injuries happened at school than at home. Most dental luxation and avulsion injuries in Hong Kong primary school children were caused by fall. Boys were more commonly affected than girls, and Class II incisor relationship was a significant risk factor. Motor vehicle accident or fight was not a common risk factor for dental injury in children. As most of the injuries occurred at school, it may be beneficial to educate primary school teachers about the emergency care of children with dental trauma.
 
Acknowledgement
The author thanks Dr Denise Fung for her statistical advice in this study.
 
References
1. Injury survey 2008. Hong Kong: Centre for Health Protection, Department of Health; 2010.
2. Chan CC, Cheng JC, Wong TW, et al. An international comparison of childhood injuries in Hong Kong. Inj Prev 2000;6:20-3. Crossref
3. Petersson EE, Andersson L, Sörensen S. Traumatic oral vs non-oral injuries. Swed Dent J 1997;21:55-68.
4. Andreasen FM, Andreasen JO. Luxation injuries of permanent teeth: general findings. In: Textbook and color atlas of traumatic injuries to the teeth. 4th ed. Oxford: Blackwell-Munksgaard; 2007; 372-403.
5. Glendor U. Epidemiology of traumatic dental injuries—a 12 year review of the literature. Dent Traumatol 2008;24:603-11. Crossref
6. Andersson L. Epidemiology of traumatic dental injuries. Pediatr Dent 2013;35:102-5. Crossref
7. Zhang Y, Zhu Y, Su W, Zhou Z, Jin Y, Wang X. A retrospective study of pediatric traumatic dental injuries in Xi’an, China. Dent Traumatol 2014;30:211-5. Crossref
8. British standard incisor classification. Glossary of Dental Terms BS 4492. London: British Standard Institute; 1983.
9. Glendor U, Marcenes W, Andreasen JO. Classification, epidemiology and etiology. In: Textbook and color atlas of traumatic injuries to the teeth. 4th ed. Oxford: Blackwell-Munksgaard; 2007: 217-54.
10. Lew KK, Foong WC, Loh E. Malocclusion prevalence in an ethnic Chinese population. Aust Dent J 1993;38:442-9. Crossref
11. Andreasen JO, Bakland LK, Matras RC, Andreasen FM. Traumatic intrusion of permanent teeth. Part 1. An epidemiological study of 216 intruded permanent teeth. Dent Traumatol 2006;22:83-9. Crossref
12. Eyuboglu O, Yilmaz Y, Zehir C, Sahin H. A 6-year investigation into types of dental trauma treated in a paediatric dentistry clinic in Eastern Anatolia region, Turkey. Dent Traumatol 2009;25:110-4. Crossref
13. Bendo CB, Paiva SM, Oliveira AC, et al. Prevalence and associated factors of traumatic dental injuries in Brazilian schoolchildren. J Public Health Dent 2010;70:313-8. Crossref
14. Noori AJ, Al-Obaidi WA. Traumatic dental injuries among primary school children in Sulaimani city, Iraq. Dent Traumatol 2009;25:442-6. Crossref
15. Taiwo OO, Jalo HP. Dental injuries in 12-year-old Nigerian students. Dent Traumatol 2011;27:230-4. Crossref
16. Sandalli N, Cildir S, Guler N. Clinical investigation of traumatic injuries in Yeditepe University, Turkey during the last 3 years. Dent Traumatol 2005;21:188-94. Crossref
17. Díaz JA, Bustos L, Brandt AC, Fernández BE. Dental injuries among children and adolescents aged 1-15 years attending to public hospital in Temuco, Chile. Dent Traumatol 2010;26:254-61. Crossref
18. Toprak ME, Tuna EB, Seymen F, Gençay K. Traumatic dental injuries in Turkish children, Istanbul. Dent Traumatol 2014;30:280-4. Crossref
19. Atabek D, Alaçam A, Aydintuğ I, Konakoğlu G. A retrospective study of traumatic dental injuries. Dent Traumatol 2014;30:154-61. Crossref
20. Hecova H, Tzigkounakis V, Merglova V, Netolicky J. A retrospective study of 889 injured permanent teeth. Dent Traumatol 2010;26:466-75. Crossref
21. Chan YM, Williams S, Davidson LE, Drummond BK. Orofacial and dental trauma of young children in Dunedin, New Zealand. Dent Traumatol 2011;27:199-202. Crossref
22. Glendor U. Aetiology and risk factors related to traumatic dental injuries—a review of the literature. Dent Traumatol 2009;25:19-31. Crossref
23. Zaragoza AA, Catalá M, Colmena ML, Valdemoro C. Dental trauma in schoolchildren six to twelve years of age. ASDC J Dent Child 1998;65:492-4,439.
24. Kania MJ, Keeling SD, McGorray SP, Wheeler TT, King GJ. Risk factors associated with incisor injury in elementary school children. Angle Orthod 1996;66:423-32.
25. Andersson L, Andreasen JO. Important considerations for designing and reporting epidemiologic and clinical studies in dental traumatology. Dent Traumatol 2011;27:269-74. Crossref

Pages